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Computer modelling of metabolic adaptions 
during mitochondrial dysfunction and machine 
learning to predict novel mitochondrial disease 
genes 
 
Alexander Gary Smith 
Mitochondria are organelles found in almost every eukaryote and are primarily 
responsible for generating chemical energy in the form of adenosine triphosphate. 
This thesis investigates two main causes of mitochondrial dysfunction: mitochondrial 
toxicity arising from side-effects of drugs; and mitochondrial diseases arising from 
defects in nuclear-encoded genes. 
Novel chemical entities being developed as drug leads are screened for cellular 
toxicity in which mitochondrial dysfunction is a major cause. However, our lack of 
understanding of the metabolic adaptations to mitochondrial dysfunction limits the 
accurate screening of mitochondrial dysfunction for pharmaceutical companies, thus 
preventing potentially useful drugs from being developed. To further our 
understanding of these adaptations, I analysed a large-scale metabolomics data set 
of rats administered a known mitochondrial complex III inhibitor. The analyses 
revealed many perturbed pathways which can be exploited as biomarkers of mild 
mitochondrial dysfunction, a condition which is currently clinically undetectable 
during the drug development process. To direct future studies on mitochondrial 
dysfunction, a multi-organ model of mitochondrial metabolism was generated and 
used to simulate inhibition of the mitochondrial respiratory complexes. The 
simulations of complex III inhibition accurately predicted many of the metabolite 
behaviours identified in the metabolomics analyses and provided theories for their 
significance. Simulations of the other complexes’ inhibitions identified many unique 
behaviours which can be used to direct future studies, studies which would greatly 
improve our understanding of the metabolic adaptations and provide higher 
confidence biomarkers.  
Mitochondrial dysfunction is linked to many late onset diseases such as Parkinson’s, 
and inborn errors of mitochondrial metabolism cause severe neurological and 
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physiological diseases. Patients with suspected mitochondrial disease have their 
DNA sequenced and analysed. Diagnosis of mitochondrial disease by sequencing 
requires knowledge of the mitochondrial proteome, which is currently incomplete. A 
predicted mitochondrial proteome was generated using a support vector machine 
trained using the abundance of protein localisation data available in the MitoMiner 
database. The support vector machine identified 442 novel mitochondrional proteins. 
The current success rate of diagnosing mitochondrial disease using sequencing is 
currently limited by our inability to filter and prioritise a patient’s DNA variants. 
Patients which do not have a variant in one of the already known mitochondrial 
disease genes are usually left with over hundreds of potential disease-causing 
variants. A probability of being disease-causing for each gene in the mitochondrial 
proteome was generated using two trained neural networks. The networks were 
trained on a large amount of different data sources for differentiating mitochondrial 
disease genes including protein-protein interaction network metrics, gene tissue 
expression and protein evolution. The predicted probabilities allow for better filtering 
and prioritisation of a patient’s variants for candidate disease-causing genes to be 
experimentally verified. The predicted mitochondrial proteome and their predicted 
disease-causing probabilities are currently used in an NGS analysis pipeline at the 
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  Introduction 
 
1.1. The fundamentals of mitochondria 
Mitochondria are organelles often referred to as the ‘powerhouse of the cell’, a 
reference to their primary function of generating cellular energy. They can be found 
in almost every eukaryote where they make up a large portion of the total cellular 
volume [1]. Eukaryotes which have no mitochondria are believed to have an 
ancestor related to the mitochondria [2]. Current evidence suggests that these 
organelles originated from a symbiotic relationship between free-living bacteria, an α-
proteobacteria distantly related to the taxa Rickettsiales [3], and an archaeal host-
cell [4] which took up these bacteria permanently [5], an event which would have 
occurred at an early stage of eukaryotic evolutionary history. 
Mitochondria are rod-shaped organelles that form into a dynamic interconnected 
network which is under a constant state of fission and fusion. The variable 
morphology of mitochondria in vivo is critical for mitochondrial biogenesis and aids in 
the mitigation of metabolic and environmental cellular stresses [6]. Dysfunction of the 
interconnected network has been associated with many neurodegenerative, 
cardiovascular, endocrine and neoplastic diseases such as Alzheimer’s disease and 
cancer [7]. Mitochondria have also been shown to form physical contacts with the 
Golgi apparatus [8] and endoplasmic reticulum [9]. 
Figure 1.1 shows the standard double membrane structure of a single 
mitochondrion. The outer membrane is a permeable membrane which separates the 
cytosol and inter membrane space. Voltage-dependent anion channels (VDAC) allow  




free movement of nearly all solutes under a molecular mass of 5kDa across the 
outer membrane, making the metabolite content of the intermembrane space 
virtually indistinguishable from that of the cytosol [10]. 
In contrast, the inner membrane is completely impermeable and separates the inter 
membrane space from the matrix, an embedded central compartment. A family of 
proteins labelled the mitochondrial transporters facilitate the hyper selective transport 
of metabolites across the inner membrane into the matrix [11]. The surface area of 
the inner membrane is considerably increased by its folded structure protruding into 
the matrix. Each of the folds, called a crista, is separated from the inter membrane 
space by tubular structures, known as crista junctions, which tightly regulate the 
protein and metabolite levels within the cristae [12]. The shape of the cristae is 
known to affect mitochondrial dependent cell growth efficiency [13]. 
The production of adenosine triphosphate (ATP), the energy currency of the cell, is 
an essential function of mitochondria. Lying within the inner membrane is a set of 
complexes (I-IV) collectively referred to as the electron transport chain (ETC). The 
ETC, along with ATP synthase, is the site of oxidative phosphorylation, the primary 
pathway for ATP generation in mitochondria (Figure 1.2). ATP synthase produces 
ATP from adenosine diphosphate (ADP) and inorganic phosphate (Pi) [14]. Its 
activity is based on the charge (Δψ) and proton (ΔpH) gradients, together known as 
Figure 1.1. Illustration of mitochondria within a cell and the structure of a single 
mitochondrion. 




the proton motive force, across the inner membrane. The controlled re-entry of 
protons into the mitochondrial matrix by ATP synthase drives rotation of an ATP 
synthase subunit called the c-ring, which is coupled to the production of ATP from 
ADP. In animals, approximately 2.7 protons are required to produce one molecule of 
ATP [15]. 
Proton motive force is primarily generated by the ETC. Complex I [16], III [17] and IV 
[18] pump protons out of the matrix across the inner membrane. This process is 
coupled with the movement of electrons through the ETC from complex I to complex 
IV. Electrons from NADH (nicotinamide adenine dinucleotide) enter the ETC at 
complex I (NADH dehydrogenase) and travel down a sequence of iron-sulphur 
clusters coupled with the pumping of four protons out of the matrix. Hydrophobic 
ubiquinol within the inner membrane reacts with the electrons to form free moving 
ubiquinone. Additional ubiquinone is added to the pool via electrons donated by 
FADH2 (flavin adenine dinucleotide) at complex II (succinate dehydrogenase) [19]. 
The electrons are then delivered to complex III (cytochrome c oxidoreductase) by 
reduced ubiquinone and four protons per ubiquinone are pumped out of the matrix. 
The reaction at complex III produces reduced cytochrome c which are used to 
deliver the electrons to complex IV (cytochrome c oxidase). Electrons move through 
complex IV, causing the pumping of four protons out of the matrix, which are 
ultimately used to reduce oxygen into water using four matrix protons. 
 
Figure 1.2. Illustration of the electron transport chain (ETC) and ATP synthase 
reactions involved in oxidative phosphorylation (OXPHOS). The blue arrow 
indicates the flow of electrons. 




The complex II reaction involves the conversion of succinate into fumarate which 
connects the ETC to the citric acid cycle, a cyclical pathway at the centre of 
metabolism. The citric acid (TCA) cycle occurs in the mitochondrial matrix and is the 
end point of a variety of metabolic pathways including glycolysis, fatty acid β-
oxidation, ketone body degradation, nucleotide metabolism and various amino acid 
metabolisms [20]. Mitochondria are also involved in the production of many other 
essential compounds including steroids [21], haem [22] and iron-sulphur cluster 
assembly [23].  
Other functions of mitochondria include maintaining calcium ion (Ca2+) homeostasis, 
Ca2+ signalling [24] and apoptosis [25]. The mitochondria act as storage sites for 
cellular Ca2+ when cytoplasmic Ca2+ concentration is too high. Dramatic and 
constant increases in mitochondrial Ca2+ concentration has been shown to cause the 
permeabilization of the mitochondrial membranes [24]. The permeabilization causes 
the release of mitochondrial proteins into the cytoplasm. Several mitochondrial 
proteins, such as cytochrome c, are involved in the mitochondrial apoptotic pathway 
[26] that, once released into the cytoplasm, induce apoptosis. 
 
1.2. The mitochondrial proteome 
The mitochondrial proteome is the library of proteins which at some point in time 
localise within the mitochondria. Their localisation to the mitochondria implicates 
these proteins in many essential functions making them an important set of proteins. 
Inside each mitochondrion is its own circular DNA called mitochondrial DNA 
(mtDNA), located within its matrix. mtDNA encodes for thirteen subunits of the 
electron transport chain complexes, two ribosomal RNAs and twenty-two transfer 
RNAs - a total of thirty-seven genes [27]. Eukaryotes can have multiple different 
copies of the mitochondrial genome within a single cell, known as mitochondrial 
heteroplasmy. Current research predicts that the mitochondrial proteome consists of 
around 1,500 proteins [28], a large portion of which must be nuclear encoded. 
However, the exact set of mitochondrially localised nuclear encoded proteins is an 
on-going topic of research, with less than 900 proteins having been experimentally 
verified and accepted. 




Several different experimental methodologies have been used to try and identify 
proteins which belong to the mitochondrial proteome. MitoMiner is a database which 
aims to collate all mitochondrial localization data sets for selected species of 
vertebrates and fungi [29]. The database has a large amount of experimental data 
sets such as mass spectrometry protein localisation from over 30 different studies 
and green fluorescent tagging (GFP) data sets from multiple species. Large scale 
experimental studies of protein localisation such as the Human Protein Atlas (HPA) 
antibody staining project [30] and the dynamic organellar mapping of HeLa cells [31] 
are included in MitoMiner. The database also includes computational data sets such 
as Gene Ontology (GO) annotations [32] and mitochondrial targeting sequence 
predictions from multiple different programs, such as MitoFates [33]. With the 
abundance of available protein localisation studies there have been multiple 
attempts to predict the human mitochondrial proteome. Several older attempts such 
as MitoProteome [34] and MitoP2 [35] are no longer available. MitoCarta [36], and its 
successor MitoCarta 2.0 [37], are the most accredited mitochondrial proteomes. 
 
1.3. Mitochondrial disease 
The numerous essential functions of the mitochondria mean that even the smallest 
change in mitochondrial homeostasis can have a drastic effect on humans. 
Mitochondrial dysfunction is associated with many serious inborn and late onset 
neurological and physiological diseases. For example, Parkinson’s disease, a 
generally late onset neurodegenerative disease, has been shown to have a 
complicated relationship with mitochondrial dysfunction [38]. Research in the 1990’s 
identified a link between the mitochondria and Parkinson’s when drug-induced 
complex I inhibition in non-human primates caused a similar phenotype to patients 
suffering from Parkinson’s disease [39,40]. PINK1 and parkin, two of the major 
Parkinson’s associated proteins in humans, have been shown to interact in a 
pathway related to mitochondrial quality control. PINK1, which localises in the 
mitochondria, recruits cytosolic parkin to the outer membrane of damaged 
mitochondria to mediate selective autophagy of the damaged organelles [41]. The 
impairment of either protein leads to the accumulation of dysfunctional mitochondria 




causing neurodegeneration in Parkinson’s disease [42]. However, the complex 
relationship between mitochondria and Parkinson’s disease is still not fully 
understood and is currently a hot topic of research in the field of neurodegenerative 
diseases [43]. 
Patients with inborn mitochondrial dysfunction usually have many serious and often 
fatal symptoms. There are many hallmarks of mitochondrial disease, such as 
apparent maternal inheritance, multiple organs affected, exercise intolerance, and 
the accumulation of lactic acid in the body, but the diagnosis of mitochondrial 
disease is often not straightforward or unrecognised. Due to the intricate network of 
pathways in the mitochondria, the severity of the hallmarks and the clinical 
phenotype of patients varies from patient to patient depending on the type and 
location of the individual’s mutation(s). For example, Maple syrup urine disease 
(MSUD) is caused by a mutation to the branched-chain α-ketoacid dehydrogenase 
complex involved in branched-chain amino acid (BCAA) metabolism [44]. The 
disease has the clinical hallmark of the accumulation of BCAAs in plasma but the 
severity of symptoms ranging from a maple syrup odour in urine to Leigh syndrome, 
a progressive neurodegenerative disorder, is based on which of the complex 
subunits is mutated [45].  The diagnosis of patients with mtDNA mutations can be 
particularly difficult as mitochondrial heteroplasmy has been shown to influence 
clinical phenotype [46].  
 
1.4. Mitochondrial drug safety 
Mitochondrial dysfunction can be drug-induced as mitochondria, the centre of 
metabolism, are highly involved in xenobiotic metabolism. Drug-induced 
mitochondrial dysfunction causes more subtle, but just as serious, symptoms as 
mitochondrial disease. Research over the last 50 years has identified many 
medications that cause mitochondrial dysfunction [47,48]. Mitotoxicity has been 
attributed to certain anti-diabetics [49], anti-inflammatory [50], anticancer [51] and 
anti-epileptic [52] drugs. Despite causing mitotoxicity, many medications are still 
prescribed as treatments as the health benefits of the treatment vastly outweigh the 
side effects of the generally low levels of mitotoxicity. A famous example being 




valproic acid (VPA) which causes hepatotoxicity but remains the world’s most 
prescribed medication for epilepsy and bipolar disorder [53].  
Mitochondria are also the intended targets of many drugs. Cancer cells alter their 
metabolism to promote growth by increasing glucose uptake and promoting 
glycolysis, the conversion of glucose into ATP, known as the Warburg effect [54].  
Potential cancer treatments have been developed which aim to disrupt cellular 
metabolism by inhibiting the ETC of mitochondria in cancer cells to prevent 
uncontrolled proliferation and induce apoptosis [55]. As mitochondria are found in 
almost every eukaryote, drugs have been developed which target the mitochondria 
of invasive and harmful species to humans. These target a wide range of species 
such as parasites [56] which aim to prevent the function of the mitochondria and kill 
off the invasive species. 
Regardless of any drug’s intended target, pharmaceutical companies must screen 
every prospective drug for mitotoxicity early in the drug development process. The 
issue with current methods for screening partial mitotoxicity is that partial mitotoxicity 
does not have a large effect on the healthy animals used for pre-clinical testing, 
resulting in the need for a large amount of animal testing. In addition, the drugs may 
not affect healthy humans during early clinical trials, but severely affect elderly and 
infirm patients who have compromised mitochondrial function. There is therefore a 
need to recognise the signs of even weak mitotoxicity during early phase clinical 
trials and any patient undergoing any form of treatment should be monitored for 
mitochondrial dysfunction as even the most commonly used drugs, such as 













2.1.1. The drug development process 
The cost of developing a new drug which reaches the market is between 92 and 884 
million USD [58]. A major contributor to this huge cost is the high attrition rate at late 
stages of the drug development process. In a study of 812 compounds put forward 
as drug candidates by four major pharmaceutical companies, 390 of those reached 
clinical trials but only two progressed to the final stage, Phase IV [59]. Identification 
of drug candidates begins by high-throughput screening of thousands of compounds 
which go through multiple in vitro assays and optimisations until only a couple of 
candidates remain. Lead candidates are then tested preclinically for safety concerns 
before entering clinical trials [60]. In the study, the reason for the termination of the 
drug development process was given for 605 drugs where 59% of these were 
terminated preclinically [59]. Non-clinical toxicology accounted for the largest number 
of terminations (40%) with 89% of these being at the preclinical stage [59]. An 
increase of 10% in the efficiency of preclinical screening and termination of lead 
candidates which later fail in clinical trials would save an estimated 100 million USD 
in development costs per drug [61]. 
Non-clinical toxicology testing assesses the potential adverse effects caused by a 
drug in humans. Lead compounds which are flagged preclinically for toxicity are 
Chapter 2                                      Metabolic adaptations to mitochondrial dysfunction  
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investigated thoroughly for mitotoxicity due to the severe symptoms associated with 
mitochondrial dysfunction. Drugs are initially tested in vitro in cells grown in 
galactose to promote OXPHOS activity [62], and in isolated mitochondria. 
Mitochondrial function is assessed by various assays such as monitoring oxygen 
consumption, investigating membrane potential and investigating mtDNA replication 
or depletion [63]. Candidates which pass safety standards are then tested in vivo in 
healthy rats or mice to assess the potential dose response in humans. The animals 
are monitored for the clinical signs of mitotoxicity such as changes in core body 
temperature, irregular breathing patterns and changes in behaviour. The dose 
response of suspected mitotoxic drugs are assessed in vivo using various assays 
such as measuring arterial blood gas levels of O2 and CO2 and measuring 
lactate/pyruvate ratios of plasma. Risk assessment of the drug is performed based 
on the in vitro and in vivo screenings which decides on the advancement or 
termination of the drug development process.  
 
2.1.2. The problems with current methods 
Early identification of mitotoxicity and subsequent risk assessment is a critical step in 
the drug development process and seeks to help reduce the high attrition rate and 
costing. However, difficulties in correlating the in vitro and in vivo results make 
mitotoxicity screening an expensive and time-consuming process. Drug-induced 
mitochondrial dysfunction is generally centered around the high energy tissues, such 
as brain and liver, but drug concentration and activity varies between tissues. 
Mitochondria are also believed to have an underlying reserve capacity allowing them 
to adapt to certain stresses in vivo [64]. These in vivo features are absent in vitro 
causing the discrepancy between in vitro and in vivo responses, resulting in the need 
for extensive in vivo studies that are both expensive and a potentially avoidable use 
of animal models. Current in vivo assays are performed on isolated liver 
mitochondria taken from the treated animals, but the process of isolating the 
mitochondria from the liver can wash away the effect of the drug. These issues, 
compounded by the general lack of understanding of mitochondrial adaptations 
under specific stresses, make the current methods for mitotoxicity screening both 
Chapter 2                                      Metabolic adaptations to mitochondrial dysfunction  
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inefficient and inaccurate at identifying the precise cause of any drug-induced 
mitochondrial dysfunction.  
Mitochondrial reserve capacity is the amount of additional ATP that can be produced 
by OXPHOS when the energy demands of a cell are suddenly increased. Cells in a 
natural state of high energy demand, such as those under metabolic stress, will have 
a reduced mitochondrial reserve capacity. The age-related decline in OXPHOS 
efficiency has been implied to cause an age-related decline in mitochondrial reserve 
capacity [65]. Therefore, the healthy, young rats or mice used for the in vivo testing 
have a relatively high mitochondrial reserve capacity. This causes a steep dose-
response curve where only a minor difference in the concentration of an 
administered drug can be the difference between no clinical signs of mitotoxicity and 
animal fatality; the clinical signs of mild mitotoxicity are non-existent. However, the 
intended human recipients of the drug will likely have a reduced mitochondrial 
reserve capacity due to age and cellular stress from illness. The mild mitotoxicity 
which is largely undetectable in the animal models may cause clinical effects on the 
intended patients. 
The first step towards solving both these issues is furthering our understanding of 
the metabolic adaptations which occur during mitochondrial dysfunction, both in 
general and in relation to specific types of mitochondrial dysfunction.  
 
2.1.3. Biomarkers of mitochondrial dysfunction 
A biomarker (“biological marker”) is a molecule found in tissue or bodily fluids which 
indicates either a normal or abnormal process of a disease or condition [66]. They 
are generally measured in readily available bodily fluids, such as blood or urine, to 
detect or monitor sub-clinical disease, and to monitor the response to treatments. 
For example, prostate cancer can be detected and monitored by the level of 
prostate-specific-antigen (PSA) found in blood plasma [67]. The identification of a 
plasma biomarker of mitochondrial dysfunction would enable the identification of 
mitotoxicity at an early stage of drug development using a relatively non-invasive 
technique, which is both inexpensive and would not require a large number of animal 
Chapter 2                                      Metabolic adaptations to mitochondrial dysfunction  
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models. The biomarker could be used to monitor the level of mitotoxicity to 
investigate the dose-response curve without the need for clinical phenotypes and 
enable better risk assessment of a drug’s potential use in humans. In addition, any 
patient undergoing treatment with a drug believed to cause mitotoxicity can be 
monitored to ensure that damaging levels of mitochondrial dysfunction are avoided. 
This is especially important for patients taking a concoction of medications with an 
already reduced mitochondrial reserve capacity. 
Advances in technology and experimental procedures over the last decade has 
enabled the rise of ‘omic’ based studies; genomics, transcriptomics, proteomics and 
metabolomics [68]. Metabolomics focuses on the measurement of metabolites, the 
small molecules involved in metabolism, most commonly performed by either mass 
spectrometry [69] or nuclear magnetic resonance (NMR) spectroscopy [70]. The 
measurement of every metabolite, known as the metabolome, generates a global 
metabolic profile of a cell, tissue or organism under a certain set of conditions. The 
metabolome is sensitive to changes in the transcriptome and proteome as it is the 
final downstream product of gene transcription and is the closest measurable level to 
biological phenotype. As such, metabolomics has emerged as a leading method of 
biomarker identification [71] for many diseases and conditions such as cancer [72].  
Metabolomics only gives a snapshot of a system’s metabolic activity as metabolic 
profiles are highly dynamic. The human metabolome is expected to be more than 
19,000 metabolites [73]. For biomarker identification, the size of the metabolome and 
the dynamic nature of metabolic profiles necessitates a large set of metabolites to be 
measured to accurately infer metabolic activity. The approach of measuring the 
largest possible subset of the metabolome in an unbiased way to investigate 
metabolic activity is often referred to as untargeted metabolomics [74]. Measuring 
the metabolic profile at different time points is also essential to unravelling the 
dynamic nature of metabolism. Once the metabolic activity of a system under certain 
conditions is understood, metabolites which are intricately involved in the metabolic 
activity or adaptions can be identified and used as biomarkers.  
Recent attempts to identify metabolic biomarkers of mitochondrial dysfunction was 
performed using small scale untargeted metabolomics on patients with a monogenic 
form of Leigh syndrome [75]. Leigh syndrome is a severe neurological disease 
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caused by a loss of function mutation in LRPPRC which results in a decline in 
mitochondrial respiration and has many shared hallmarks with mitochondrial 
disease. The study measured a relatively small subset of metabolites (n = 143) in a 
cohort of patients and compared them to age matched controls. The study identified 
many significant metabolites using simple statistical methods. The most notable 
biomarkers included increased plasma levels of β-hydroxybutyrate, a ketone body 
used as an alternative fuel source, lactate, the most common hallmark of 
mitochondrial disease, pyruvate, an intermediate in glycolysis, and various fatty acid 
carnitines, the molecular form of fatty acids when they are being transported into 
cells for metabolism. The small subset of measured metabolites and the relatively 
unknown mechanism causing the mitochondrial dysfunction prevents the study from 
being utilized in trying to understand the precise metabolic adaptations which occur 
during mitochondrial disease. Furthering our understanding of the metabolic 
adaptations which occur during mitochondrial dysfunction by performing large scale 
untargeted metabolomics in other disease models will help filter out the list of 
significant metabolites identified in this study and potentially lead to biomarkers for 
mitochondrial disease which has been experimentally verified in humans.   
 
2.1.4. Analysis of metabolomics data sets 
Untargeted metabolomics produces large data sets which are usually compared with 
a control group. Statistical analysis of the comparison identifies the metabolites that 
are significantly different between the two groups. The large data sets are pre-
processed before statistical analysis to mitigate the large difference in concentration 
level between different metabolites which aims to improve the biological 
interpretability of the data [76]. The most common methods for identifying 
significantly different metabolites are the dimensionality reducing techniques of 
principle component analysis (PCA) and partial least squared discriminant analysis 
(PLS-DA) [77].  
PLS-DA is the categorial adaptation of regression modelling that has become the 
primary method for metabolomics analysis in recent years. For example, PLS-DA 
was used to analyse metabolomic data collected from patients suffering with 
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Parkinson’s disease [78] and esophageal cancer [79] with the aim of identifying 
biomarkers. It is a supervised machine learning technique that generates a model 
that can classify unknown samples. The classification power of PLS-DA models is no 
better than simpler methods, but PLS-DA comes with the added ability to quantitively 
identify the important variables [80]. A variance importance in projection (VIP) score 
is assigned to each variable which represents the variable’s classification power. The 
assignment of VIP scores makes PLS-DA a useful tool in exploratory analysis and, in 
the case of metabolomics, enables the identification of significant metabolites. 
However, metabolomics data sets generally have a large fold difference between the 
number of samples (n) and the number of variables (metabolites). This has been 
identified as an issue for PLS-DA leading to high error rates and the unreliable 
classification of samples [81]. Therefore, PLS-DA should be used in conjunction with 
other methods when performing exploratory analysis on metabolomics data sets 
[80]. 
Support vector machines (SVMs) are a supervised machine learning algorithm [82] 
which do not suffer from the same drawbacks as PLS-DA. A comparative study on 
the predictive power of PLS-DA versus SVMs identified SVMs as the superior choice 
for metabolomics studies [83]. Exploratory analysis can be performed using 
recursive feature elimination (RFE) with SVMs. Recursive feature elimination (RFE) 
is used when generating SVM models to determine the minimal set of features, i.e. 
metabolites, of the data set that generate the most accurate SVM model based on 
sample classification. The algorithm starts by generating a classification model for 
each individual metabolite. The metabolite that generates the best model, based on 
classification accuracy, is kept and its accuracy is stored. The algorithm then 
generates a new model using the best performing metabolite combined with one 
additional metabolite, for every pairwise combination of metabolites. The two best 
performing metabolites are kept, and their accuracy is stored. The algorithm 
continues this recursive process of adding a single metabolite to the previous set of 
best performing metabolites until all metabolites are added. Assessing how 
classification accuracy changes as metabolites are added identifies the smallest 
subset of metabolites that generate the most accurate classification model, along 
with a ranking of the metabolites based on their classification power. In data sets 
where sample numbers are small, and variables have high variance, SVM-RFE had 
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great success in identifying the important variables for classification, making it the 
superior tool for biomarker identification in metabolomics studies [84]. Recent studies 
have used SVMs to explore the metabolomics of patients with ovarian cancer [85] 
and celiac disease [86]. 
Both PLS-DA and SVMs can be used in conjuncture with cross-validation which 
helps to avoid model overfitting, where a model is too tightly tuned to a data set 
causing the model to predict poorly on new unclassified data. Cross-validation 
involves partitioning the data into two sets – a training set and a validation set – and 
training the machine learning algorithm with the training set whilst using the 
validation set to assess model performance. The process of partitioning and 
creating/assessing a model is repeated multiple times depending on which type of 
cross-validation method is used. The average accuracy of each partition is then used 
to assess the overall model performance, known as cross-validation accuracy. 
The combination of PLS-DA, SVM-RFE and other simpler statistical methods (such 
as hypothesis testing and PCA) should be used when performing exploratory 
analysis on metabolomics data. By combining the results of each method, the most 
robust subset of significant metabolites can be identified and examined for potential 
biomarkers.  
 
2.1.5. Chapter summary 
In this chapter, I describe the data pre-processing and statistical analysis performed 
on a metabolomics data set collected from a study on drug-induced mitochondrial 
complex III inhibition in rats. The identified metabolic adaptations are discussed in 
the context of mitochondrial dysfunction, and potential biomarkers for both mild and 
complete mitochondrial dysfunction are identified and discussed. 
 




2.2.1. Metabolomics study outline 
GSK932121A is a potent inhibitor of mitochondrial complex III in Plasmodium 
falciparum and began development as an antimalarial drug. However, the drug 
showed an affinity for human mitochondrial complex III and thus mitotoxicity [87], 
causing its development to be halted. Subsequently, GSK932121A was used in a 
large-scale metabolomics study focused on investigating mitochondrial dysfunction 
in vivo. The study used twenty female rats separated into three groups: a control 
group of six rats; a ‘low dose’ group of seven rats; and a ‘high dose’ group of seven 
rats. The low dose group were administered 12.5 mg/kg, known to be non-lethal but 
cause mitotoxicity, and the high dose group were administered 50 mg/kg, known to 
be lethal if the animals were left for greater than four hours, both via intraperitoneal 
injection to the body cavity. Pre-dose plasma samples were taken from all rats, 
followed by plasma samples collected at 0.5, 1, 2 and 4 hours after dosage. Liver 
samples were collected as a terminal procedure at 4 hours, giving a total of 6 
samples collected for each rat. All experiments and sample collections were 
performed by GlaxoSmithKline, and Metabolon, Inc. generated the metabolomics 
data for each sample in the form of peak intensities using four different techniques: 
UPLC-MS/MS with negative ion mode electrospray ionization, UPLC-MS/MS with 
positive ion mode electrospray ionization, LC polar platform and GC-MS. All animal 
studies were ethically reviewed and carried out in accordance with Animals 
(Scientific Procedures) Act 1986 and the GSK Policy on the Care, Welfare and 
Treatment of Animals. 
 
2.2.2. Data set quality control 
Administration of the drug by intraperitoneal injection to the body cavity can result in 
‘gut dosing’ which causes the drug to remain within the gut of the animal and greatly 
reduces the exposure of the animal’s high energy organs to the drug. The terminal 
liver samples were all tested for drug concentration where samples with abnormally 
low drug concentration were removed from the study. 
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Metabolites with greater than 35% of measurements missing (over case and control) 
were removed from the data set as inference would be weak over such a small 
sample set. Missing measurements for the remaining metabolites were imputed from 
the known measurements using the nearest neighbour algorithm, performed using 
MATLAB [88]. Imputation of missing values was necessary as support vector 
classification models cannot deal with empty values. Z-scores of every metabolite in 
each sample were generated using standardisation over the complete data set 
(control, low dose and high dose samples) to evaluate class separation and identify 
potential outliers, performed using R [89].  
 
2.2.3. Statistical methods 
Principle component analysis was performed after normalization (mean of zero and 
standard deviation of one) of the data sets to perform initial investigation of sample 
separation using R. The large metabolomics data set was then separated into a 
control and low dose data set and a control and high dose data set for subsequent 
analyses. Initial exploration of the two data sets was done by hypothesis testing to 
begin identifying which metabolites were significantly different between case and 
control. Welch’s two-sample t-test [90] was used to calculate p-values that were then 
corrected for multiple testing using the Benjamini-Hochberg false discovery rate [91] 
(q-values). Both steps were performed on log-transformed data by utilizing the 
Python [92] ‘scipy’ [93] and ‘statsmodels’ [94] packages. All correlation tests 
performed in the study were done using a two-tailed Spearman’s rank-order 
correlation test [95] and performed in R. 
 
2.2.4. Machine learning classification models 
For the control and low dose data sets, SVMs were used to generate a support 
vector classification (SVC) model, which predicted the class membership of each 
data sample. In this study, a linear kernel was used with RFE and cross-validation to 
generate SVC models using a c-parameter of 0.01 and squared hinge loss [96]. As 
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SVMs were used in combination with other analytical methods, square hinge loss 
was used to avoid attaining a sparse solution. Various values of c-parameter were 
explored, only the extremities made a large difference on the accuracies of the 
model with 0.01 providing the best accuracy with a reasonably small vector margin.  
L2 regularisation was used to address the collinearity problem of metabolites and 
reduce overfitting. The SVC models were generated using stratified 6-fold cross 
validation, meaning each cross-validation step withheld one control sample and one 
or two low dose samples. Seven SVC models were trained for each of the 6 time 
points to ensure that every possible combination of control and low dose sample was 
used in the validation set at least once during cross-validation. The models were 
generated on data standardised to a mean of zero and standard deviation of one. 
The methods were implemented in Python using the ‘sklearn’ package [97]. 
A single PLS-DA model was generated for each of the 6 time points in the control 
and low dose data set. PLS-DA models and VIP scores were generated using 
MATLAB v8.6.0 and PLS-Toolbox v8.1 [98]. All data were standardised to a mean of 
zero and standard deviation of one and leave-one-out cross-validation, where one 





significance:       
1 point 
Medium 
significance:           
2 points 
High 




0.3 ≥ x > 0.15 0.15 ≥ x > 0.10 x ≤ 0.10 
SVM RFECV: 
Mean rank 
200 ≥ x > 100 100 ≥ x > 25 x ≤ 25 
PLS-DA: VIP 
score 
2.0 ≤ x < 2.5 2.5 ≤ x < 3.5 x ≥ 3.5 
Table 2.1. The criteria for consistency points for each of the three analyses 
performed in this study based on different significance levels. 
Chapter 2                                      Metabolic adaptations to mitochondrial dysfunction  
19 
 
2.2.5. Metabolomics network visualisation 
The network representation of central metabolism was generated in Cytoscape [99] 
with metabolites as the nodes and reactions as the edges. All information was taken 
from KEGG [100] and utilized the KEGG reaction and compound IDs. The colour of a 
node represents the fold-change of the metabolite between case and control, red 
being increased (higher in case than control) and blue decreased (lower in case than 
control). Nodes coloured in white were measured but found not significantly different, 
whilst grey nodes were not measured at all. The size of the node was proportional to 
the metabolites consistency level between control and low dose based on a 
cumulative scoring system evaluated over the three analyses performed in this study 
(Table 2.1). A higher score meant greater consistency and a larger node size. 
Metabolites were placed into consistency levels ranging from 1 to 9, with 9 being the 
highest consistency which indicated that all three analyses identified the metabolite 
as highly significant.  
 
2.3. Results 
2.3.1. Clustering of samples 
The mitochondrial drug exposure level of all the rats administered the lower dosage 
of 12mg/kg was relatively uniform (Figure 2.1a) aside from two samples which had 
abnormally low concentrations of the drug and thus removed from further analysis. 
Two of the high dose samples administered 50mg/kg, sample 18 and 20, had 
exposure levels like that of the low dose sample and clustered with the low dose 
samples based on hierarchical clustering (Figure 2.1b). These two samples were 
therefore moved into the low dose group leaving six control rats, seven low dose rats 
and only four high dose rats. The rest of the high dose samples showed a larger 
variation in exposure levels, with sample 17 having a particularly extreme exposure 
level. 
Before analysis the liver and plasma data sets were put through quality controls and 
imputation, resulting in the liver subset consisting of 844 measured metabolites and 
the plasma subset consisting of 787 measured metabolites. The extremity of sample 
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17 was reflective in the plasma 4-hour metabolite Z-scores where it showed the 
greatest variance among the samples, although this was not as obvious for the liver 
4-hour metabolites (Figure 2.2). All other samples, including the controls, had a 
larger variance in liver than plasma at 4 hours, with the low dose group having the 
lowest variance overall. None of the samples appeared to be outliers so all 
remaining samples were used for further analysis.  
For the plasma predose, 0.5-hour and 1-hour samples, none of the three groups 
showed any meaningful separation on a PCA plot (Figure 2.3). At two hours, the 
control group clustered away from the two dosage groups, which both clustered 
together showing no clear separation. The plasma 4-hour samples had clear 
separation between each of the three groups along with relatively small confidence 
ellipses. The liver 4-hour samples had a modest amount of separation where the 
high dose samples were the most differentiable from the rest, but the low dose and 
control samples clustered near to each other.  
2.3.2. Identifying statistically significant biomarkers by hypothesis testing 
The full results of all analyses, along with each metabolite’s assigned consistency 
level can be found in Supplementary File 2.1. In both the control vs. low dose and 
control vs. high dose data set, hypothesis testing for the plasma predose, 0.5-hour 
and 1-hour time points identified almost no metabolites as significantly different after 
adjusting for multiple testing, using a very lenient significance threshold of q = 0.3 
(Figure 2.4, Table 2.2). In contrast, the plasma 2-hour and 4-hour time points had 
many metabolites found to be significantly different in both data sets. For the control 
vs low dose data set, plasma 2-hours had 202 metabolites with a q-value less than 
or equal to 0.3 while plasma 4-hours had 192 metabolites. The control vs high dose 
data set identified 174 metabolites at plasma 2-hours and 351 metabolites at plasma 
4-hours. In the liver 4-hour samples, the control vs low dose data set only identified 4 
metabolites as significant whilst the control vs high dose data set had 192 
metabolites significantly different between case and control. A lenient value for 
significance was selected as a larger subset of metabolites was needed to 
understand the metabolic adaptations occurring due to mitochondrial dysfunction, 
allowing for the identification of a more biologically relevant biomarker. The higher 
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false discovery rate was counteracted by using the results of the hypothesis testing 





Figure 2.2. Box-plots of metabolite z-scores for each sample. 
Figure 2.1. A) Bar chart to show the measured drug exposure level in each sample. 
B) Hierarchical clustering of the samples at the plasma 4 hour time point. 
 





Figure 2.3. Principle component analysis (PCA) plots for each of the time points. 
Each ellipsoid represents the group’s 95% confidence interval.  
Figure 2.4. Violin plots of the q-values for all metabolites at each time point for both 
data sets, control vs low dose and control vs high dose. The lines on each violin 
indicate the upper quartile, mean and lower quartile. The dotted line indicates the 
threshold for significance used, q = 0.3. 











2.3.3. Identifying statistically significant biomarkers by support vector machine 
(SVM) recursive feature elimination with cross validation (RFECV) 
Seven SVM models for classification were generated at each time point in the control 
vs. low dose data set. A generalized additive model, a type of generalized linear 
model, was fit to each of the time points using the cross-validation accuracy of the 
seven models at every RFECV increment, shown in Figure 2.5. The cross-validation 
accuracies of the plasma predose, 0.5-hour and 1-hour time points remained below 
75% accuracy throughout the RFECV process. In combination with the PCA and 
hypothesis testing results, these three time points were found to be not significantly 
different between case and control and were discarded from further analysis.  
The remaining three time points consistently achieved greater than 75% cross-
validation accuracy, with the plasma 2-hour and 4-hour models achieving over 85% 
accuracy. The RFECV process ranked each metabolite based on its classification 
power, a lower rank indicating higher classification power. These values were 
averaged over the seven SVM models per time point resulting in 107 metabolites 
Dosage time point Low dose High dose 
Plasma pre-dose 0 0 
Plasma 0.5 hour 0 8 
Plasma 1 hour 3 3 
Plasma 2 hour 202 174 
Plasma 4 hour 192 351 
Liver 4 hour 4 192 
Table 2.2. The number of metabolites for each time point which were identified as 
significantly different between case and control based on hypothesis testing (q ≤ 0.3).  
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having a mean rank less than or equal to 100 at plasma 2-hours, 106 for plasma 4-
hours and 134 for liver 4-hours. Machine learning models could not be generated for 
the control and high dose data set as the number of high dose samples (n = 4) was 
too small to ensure the reliability of the models.  
2.3.4. Identifying statistically significant biomarkers by partial least squares 
discriminant analysis (PLS-DA) 
PLS-DA models were generated for the plasma 2-hour, plasma 4-hour and liver 4-
hour time points for the control vs. low dose data set. All three of the models were 
generated using two latent variables and resulted in clear separation of the two 
groups (Figure 2.6a). Both the plasma 2-hour and plasma 4-hour models had a Root 
Mean Squared Error Cross Validation (RMSECV) of less than 0.3 along with an R2 
greater than 0.67, indicating that both were good models for classification with 
minimal overfitting [101]. The liver 4-hour model had an RMSECV of 0.41 along with 
an R2 of 0.33 which does not indicate a particularly good model for classification. 
Figure 2.5. Cross-validation accuracies of the support vector classification models 
generated for each time point during the recursive feature elimination process. Each line 
represents a generalized additive model fit using the cross-validation accuracies of the 
seven SVC generated for each time point. 
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However, this coincides with the results of both the SVM and hypothesis testing 
indicating that the liver 4-hour time point was only marginally significantly different 
between case and control. In spite of this result, the model was kept for further 
analysis. 
VIP scores for every metabolite were taken from each of the models, a metabolite 
with a VIP score greater than 1 had a significant amount of classification power, with 
a higher score meaning higher classification power (Figure 2.6b). The plasma 2-hour 
model identified 299 metabolites as significant (VIP ≥ 1), with 130 of these being 
highly significant (VIP ≥ 2). In the plasma 4-hour model, 306 metabolites were 
significant with 122 of these being highly significant, whilst the liver 4-hour model had 
301 metabolites significant with 132 of these being highly significant. 
Figure 2.6. A) Latent variable (LV) plots of the PLS-DA models generated for the 
plasma 2-hour, plasma 4-hour and liver 4-hour time points. B) Violin plots of the VIP 
scores for each of the PLS-DA models. The lines on each violin indicate the upper 
quartile, mean and lower quartile.  




2.3.5. Identifying a set of biomarkers for mild mitochondrial dysfunction  
Using a VIP threshold of 1 at each time point identified a subset of metabolites found 
significantly different between the control and low dose samples which, along with 
their fold change, could have been used to interpret the metabolic adaptations 
occurring due to mild mitochondrial dysfunction. However, due to the problems with 
PLS-DA, this choice of threshold was assessed by comparing the results of the PLS-
DA modelling with the hypothesis testing and RFECV results. The cross comparison 
between the number of metabolites found significant for each of the methods is 
shown in Figure 2.7. 
Figure 2.7. Venn diagrams showing the number of significant metabolites identified by 
each method for the low dose rats. PLS-DA with VIP ≥ 2.0, SVM-RFE with mean rank 
≤ 200 and hypothesis testing with q-value ≤ 0.3.  
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Figure 2.8a shows each metabolite’s VIP score plotted against its q-value from 
hypothesis testing, along with a fitted generalized additive model. Spearman’s rank-
order correlation identified significant correlation between these two results for all the 
time points (plasma 2-hour: Rho = -0.95, plasma 4-hour: Rho = -0.95, liver 4-hour: 
Rho = -0.83). Based on the generalized additive models, a VIP score of 1 
corresponded to a q-value of around 0.5 in the plasma time points and 0.85 in the 
liver time point, which were extremely high. If the subset of metabolites was selected 
based on these q-values, the subset would be riddled with false positive results. The 
q-values reduced quickly as the VIP scores increased, with a VIP score of 2 being 
much closer to the 0.3 q-value significance threshold used earlier in the study. The 
higher q-values present in the liver 4-hour time point were accepted under the 
assumption that this time point was only minorly significantly different between 
control and low dose.  
Figure 2.8b shows similar analysis for metabolite VIP scores and metabolite mean 
RFECV rank, along with its fold-change difference in low dose compared to control. 
Significant correlation was found between metabolite VIP score and mean RFECV 
rank for all three time points (plasma 2-hour: Rho = -0.84, plasma 4-hour: Rho = -
0.85, liver 4-hour: Rho = -0.81). The plot showed that, compared to metabolites with 
a VIP score of 1, metabolites with a VIP score of 2 had on average a much lower 
mean rank and larger fold-change difference. 
Both these results indicated that a VIP threshold of 1 would not be strict enough and 
would result in a potentially large number of false positives. This in turn would make 
the interpretation of the metabolite adaptations caused by mild mitochondrial 
dysfunction particularly difficult, leading to the identification of incorrect biomarkers. 
The threshold for metabolite significance was thus set at a VIP score of 2. This 
generated a subset of 130 metabolites for plasma 2-hours, 122 metabolites for 
plasma 4-hours and 132 metabolites for liver 4-hours. A summary of the statistics for 
each of these significant metabolites can be found in Appendix I: Table 1-3. 
The consistency of these metabolites was evaluated based on each of the three 
analyses performed and ranked using a cumulative points system (Table 2.1). The 
plasma 2-hour time point had a total of 63 metabolites placed into level 5 or greater 
whilst the plasma 4-hour time point had 60 metabolites (Figure 2.9). The liver 4-hour 
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time point had 41 metabolites in level 5 or greater, although none of these were 
greater than level 7. 
The significant metabolite subsets for each time point were used to generate network 
heatmaps (Figure 2.10, Supplementary File 2.2). The heatmap identified multiple 
pathways which had clusters of significant metabolites; purine metabolism, 
pyrimidine metabolism, glutathione metabolism, ketogenesis and 
glucose/carbohydrate metabolism.  
 
Figure 2.8. A) Scatter plot of a metabolite’s q-value against its VIP score with a fitted 
generalized additive model indicated by the line, along with its confidence interval. B) 
Volcano plots of a metabolite’s VIP score against its fold-change difference in low dose 
compared to control. Each metabolite is coloured by its RFECV mean rank. 
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2.3.6. Identifying a set of biomarkers for complete mitochondrial dysfunction 
The analysis of the control vs low dose data set identified a set of potential 
biomarkers for mild mitochondrial dysfunction. A biomarker for mild mitochondrial 
dysfunction can only be a biomarker for complete mitochondrial dysfunction if it is 
also a biomarker for fatal levels of mitochondrial dysfunction, such as the high dose 
samples used in this study. In addition, the level of the metabolite must be correlated 
with the exposure level of the drug to enable the identification of the level of 
mitochondrial dysfunction occurring. For each metabolite belonging to each of the 
significant metabolite subsets, the correlation was calculated between the 
metabolite’s measured level and the drug exposure level of the sample that it was 
collected from, across both the low and high dose samples. 
Figure 2.11a shows each metabolite’s calculated Rho value, along with its respective 
control vs high dose q-value. Metabolites with a q-value less than 0.15 and an 
absolute Rho value greater than 0.5 were highlighted in red, which were the potential 
biomarkers for complete mitochondrial dysfunction. The plasma 2-hour time point 
only had two metabolites which fit this criterion, with only one of those having a 
relatively high consistency level in the control vs low dose data set (Figure 2.11b). 
For plasma 4-hours, there were 20 metabolites which fit the criteria, with five of these 
belonging to the highest consistency level in control vs low dose. Finally, the liver 4-
hour time point had 32 metabolites which fit the criteria and 10 of these were in a 
consistency level of 5 or greater. 
Figure 2.9. Bar charts to show the number of metabolites for each biomarker consistency 
level based on the point criteria described in Table 2.1. A higher consistency level 
indicates significance across multiple methods.  




Figure 2.10. A network heatmap representation of the liver significant metabolite 
subset, nodes as metabolites and edges as reactions. Metabolites in red are 
increased in the low dose rats compared to control, blue are decreased whilst white 
are those found not significantly different. Metabolites not measured at all in this study 
were coloured in grey. Node size is proportional to their consistency level.  







Figure 2.11. A) Scatter plots of a metabolite’s control vs high dose q-value against its 
correlation coefficient Rho, which indicates the correlation between the level of the 
metabolite in a sample and the drug exposure level of the sample. Metabolites in red 
meet the criteria for potential biomarkers. B) Bar charts of the control vs. low dose 
consistency levels of the metabolites which meet the criteria for potential biomarkers. 




2.4.1. Tissue dose response 
In multi-tissue organisms, each tissue has different metabolic activity based on its 
role, function and environment. In animals, the highly metabolically active tissues, 
like in the brain and liver, also have relatively high energy demands. This makes 
these tissues particularly susceptible to mitochondrial toxins, and the reason why 
symptoms related to these organs, such as hyperammonemia and 
neurodegeneration, are some of the most common clinical signs of mitochondrial 
dysfunction. This study aims to shed light on the metabolic adaptations which occur 
in a high energy organ, the liver, during mitochondrial dysfunction.  
The low dose administered to the rats was known to be non-lethal. It was therefore 
not unexpected that all three of the analyses performed did not show a large 
significant difference between the low dosed and control rats (Figure 2.3). The minor 
differences were the metabolic responses due to the mild mitochondrial dysfunction 
which were able to cope with the added stress. These responses, despite being 
relatively minor, are of key interest as they could be used to identify mitochondrial 
dysfunction early and shed some insight into the order in which metabolic adaptions 
occur. These reasons ensured the investigation into the low dose liver sample 
despite showing only a minor significant difference between dosed and control. The 
higher dose, known to be lethal if the animals were left for greater than four hours, 
was identified as significantly different between dosed and control in both the PCA 
plot and hypothesis testing. The higher level of mitochondrial dysfunction caused 
huge amounts of metabolic adaptations which were unable to cope with the added 
stress, a likely situation in multiple organs and the major reason for the dose 
lethality.  
The Z-score distribution for the high dose liver samples shows that the metabolite 
levels in the liver do not seem to be an accurate reflection of an organism’s drug 
exposure level and, by extension, mitochondrial dysfunction level (Figure 2.1, 2.2). 
Despite having a largely variable drug exposure level in each sample, particularly 
sample 17, the variance of the Z-scores for each sample does not differ greatly 
within the high dose group. Along with the low significance of the liver low dose 
Chapter 2                                      Metabolic adaptations to mitochondrial dysfunction  
33 
 
samples, this indicates that the adaptations which occur at all levels of 
mitochondrional dysfunction only caused subtle changes in metabolite 
concentrations in the liver, which is most likely caused by the essential functions of 
the tissue, such as converting ammonia into urea, restricting the adaptability of the 
tissue.  
Blood plasma transports many compounds around an organism’s body, including 
metabolites, hormones, waste products and proteins, and contains no mitochondria. 
Therefore, the concentration of metabolites in the plasma reflects the organism 
metabolic state, a cumulative representation of every organ’s metabolic activity. 
Because of this, and the fact that it is easily accessible and in abundance, blood 
plasma is commonly used to monitor diseases such as diabetes. Based on the 
results of this study, blood plasma changes are seen during mitochondrial function 
which indicates that blood plasma can also be used to monitor both mild and fatal 
levels of mitochondrial dysfunction once a biomarker has been identified.  
The distribution of Z-scores for all the dosed rats in the plasma showed a better 
reflection of each rat’s drug exposure level (Figure 2.2). The high dose group had a 
generally larger variance than the low dose group. The high dose group also had a 
larger within group variance which reflected each samples exposure level. This is 
most likely because the plasma metabolite levels reflect the cumulative subtle 
adaptations occurring in each of the organism’s organs during mitochondrial 
dysfunction which are easier to identify in the metabolite concentrations than the 
subtle changes occurring in the liver. These results show that plasma is a viable 
body fluid for detecting and monitoring mitochondrial dysfunction. In addition, based 
on the PCA plot of the plasma four hour samples, it should be possible to distinguish 
between mild and fatal levels of mitochondrial toxicity (Figure 2.3). 
The low dose rats had significantly different plasma metabolite levels two hours after 
dosing. The delay of two hours can be attributed to many things such as the time 
needed for the transportation and accumulation of the drug in the high energy 
organs. Rats belonging to the high dose group showed significantly different plasma 
profiles potentially as early as 0.5 hours after dosing, based on the hypothesis 
testing (Figure 2.4). The difference in response time of the low dose compared to 
high dose suggests that the response time of an organism’s metabolic activity to a 
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known mitotoxin has the potential to be used as an indicator for its toxicity level, and 
that early measuring of biomarkers may be necessary but further exploration of this 
theory is required. 
 
2.4.2. Metabolic adaptations to mild mitochondrial dysfunction  
The metabolomics data set generated for this study measured 844 metabolites in 
each plasma sample, over five time points, and 787 metabolites in the terminal liver 
sample which, in comparison to most metabolomics studies, would be considered a 
large and comprehensive data set. However, due to the huge size of the human 
metabolome and its dynamic nature, the interpretation of metabolomics data is 
difficult and can be ambiguous. The measuring of a metabolic profile at a single point 
in time acts as a snapshot of an organism’s metabolic activity. Metabolic profiles are 
extremely dynamic so multiple snapshots would be required to accurately identify the 
precise metabolic changes occurring over time. In addition, changes in metabolite 
concentrations between case and control do not have a clearly defined translation 
into changes in pathway activity between case and control. For example, a 
metabolite which is increased in case compared to control could be due to either an 
increase in upstream pathway activity or a decrease in downstream pathway activity. 
Therefore, the results of the analysis performed on this data set should be 
considered only the first step in elucidating the metabolic adaptations occurring in 
mild mitochondrial dysfunction.  
The significant metabolite subsets for each time point contained around 15% of the 
total measured metabolites. This subset could have been expanded, and a larger set 
would allow for better interpretation for metabolic activity, by selecting a more lenient 
VIP score threshold. However, this would be a trade off with potentially adding many 
false positives which would only add greater uncertainty to an already difficult 
situation to interpret (Figure 2.8). The subsets are large enough to enable the 
identification of pathways altered in the low dose rats compared to controls. The 
potential reasoning for the pathway changes, along with any problems associated 
with the altered activity, can be hypothesised and the problems associated with the 
perturbation discussed. The complete significant metabolite subsets for each 
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sample, classified into their primary pathways, can be found in Supplementary File 
2.3. A small portion of each of the subsets contained metabolites which are either 
unknown (labelled as ‘X’) or metabolites which are externally related, such as those 
related to diet. These metabolites provided no insight into the metabolic adaptations 
occurring and were subsequently ignored. 
Current understanding of mitochondrial function and the network of pathways 
involved in oxidative phosphorylation (OXPHOS), the main pathway for ATP 
generation in mitochondria, leads to expected perturbations in certain pathways 
during mitochondrial dysfunction. The inhibition of OXPHOS causes a lack of ATP 
production which must be compensated for by the other major ATP producing 
pathways, which includes glycolysis, fatty acid β-oxidation and amino acid 
catabolism (Figure 2.12). Each of these pathways generates ATP by feeding the 
tricarboxylic acid (TCA) cycle and are expected to have increased activity during 
mitochondrial dysfunction. A second major effect of OXPHOS dysfunction is on the 
NAD/NADH ratio as NADH builds ups. Changes in the NAD/NADH ratio can have 
widespread metabolic implications as it impacts many enzymes dependent upon 
NAD or NADH, e.g. dehydrogenases. 
Glycolytic metabolism 
Glycolysis is the conversion of sugars, such as glucose or fructose, into pyruvate 
which generates two ATP molecules per sugar and feeds the TCA cycle via acetyl-
CoA. The pathway is considered a faster, but less efficient production of ATP than 
OXPHOS and is expected to have increased activity during mitochondrial 
dysfunction. The liver significant subset contained 12 different metabolites involved 
in glycolysis, including a decrease in multiple sugars such as glucose, fructose and 
mannose, and an increase in the downstream metabolite phosphoenolpyruvate 
(PEP). These changes are consistent with an increase in glycolysis in the liver during 
mitochondrial dysfunction. Both plasma subsets contained only two metabolites 
involved in glycolysis, with only mannose being part of both subsets. The lack of 
glycolytic metabolites in the plasma indicates that increased glycolysis may not be 
detectable in the plasma during mild mitochondrial dysfunction. Mannose, a sugar 
monomer which can be converted into glucose, was increased at both plasma time 
points, the opposite to its measurement in liver. Mannose metabolism is heavily 
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involved in glycosylation, a post-translation modification. A system under increased 
stress such as mitochondrial dysfunction will undergo many adaptations which could 
potentially require an increased amount of post-translational modifications, a 
potential reason for the increased levels of mannose in plasma during mitochondrial 
dysfunction. 
 
Fatty acid β-oxidation 
Fatty acid β-oxidation is the breakdown of fatty acids into acetyl-CoA to feed the TCA 
cycle. Although no ATP is directly produced during this process, the pathway is 
expected to have increased activity during mitochondrial dysfunction to feed the TCA 
cycle and to regenerate OXPHOS electron donors, NADH and FADH2, from their 
reduced forms. All three time point subsets had many metabolites which are involved 
in β-oxidation, the plasma 2 hour subset had 20 metabolites, the plasma 4 hour 
subset had 11 metabolites and the liver 4 hour subset had 7 metabolites 
Figure 2.12. Overview of the citric acid cycle and the interactions with glycolysis, 
fatty acid β-oxidation and various amino acid metabolism pathways. Red 
pathways have increased levels of intermediates in the plasma and liver during 
mild mitochondrial dysfunction whilst blue pathways have decreased levels.  
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(Supplementary File 2.3). Most of these metabolites were fatty acid chains of varying 
length, all bar one of which were found to be increased at all time points. This is 
consistent with a large increase in the mobility of fatty acids and an increase in fatty 
acid β-oxidation in the liver, behaviour which is expected to occur in most tissues.  
The large representation of fatty acids in the plasma 2 hour subset suggests that an 
increase in fatty acid β-oxidation is one of the immediate responses to mitochondrial 
dysfunction. The smaller set of fatty acids in the plasma 4 hour subset suggests that 
either fatty acid β-oxidation decreases in activity over time or that more extreme 
adaptions occur at later stages of the adaptation process causing other metabolites 
to become more significantly different. The plasma 4 hour subset contained the 
increase of three different 3-hydroxy fatty acids, one of which was also present and 
increased in the plasma 2 hour subset. The accumulation of 3-hydroxy fatty acids in 
plasma is indicative of defects in fatty acid β-oxidation and has been identified in 
patients suffering from glycogen storage disease [102] and shown to mimic long‐
chain 3‐hydroxyacyl‐CoA dehydrogenase deficiency [103], an error in the metabolism 
of long-chain fatty acids. This indicates that erroneous fatty acid β-oxidation was 
occurring somewhere within the organism which may be the reason for the lower 
representation of fatty acids in the plasma 4 hour subset compared to the plasma 2 
hour subset.  
The transportation of long-chain fatty acids across the inner mitochondrial membrane 
for fatty acid β-oxidation requires the carnitine shuttle (Figure 2.13). Fatty acids are 
converted into carnitine-fatty acid complexes in the cytosol, which freely move 
across the outer mitochondrial membrane and get transported across the inner 
mitochondrial membrane by carnitine-acylcarnitine translocase (CACT). The 
complex is then separated into a fatty acid and carnitine in the matrix, where the fatty 
acid enters β-oxidation. Both plasma subsets contained around ten different fatty 
acid carnitines, almost all of which were increased, along with a decrease in 
carnitine. The accumulation of fatty acid carnitines has been identified in the blood 
plasma of patients with fatty acid and branched-chain amino acid disorders [104]. 
Fatty acid carnitines that accumulate in the plasma are a spill over from fatty acid 
transport to tissues, where different tissues have been shown to produce a different 
fatty acid carnitine plasma profile [105]. As the inner mitochondrial membrane is 
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impermeable, an accumulation of fatty acid carnitines in the plasma is most likely the 
result of a defect in CACT, the transport across the inner membrane. In patients with 
CACT deficiency, the accumulation of fatty acid carnitine does occur in the plasma 
and has a high mortality rate [106]. The decrease in carnitine supports the argument 
of a transport defect as carnitine is recycled through the carnitine shuttle process, 
and a blockage in this process would result in carnitine being trapped in the fatty acid 
carnitine complex. The liver subset contained four different carnitine-fatty acids, 
three of which were decreased, which does not clearly indicate that the liver is the 
tissue encountering the carnitine shuttle problem. 
 
Amino acid metabolism 
Various amino acids can be metabolised and fed into the TCA cycle (Figure 2.12). 
The liver subset contained three amino acids which were increased: serine, 
threonine and valine, while alanine and glutamine were decreased. The decrease in 
alanine and glutamine is most likely related to their intricate involvement in the liver’s 
essential functions. Alanine can be directly converted into pyruvate using alanine 
transaminase (ALT), an enzyme which is regularly monitored in patients to test for 
liver function. During mitochondrial dysfunction, an increase in alanine metabolism 
Figure 2.13. Overview of the carnitine shuttle, the method of transporting fatty 
acids from the cytosol into the mitochondrial matrix for fatty acid β-oxidation. 
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will help feed the TCA cycle for ATP production. However, a common hallmark in 
patients with mitochondrial disease is an increase in alanine concentration in the 
plasma, where alanine is produced from pyruvate in the liver and exported to the 
plasma [107]. The contradicting result identified in this study suggests that the 
excretion of alanine, which also comes with lactate and not seen in this study, is an 
adaptation which may only occur during high levels of mitochondrial dysfunction. 
A potential reason for the glutamine deficiency is that glutamine has been implicated 
in maintaining an organism’s acid-base balance [108], where it is released from the 
liver and collected in the kidney during ketosis, the accumulation of ketone bodies in 
the blood. Ketone bodies are molecules produced in the liver from fatty acids which 
are then transported to other organs, particularly the heart and brain, and 
metabolised as an energy source. All three of the subsets had increased level of 3-
hydroxybutyrate, a ketone body, and acetoacetate was increased in the plasma 2 
hour subset, suggesting that ketosis was present during mild mitochondrial 
dysfunction. The decrease in glutamine could also be due to increased 
glutaminolysis metabolism, which is a critical pathway for cells undergoing high 
levels of glycolysis, which is expected during mitochondrial dysfunction [109]. 
Glutamine metabolism was found to be sufficient in maintaining the levels of acetyl-
CoA and oxaloacetate when the mitochondrial pyruvate transporter was inhibited 
[110], making it a relatively efficient pathway for feeding the TCA cycle. 
Serine and threonine are two structurally and functionally similar amino acids, and 
their accumulation in liver could be due to many different reasons (Figure 2.14). 
Serine activity has recently gained much attention in cancer research, where it has 
been established as an important amino acid for cell growth and proliferation [111]. It 
is also increased as part of the remodelling of one-carbon metabolism that occurs 
during mitochondrial dysfunction [112]. The metabolism of serine and threonine in 
the liver is predominantly via their conversion into glycine [113,114]. The conversion 
of serine into glycine produces pyruvate, which can feed the TCA cycle, and the 
produced glycine is used to regenerate NADH from NAD+ in the mitochondria via the 
glycine cleavage system [115]. The NAD/NADH ratio in mitochondria is critical for 
mitochondrial function [116]. The liver subset identified an increase in NAD+, 
indicating a shift in the NAD/NADH ratio and supports the argument that both serine 
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and threonine metabolism, in addition to the glycine cleavage system, are important 
during mitochondrial dysfunction. 
Serine also plays a key role in one-carbon metabolism by acting as a one-carbon 
donor for the tetrahydrofolate (THF) cycle [111], which supports purine and 
pyrimidine nucleoside synthesis. The production of purine and pyrimidine 
nucleosides is necessary for protein synthesis [117]. During times of cellular stress, 
such as mitochondrial dysfunction, many changes in pathway activity are expected 
and requires a large amount of protein synthesis, e.g. increased production of 
glycolytic enzymes and proteins to counter increased oxidative stress. The liver 
significant metabolite subset contained many nucleosides including guanosine and 
cytidine, which were increased, along with an increase in multiple other forms of 
nucleoside such as 7-methylguanine and pseudouridine. This accumulation of 
nucleosides supports the hypothesis of increased protein synthesis during 
mitochondrial dysfunction.  
 
Figure 2.14. Overview of serine and threonine metabolism and their involvement 
in the tetrahydrofolate (THF) cycle, the methionine cycle and the production of 
glutathione (GSH).  
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The THF cycle also supports methionine metabolism and the production of S-
adenosyl methionine (SAM), which is critical for protein methylation, a post-
translational modification. If mitochondrial dysfunction causes an increase in protein 
synthesis, this behaviour will most likely accompany an increase in post-translation 
modifications. The same discussion can be made to rationalise the increase in 
threonine as it has been implicated in the methylation of histones which play an 
important role in gene regulation [118], closely related to protein synthesis.  
Nicotinamide adenine dinucleotide phosphate (NADP+) in its reduced form NADPH, 
can be used in replacement of NADH for certain critical mitochondrial reactions and 
can be converted directly into NADH [119]. The THF cycle has been identified as a 
major regenerator of NADPH from NADP+ [116]. NADPH also has its own critical 
function in maintaining glutathione metabolism [120], important for reducing reactive 
oxygen species (ROS) levels. Minor levels of ROS are produced during normal 
OXPHOS [121], but during mitochondrial dysfunction the levels of ROS are known to 
increase massively due to electron leak [122], which has fatal effects on 
mitochondria, e.g. mtDNA damage. Glutathione (GSH) is one of the most important 
scavengers of ROS, by reacting with free ROS it is converted into glutathione 
disulphide which can be regenerated back into GSH using NADPH. The ratio of 
GSH/GSSG is used as a marker for cellular oxidative stress levels [123]. 
In the liver significant metabolite subset, GSH is decreased along with an increase in 
multiple -glutamyl amino acids. An important metabolite in the cyclical synthesis of 
GSH is 5-oxoproline, which is primarily generated by the degradation of GSH (Figure 
2.15). However, 5-oxoproline can also be generated from the degradation of -
glutamyl amino acids, generating 5-oxoproline and releasing the amino acid. This 
process has been suggested to occur when cysteine levels are limited [124], as 
cysteine is also an important metabolite in the cyclical synthesis of GSH. Multiple -
glutamyl amino acids were decreased in both plasma subsets, with 5-oxoproline 
found decreased at plasma 4 hours which suggests that this activity was occurring 
organism wide resulting in the mass transportation of -glutamyl amino acids around 
the organism. Four -glutamyl amino acids were found increased in the liver whilst -
glutamyl valine was found to be decreased along with an increase in valine. This 
supports the theorem of increased -glutamyl amino acid degradation and identifies a 
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potential -glutamyl amino acid degradation affinity. These facts confirm that during 
mild mitochondrial dysfunction there is a high level of oxidative stress, and that the 
regeneration of NADPH is a critical role of the THF cycle. Furthermore, both serine 
and threonine can be metabolised into cysteine, required for GSH synthesis, via 
cystathionine and α-ketobutyric acid respectively, the latter of which was found 
increased in plasma 4 hours. Therefore, serine and threonine accumulation in liver 
may be related to their involvement in maintaining redox homeostasis during mild 
mitochondrial dysfunction. 
The availability of serine in mitochondria has been implicated in mitochondrial 
dynamics [125]. Serine is a critical metabolite in the production of phosphatidylserine 
(PS). PS, along with phosphatidylcholine (PC) and phosphatidylethanolamine (PE), 
are major components of both mitochondrial membranes [126]. The accumulation of 
fatty acids, which this study has confirmed to be occurring during mild mitochondrial 
dysfunction, has been shown to promote the synthesis of phospholipids [127,128]. 
Phosphatidylserine is produced by the reaction of PC or PE with serine, which are 
Figure 2.15. Overview of glutathione metabolism, biosynthesis and regeneration from 
glutathione disulfide. Purple shows the compensatory mechanism of -glutamyl amino 
acid degradation.   
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themselves produced by choline and ethanolamine. In the liver metabolite subset, 
both choline and CDP-ethanolamine, an intermediate metabolite in PE synthesis, are 
both increased. This evidence suggests that the production of phospholipids occurs 
during mitochondrial dysfunction, most likely as part of the fission/fusion repair 
mechanism in which serine and choline both play a key part which adds to the list of 
potential reasons for the identified serine accumulation. The important functions of 
serine and threonine and their increased levels highlights them both as important 
metabolites to be studied further in the context of mitochondrial dysfunction. 
 
Phospholipids 
Glycerophospholipids are glycerol-based phospholipids, the major component of cell 
membranes [129]. The breakdown of cell membranes occurs during 
neurodegeneration, a common symptom of mitochondrial dysfunction, resulting in 
the accumulation of choline containing metabolites in the brain [130]. All three 
subsets contained a large amount of different glycerophospholipids, with the liver 
having a decreased level of glycerophosphorylcholine and 
glycerophosphorylethanolamine, along with an increase in glycerol-3-phosphate, a 
major component of glycerophospholipids. These indicate the breakdown of cell 
membrane proteins in the liver, with the plasma shuttling glycerophospholipids 
around the body to be potentially broken down in other tissues. The breakdown of 
glycerophospholipids in the liver can be used as a source of choline via the Kennedy 
pathway [131] and ultimately leads to the production of PC [132]. An alteration in 
choline metabolism has been identified as a hallmark of cancer [133], with choline 
metabolites and PC being integral for cell growth and death [134]. This highlights the 
importance of choline metabolism during mitochondrial dysfunction. Moreover, the 
breakdown of glycerophospholipids suggests that serious structural changes to the 
cellular membrane occurs during mild mitochondrial dysfunction. 
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Branched chain amino acids 
Valine, isoleucine and leucine are the branched-chain amino acids (BCAA’s), whose 
metabolism feeds directly into the TCA cycle. BCAA metabolism is one of the amino 
acid metabolism pathways which is activated during exercise [135] and thought to be 
promoted by fatty acid β-oxidation [136], which suggests that BCAA metabolism 
activity is expected to increase during mitochondrial dysfunction. The accumulation 
of BCAA’s has been linked to the inhibition of glycolysis in the heart [137]. Valine 
was identified as increased in the liver, but there was also many other intermediate 
BCAA metabolites which were found increased in both the liver and plasma. In this 
study, the intermediates of BCAA metabolism did not seem to cause inhibition of 
glycolysis. However, almost all the BCAA metabolism intermediates identified in all 
three subsets are biomarkers for a range of different metabolic defects.  
Both 4 hour subsets had 3-hydroxy-2-ethylpropionate increased, the accumulation of 
this metabolite is the hallmark of short/branched-chain acyl-CoA dehydrogenase 
deficiency [138], a defect in isoleucine metabolism. All the subsets also had an 
increase in 3-hydroxy-3-methylglutarate which is only produced by defective 3-
hydroxy-3-methylglutaryl-CoA lyase [139], the final step in leucine degradation which 
catalyses the conversion of 3-hydroxy-3-methylglutaryl-CoA to acetyl-CoA and 
acetoacetate. Finally, both plasma subsets had an increase in 3-methyl-2-
oxobutyrate, which is only produced by incomplete BCAA metabolism and a hallmark 
of maple syrup urine disease [140], and 3-hydroxyisobutyrate, which is an 
intermediate of valine metabolism. The accumulation of 3-hydroxyisobutyrate is 
caused by 3-hydroxyisobutyryl-CoA dehydrogenase deficiency and has been 
identified as a complex I-III inhibitor [141]. These indicate a defect in all three BCAA 
metabolism pathways which is related to multiple enzymes. The cause of each of the 
defects is not obvious, but each of the defects mentioned causes serious clinical 
symptoms. Therefore, the identification of the cause of the suspected defects should 
be the focus of future study. 
 
 




The decrease in ATP production caused by mitochondrial dysfunction is expected to 
cause a decrease in the ATP/ADP ratio. In the mitochondria, two ADP molecules can 
be recycled into a single ATP molecule, and one adenosine monophosphate (AMP). 
Evidence of this recycling was present in the liver subset, with AMP increased along 
with its degradation products: adenylosuccinate, xanthine and xanthosine [142]. 
However, in the plasma 4 hour subset there was an increase in succinyladenosine 
(SAdo) which is only present in the plasma of patients with adenylosuccinate lyase 
(ADSL) deficiency [143]. Therefore, this recycling process is prevalent during mild 
mitochondrial dysfunction, and could also have erroneous activity, suggesting that 
SAdo could be an important biomarker and should be studied further. 
 
2.4.3. Mitochondrial dysfunction biomarkers 
The analysis of the metabolomics data set performed in this study identified a large 
set of metabolites which were highly significantly different between the low dose and 
control rats, all of which could be potential biomarkers for mild mitochondrial 
dysfunction. Using a consistency level threshold of six for plasma and five for liver, 
each of the three sets identified around 40 highly significant metabolites. Each 
subset consists of metabolites which are common among all three time points along 
with metabolites which are unique to a single time point. However, the biological 
relevance of the metabolite must be taken into consideration if they are to be labelled 
as biomarkers for mild mitochondrial dysfunction. Table 2.3 shows the biologically 
relevant biomarkers for mild mitochondrial dysfunction for each time point using the 
previously discussed adaptations as the basis for selection, along with some 
previously unmentioned metabolites which were included based on their extremely 
high significance. The plasma biomarkers identified are the most important due to 
the availability of blood plasma during experimentation. However, the liver 
biomarkers have been included in the table as they may be of relevance for future 
exploratory studies and many of them provide supporting arguments for the inclusion 
of many of the plasma biomarkers.  
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The unique biomarkers for the plasma 2 hour time point are a host of different fatty 
acids and two different ketone bodies, all of which were increased in the low dose 
rats compared to controls. The accumulation of fatty acids and ketone bodies in the 
plasma could be used as an identifier of early stage mild mitochondrial dysfunction 
but this result needs to be verified by future studies. The animals dosed in this study 
were not fasted before dosing, but the effects of fasting can cause an increase in 
fatty acid β-oxidation and ketosis. Future studies should ensure the same conditions 
are used to ensure that this behaviour is a response to the mitochondrial dysfunction 
and not animal fasting.  
The accumulation of 3-hydroxy fatty acids was also a unique biomarker for the 
plasma 4 hour subset. This is a biomarker of an error in fatty acid metabolism which 
seems to be present during late stage mild mitochondrial dysfunction. The 
accumulation of this metabolite could be used as a biomarker for late stage 
mitochondrial dysfunction. The amino acids glutamine and citrulline were uniquely 
decreased in the plasma 4 hour subset and can be used as late stage mild 
mitochondrial dysfunction biomarkers. Glutamine has many important functions 
which were discussed in earlier sections, whilst citrulline participates in the urea 
cycle. Late stage mild mitochondrial dysfunction also has biomarkers related to the 
TCA cycle, citrate and nicotinamide, an important structural component of NADH. 
The accumulation of these metabolites is indicative of the TCA cycle blockages and 
general struggles of the mitochondria to keep the TCA cycle running efficiently whilst 
OXPHOS is inhibited. Finally, the accumulation of succinyladenosine, a metabolite 
which is only present in human plasma when there is an issue in the purine 
nucleotide cycle, is present during late stage mild mitochondrial dysfunction, making 
it a potentially important biomarker. 
There were many metabolites which were highly significant in both plasma subsets, 
most of these have already been discussed in previous sections but the following are 
of interest as mild mitochondrial dysfunction biomarkers. Mannose is a sugar which 
would be expected to be decreased due to its consumption for glycolysis in organs. 
Therefore, its accumulation makes it an interesting biomarker for mild mitochondrial 
dysfunction, potentially related to its involvement in glycosylation. There are three 
amino acids which were decreased in both plasma subsets and could be used as 
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biomarkers for mild mitochondrial dysfunction: alanine, proline and methionine. 
Alanine is important for pyruvate production to feed glycolysis, methionine for its 
methionine cycle relating to methylation and GSH production, and proline for its 
metabolism which has recently emerged as an important pathway in cancer [144].  
Based on this study, mild mitochondrial dysfunction seems to cause problems with 
BCAA metabolism. 3-Hydroxyisobutyrate, a biomarker of defective isoleucine 
metabolism and a potential inhibitor of complex I-III, seems to accumulate in both 
plasma subsets making it a potentially critical biomarker for mild mitochondrial 
dysfunction. Mild mitochondrial dysfunction also causes a large amount of oxidative 
stress. The decrease in multiple -glutamyl amino acids was seen in both plasma 
subsets, and their accumulation seen in liver. These metabolites are therefore 
particularly important during mild mitochondrial dysfunction and could be used as 
biomarkers. In this study, -glutamyl alanine and -glutamyl methione were identified 
as high significant biomarkers. Finally, a decrease in mevalonate was also identified 
in both plasma subsets. Mevalonate is part of the mevalonate pathway in which 
isoprenoids, such as heme and steroid hormones, are produced from 3-hydroxy-3-
methylglutaryl-CoA, an intermediate in ketogenesis. The reason for the decrease in 
mevalonate is not obvious but may be related to the increased production of ketone 
bodies. Nonetheless, mevalonate was included in the table of biomarkers because of 
its extremely high significance and should be investigated in further studies. 
The metabolites which were identified as potential biomarkers for all levels of 
mitochondrial dysfunction are shown in Table 2.4. These are the metabolites which 
are significantly different between case and control for both the low dose group and 
the high dose group, along with their measured metabolite level in each sample 
being correlated to the drug exposure level of the sample it was collected from, 
across all dosed samples. It should be noted that due to the low number of samples 
belonging to the high dose group, these results will need to be further experimentally 
tested to ensure greater confidence in the results.  
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Pathway Plasma 2 hours Plasma 4 hours Liver 4 hours 














































Phenyllactate Phenyllactate Phenyllactate 





















































Table 2.3. Proposed biomarkers of mild mitochondrial dysfunction. Each metabolite 
has a high consistency level (≥ 6 for plasma, ≥ 5 for liver). Metabolites in red were 
found increased in low dose compared to controls, whilst blue were found 
decreased. 
Chapter 2                                      Metabolic adaptations to mitochondrial dysfunction  
50 
 
For the plasma 2 hour time point, only 12% of the metabolites which belonged to the 
low dose significant metabolites subset were also found to be significantly different 
between high dose and control (q-value < 0.15), whilst the plasma and liver 4 hour 
subsets had around 35%. This shows that at the earlier stages of mitochondrial 
dysfunction, the adaptations caused by mild mitochondrial dysfunction cause 
markedly different changes in metabolite concentrations than the adaptations which 
occur during high, fatal levels of mitochondrial dysfunction. Therefore, further study 
of high mitochondrial dysfunction may enable the identification of an early metabolic 
biomarker unique to high levels of mitochondrial dysfunction. Of the metabolites 
which were found to be significantly different in both the low and high dose samples 
in the liver, 70% of these had significant correlation with drug exposure level, whilst 
the plasma 4 hour had 43%. This difference was most likely caused by the fact that 
the liver adaptations are restricted by its essential functions, e.g. the urea cycle. The 
restricted adaptability of the tissue means that the pathway adaptations which occur 
during fatal levels of mitochondrial dysfunction are similar to those which occur 
during mild mitochondrial dysfunction, just at varied levels of pathway activity.  
The metabolites which fit the criteria of potential biomarkers for all levels of 
mitochondrial dysfunction were filtered based on their biological relevance (Table 
2.4). The accumulation of one of the 3-hydroxy fatty acids, 3-hydroxyoctanoate, 
along with the decrease in carnitine are both potential biomarkers. These suggest 
that the problem in fatty acid β-oxidization also occurs in high levels of mitochondrial 
dysfunction. Another potential biomarker is the accumulation of 3-hydroxyisobutyrate 
in the plasma, indicating a persistent problem with BCAA metabolism during all 
levels of mitochondrial dysfunction. This further highlights the importance for the 
future study of the cause of the erroneous BCAA activity in the context of 
mitochondrial dysfunction. The breakdown of the cell membrane also seems to occur 
in high levels of mitochondrial dysfunction shown by decreased levels of GPE and 
GPC being a biomarker in liver, with the decreased level of 1-linoleoyl-GPE identified 
as a potential plasma biomarker. Other potential biomarkers include the decrease in 
mevalonte, the accumulation of niotinamide, and the accumulation of 2-
hydroxybutyrate.  
 




The analysis of the metabolomics data set in this study identified key metabolic 
adaptions which occur during mild mitochondrial dysfunction, some of which are 
seemingly erroneous. The further study of these pathways and the identification of 
the causes of the defects could potentially identify therapeutic targets for patients 
with mitochondrial diseases. Moreover, the analyses allowed the identification of 
potential biomarkers for both mild and high levels of mitochondrial dysfunction which 
could be used to improve the drug development process and help monitor patients 
undergoing any form of medication with suspected mitotoxicity. 
Pathway Plasma 4 hours Liver 4 hours 
Glycolysis  Maltotriose, Sorbitol 
Fatty acid  
β-oxidation  
3-Hydroxyoctanoate  
Carnitine shuttle Carnitine  













Choline metabolism  Choline 





Table 2.4. Proposed biomarkers of complete mitochondrial dysfunction. 
Metabolites in red were found increased in low dose compared to controls, 



























  Modelling mitochondrial dysfunction 
 
3.1. Introduction 
3.1.1. Improving mitochondrial dysfunction biomarker identification  
The analysis of the metabolomics data set in the previous chapter highlighted critical 
pathways and potential biomarkers for mild mitochondrial dysfunction. The data set 
contained many significantly different metabolites which were whittled down to a 
small set of potential biomarkers based on their biological relevance. However, this 
biological relevance was based on mostly theoretical reasoning as our overall 
understanding of mitochondrial dysfunction is limited. Despite being considered a 
comprehensive study, the data set was not large enough to enable absolute 
confidence in the identified biomarkers and highlighted critical problems which need 
to be addressed in future studies. 
Firstly, mitochondrial metabolism is organ specific. The essential functions of each 
organ mean that the network of pathways involved in mitochondrial metabolism is 
slightly different for each organ. These essential functions, such as the generation of 
urea in the liver, cause a restriction on the adaptability of the organ to mitochondrial 
dysfunction suggesting that each organ would have a potentially unique metabolic 
profile during mitochondrial dysfunction. The plasma metabolite levels reflect the 
collective adaptations occurring in the whole organism. Therefore, to accurately 
identify a plasma biomarker for any level of mitochondrial dysfunction, we will need 
to have a better understanding of the adaptions occurring in many of the highly 
metabolically active organs such as the brain, liver and kidney. This issue could be 
addressed in future metabolomics studies by collecting terminal metabolite levels of 




multiple organs, enabling the identification of both organ specific and organism wide 
adaptations to mitochondrial dysfunction. 
Secondly, adaptations to mitochondrial dysfunction are not necessarily linear. With 
only a handful of plasma metabolite time points, and one liver time point, all 
behaviour in between must be extrapolated, usually with the assumption that the 
behaviour seen in one time point leads directly to the next, in a linear fashion. In 
reality, between two time points there could be a huge inflection point giving wildly 
different behaviour between the two measured time points which would invalidate 
any identified biomarkers in the early measured time point. Such an inflection point 
would be the perfect behaviour for biomarker identification but is currently impossible 
to identify due to the intricacy of the metabolic network and our lack of understanding 
of how adaptations change over time. This issue could be negated by including 
many time points which are measured in small time intervals, allowing for the 
monitoring of metabolite changes over time. However, this is realistically only 
possible for plasma samples in vivo. 
Thirdly, pathway activity inference from metabolite levels is difficult, but critical for 
biomarker identification. Ideally, the metabolites identified as biomarkers would be 
those which are involved in critical pathways specifically related to mitochondrial 
dysfunction, and not pathways which are just general organism stress responses. 
Most pathways involve hundreds of different metabolites, and each metabolite is 
generally involved in multiple different pathways. Therefore, the measured increase 
or decrease of a metabolite in a case sample compared to a control does not 
translate perfectly to an increase or decrease in the activity of a specific pathway, 
hindering the identification of mitochondrial dysfunction biomarkers. By measuring a 
much larger subset of metabolites, it would provide a much larger coverage of each 
of the pathways involved in mitochondrial metabolism and help identify the correct 
reason for the significant difference of a metabolite between case and control, 
allowing for better biomarker identification.   
Fourthly, different types of mitochondrial dysfunction will most likely cause different 
metabolic adaptations. The mitochondrial dysfunction analysed in the previous 
chapter was caused by mitochondrial complex III inhibition, but mitochondrial 
dysfunction can be caused by defects in multiple different types of protein including 




transporters, enzymes and the other mitochondrial complexes. Each of these would 
disrupt a different part of mitochondrial metabolism, resulting in different adaptations. 
The biomarkers identified in the previous chapter were labelled as mitochondrial 
dysfunction biomarkers, although it’s more than likely that some of these may be 
mitochondrial complex III inhibition specific. For both patient monitoring and drug 
development it would be beneficial to have both general mitochondrial dysfunction 
biomarkers and biomarkers for specific types of mitochondrial dysfunction. Knowing 
the type of dysfunction occurring would enable measures to be taken to counteract 
the specific inhibition. Current biomarkers for mitochondrial diseases are extremely 
similar which makes precise patient diagnosis a difficult and time-consuming 
process. For example, the primary biomarkers for mitochondrial disease caused by 
all four complex deficiencies are lactic acidosis [145–148], hypoglycaemia [149] and 
hyperammonaemia [150], unique biomarkers for each type of complex deficiency are 
currently unknown. To address this issue, future metabolomics studies should be 
carried out on various types of mitochondrial dysfunction. The results can then be 
compared to identify the general mitochondrial dysfunction biomarkers, along with 
biomarkers for specific types of inhibition. 
Finally, different levels of mitochondrial dysfunction will also cause different 
metabolic adaptations. In the previous chapter, the small sample size of rats 
exposed to high levels of the drug prevented the identification of specific biomarkers 
for fatal levels of complex III inhibition, but the analyses highlighted the differences in 
early stage mitochondrial dysfunction at varying levels of inhibition. Early detection of 
the level of mitochondrial dysfunction is critical for improving both the drug 
development process, and patient monitoring. A perfect biomarker for mitochondrial 
dysfunction would not only detect mitochondrial dysfunction, but also be able to 
identify the specific level of mitochondrial dysfunction occurring. Future 
metabolomics studies should include a much wider range of drug exposure levels, 
with a suitable number of samples, so that the different metabolic adaptations 
occurring at each level of inhibition can be explored, and a consensus biomarker 
identified.   
 




3.1.2. Flux balance analysis: the in silico alternative to in vivo studies 
To improve the identification of mitochondrial dysfunction biomarkers using 
metabolomics will require a large investment of both time and money. An alternative 
to performing a large amount of investigative in vivo studies is to use in silico 
predictions to direct in vivo studies. Flux balance analysis (FBA) is a constraint-
based modelling technique which has become extremely popular for studying 
biochemical networks and has been successfully used in the modelling of whole 
genome unicellular metabolism [151]. Having a model of whole organism 
mitochondrial metabolism and being able to use the model to simulate multiple types 
of mitochondrial dysfunction would drastically improve our understanding of the 
metabolic adaptions during mitochondrial dysfunction and instil higher confidence in 
biomarker selection. 
FBA models are mathematical representations of a system of chemical reactions, 
based on their stoichiometry [152]. The stoichiometric coefficients of every reaction 
in the system are combined to form a single stoichiometric matrix, which itself acts 
as a constraint on the system. During the simulation process, the system is assumed 
to be at a steady state. This constrains the flow of metabolites through the system by 
ensuring that for every metabolite in the system, the total amount being produced in 
the system must be equal to the total amount being consumed. The flow of 
metabolites through a single reaction in the system is known as a reaction flux, with 
a flux representing the forward reaction being positive and the reverse reaction being 
negative. Additional constraints can be placed on each reaction in the form of an 
upper and lower bound, defining the allowed minimum and maximum fluxes through 
a single reaction. For example, a reaction which is irreversible will have its lower 
bound set to zero, preventing the flow of metabolites in the reverse direction. The 
other essential component of an FBA model is its defining phenotype, known as the 
objective function. The objective function is the overall biological objective of the 
system which, in most biological networks, is the production of biomass for growth. 
In previous FBA models of mitochondrial metabolism, the objective function has 
been set to the production of ATP [153]. The combination of a steady state 
stochiometric matrix and the objective function creates a system of linear equations 
which can be solved using linear programming [154]. The result produces a list of 




reaction fluxes which satisfies the optimization of the objective function which, in the 
case of mitochondrial metabolism, means maximum ATP production.  
FBA does not require kinetic parameters for each of the chemical reactions, which is 
ideal for mitochondrial metabolism as these parameters are largely unknown. By 
altering the constraints on the system, different biological conditions can be 
modelled. For example, altering both the bounds to be zero on a single reaction 
prevents any flux through the reaction simulating the inhibition of a single reaction. 
This feature of FBA makes it an ideal technique for investigating mitochondrial 
dysfunction, as each complex can be inhibited to identify the potential metabolic 
adaptions which occur in the system. However, FBA cannot be used to predict 
precise metabolite concentrations, it can only provide general pathway activity 
changes. Nonetheless, due to the current lack of understanding of pathway activity 
during any type of mitochondrial dysfunction, FBA modelling of mitochondrial 
dysfunction can help provide useful information that, in combination with the results 
of both previous and future metabolomics studies, would aid in the identification of 
high confidence biomarkers. 
 
3.1.3. Flux balance analysis models 
To accurately predict in vivo mitochondrial dysfunction adaptations, an FBA model 
needs to consist of multiple highly metabolic organs including the brain, liver, kidneys 
and heart. A multi-organ FBA model of metabolism does not currently exist as most 
of the regularly maintained models focus on a single organ. However, our 
understanding of metabolism suggests that organ specific changes in central 
metabolism are relatively minor. The major functions of each organ, such as the 
production of urea in the liver, are very well defined and would be easy to implement 
into the single organ models. The smaller organ specific metabolic differences, such 
as the differences in amino acid metabolism rates, are less well defined but can be 
investigated using readily available organ specific gene expression data. Therefore, 
adapting a single organ model into different organ specific models should be 
possible. Several different organ models could be generated and subsequently 
combined into a single, multi-organ model. There are currently two popular FBA 




models used to simulate metabolism which are both written in SBML [155] and 
MIRAM [156] compliant. Both could be used as a base FBA model in the creation of 
a multi-organ model. 
Recon 2.2 is a genome-scale network of human metabolism within a single cell 
[157]. The model consists of 7,785 reactions involving 5,324 metabolites. The 
reactions within the model have been separated into nine different cellular 
compartments including the mitochondrial matrix and mitochondrial intermembrane 
space. Recon 2.2, and its predecessor Recon 2.0 [158], has been used to 
successfully model a wide range of different metabolic conditions, such as cancer 
[159]. The biggest advantage for using Recon 2.2 over other models is the fact that it 
is a genome-scale reconstruction and hence provides the most comprehensive 
reconstruction of metabolic adaptations. However, this can also be a large 
disadvantage as identifying the precise cause and reasoning for a specific metabolic 
adaptation can be difficult and time consuming. In addition, for mitochondrial 
metabolism specifically, Recon 2.2 does not consider the electrical gradient 
component of the proton motive force that is crucial for accurate modelling of 
OXPHOS activity and ATP production. 
MitoCore is a much smaller model focused on modelling the crucial pathways of 
central metabolism, and by default models cardiomyocyte metabolism [160]. The 
model consists of 324 reactions and 83 transport reactions with 74 metabolite inputs. 
The reactions are split into two cellular compartments, the cytosol and the 
mitochondrial matrix with the intermembrane space considered as cytosolic due to its 
high permeability. MitoCore has been used to successfully investigate multiple 
different types of mitochondrial metabolic defects including the deficiency of one of 
the mitochondrial transporters, the oxodicarboxylate carrier [161], and to investigate 
the specific role of glutamine during mitochondrial dysfunction [162]. The MitoCore 
model was specifically created to investigate mitochondrial metabolism so the proton 
motive force is modelled in its entirety. In addition, the model already contains the 
reactions of all the major organ specific functions, such as the urea cycle (although 
this is turned off in the default cardiomyocyte model). The smaller set of reactions 
makes investigation of the metabolic adaptations much more visible and has proven 
to provide enough information to enable accurate in vivo predictions. The MitoCore 




model was therefore used within this study as the base model for creating a multi-
organ model for simulating mitochondrial dysfunction. 
 
3.1.4. Chapter summary 
In this chapter I describe the process for creating a multi-organ FBA model using a 
pre-existing single organ model of metabolism, MitoCore. I then use the model to 
simulate varying levels of inhibition of each of the mitochondrial complexes and 
discuss the resulting adaptations. The adaptations are evaluated and potential 
biomarkers for each type of mitochondrial dysfunction, and for varying levels of 
inhibition, are identified. The chapter starts with simulations of complex III/IV 
inhibition, since metabolomics data on their inhibition were presented in the previous 




3.2.1. Creation of a multi-organ model of human metabolism  
The MitoCore model was used as the base for creating four different human organ 
specific FBA models [160]. These four organs were the heart, which is the MitoCore 
default model, the liver, the kidney and the brain. These organs were selected as 
they are the most energetically demanding organs within humans. Major organ 
specific functions were already written into the MitoCore model, which were turned 
on for their respective organ models. Minor organ specific alterations in metabolism 
were investigated using the Human Protein Atlas RNA-Seq organ expression data 
[30]. Using the organ expression data, reactions were turned on/off in specific organs 
based on their comparative expression levels across the four organs. For example, 
the enzyme required for the breakdown of phenylalanine into tyrosine had zero TPM 
(transcripts per million) in the heart and only 3 in the brain whilst it had a 500 and 
720 TPM in the kidney and liver respectively, this reaction was therefore turned off in 
the brain and heart. 




The constraints on the metabolite imports and exports in the MitoCore model are 
based on experimentally verified results for cardiomyocytes. Experimental data on 
the constraints of the other organ’s does not exist. Therefore, the organ expression 
data was also used to qualitatively scale these constraints for each organ model, 
using the cardiomyocyte constraint values as a reference. Each of the organ models 
was thoroughly checked for errors by forcing a flux through each pathway 
individually using the objective function of ATP production. The four organ models 
were then combined into a single model by encasing them in a shared transport 
system which represented the blood. Similar checks were performed on the 
complete multi-organ model to ensure the model had no pathway or constraint 
errors. Model generation was performed using custom Python scripts and the quality 
checking simulations were performed using the COBRA Toolbox [163]. 
The default objective function of the MitoCore model was to maximise ATP 
production which was applicable for all four of the organ specific models. However, 
in an organism, each of the organs has a different energetic demand with organs 
such as the brain requiring a larger amount of ATP. The resting energy expenditure 
rates of each organ has been proposed [164] and confirmed to be accurate in 
describing the organ specific energy requirements in humans across various age 
groups [165] for both men and women [166]. The objective function of the multi-
organ model was set as ATP production in all four organs with the stoichiometry of 
each organ's ATP level set based on its resting energy rate. The brain was the most 
energetically demanding with a stoichiometry of one, the liver the second highest 
with a stoichiometry of 0.87 followed by the heart at 0.43 and the kidney at 0.4. A 
complete breakdown of the reactions, their upper bound and lower bound and basal 
flux value for the multi-organ model can be found in Supplementary File 3.1. 
 
3.2.2. Liver mitochondrial complex inhibition 
Simulations of liver mitochondrial complex inhibition were performed using the multi-
organ model with the COBRA Toolbox and the geometric FBA algorithm to allow for 
flux profile comparisons [167]. The multi-organ model was simulated under basal 
conditions to establish the base flux value for all the liver complexes. For each of the 




complexes, a simulation was performed at every percent inhibition from zero to one 
hundred by altering the upper bound of the specific liver complex to lower than its 
base value. For example, for 10% inhibition of liver complex I its upper bound would 
be set to 90% of its base flux value. This resulted in 101 different flux profiles for 
each of the liver complex inhibitions which were comparable. Throughout the 
process, various upper and lower bounds had to be altered throughout the model to 
prevent the occurrence of biologically infeasible reactions such as the infinite cycling 
of metabolite transports to produce co-factors.  
 
3.2.3. MitoCore network visualisation 
A network representation of the MitoCore model was generated in Cytoscape using 
the KEGG database. Each node represented a single compound and each edge 
represented a reaction with directionally of each reaction indicated by an arrow. The 
reactions represented by a solid line occurred in the cytosolic compartment of the 
MitoCore model and reactions represented by a dashed line occurred in the 
mitochondrial matrix. Each reaction had its fluxes scaled based on the reaction’s flux 
values across all four organs, with a high flux value indicated by red and a low flux 
by yellow, reactions with zero flux were not assigned an arrow or colour. Compounds 







Compound colour Pathway 
Dark blue TCA cycle 
Light blue Lipid metabolism 
Red Fatty acid metabolism 
Orange Carbohydrate metabolism 
Green Amino acid metabolism 
Purple Purine / Pyrimidine metabolism 
Pink Co-factor biosynthesis 
Grey Other 
Table 3.1. The node colour pathway assignments for the network MitoCore 
representation. 




3.3. Results and Discussion 
Xenobiotic metabolism is primarily performed in the liver, making it the main location 
for drug-induced mitochondrial dysfunction. Investigating the organism metabolic 
adaptations which occur due to liver complex inhibition is therefore critical to 
furthering our understanding of mitochondrial dysfunction and integral for biomarker 
identification. The simulated inhibition of each liver complex caused the majority of 
metabolic adaptations to occur in the liver. Therefore, unless otherwise stated, all 
pathways and adaptations discussed were based in the liver with the entirety of the 
model, including the transport system around all four organs which simulates the 
blood, referred to as the system. The metabolic adaptations are discussed in terms 
of incrementally increased inhibition from zero percent up to full inhibition. This 
simulates the accumulation of a drug in the liver and enables the exploration of 
potential biomarkers for varying levels of inhibition. The complete list of fluxes for all 
complexes and inhibition levels can be found in Supplementary File 3.2. 
 
3.3.1. Modelling liver mitochondrial complex III/IV inhibition 
Complex III and IV facilitate the same reaction, they use quinones from the quinone 
pool to export protons out of the mitochondrial matrix to produce proton motive force, 
with complex IV ultimately consuming the quinones to produce water from oxygen. 
These two complexes occur in series during OXPHOS and have no other 
interactions outside of the OXPHOS pathway. The inhibition of either of these 
complexes creates the same problem, a huge loss of proton motive force in the 
mitochondrial matrix which prevents ATP synthase activity, and an inability to 
remove the free electrons within the inner membrane which are being produced by 
complex I and II upstream. Therefore, the adaptations which occurred during the flux 
balance analysis simulations of either complex III or complex IV inhibition were the 
same. The adaptations which occurred from zero to complete inhibition could be 
separated into two phases, the fluxes of the pathways identified as important can be 
seen in Figure 3.1. The breakdown of the adaptations into phases was based on the 
identified major changes in behaviour of the model as the inhibition level gradually 
increased. 




Over the duration of both phases, system ATP synthase levels and the OXPHOS 
activity of the other three non-inhibited organs began to decrease at one percent and 
continued to decrease until complete inhibition. In the liver, the same behaviour 
occurred with complex II, III/IV and ATP synthase. Complex I slightly increased in 
activity until five percent inhibition then began to decline until complete inhibition. 
The different behaviour of liver complex I highlights the attempt by the system to 
rectify the complex III/IV inhibition as complex I was the only unaffected means to 
produce PMF. However, the quinone by-product prevented the reaction from 
continually increasing past five percent inhibition of complex III/IV and forced it to 
decrease in activity like the rest of the OXPHOS complexes. The immediate 
decrease in system ATP synthase and OXPHOS activity across all the organs 
highlighted the severity of complex III/IV inhibition as its adaptations were not 
enough to maintain system ATP levels at any level of inhibition. 
Figure 3.1. Fluxes of important reactions throughout each of the two phases of liver 
complex III/IV inhibition. A-B are the reactions separated based on their flux magnitude. 





Figure 3.2. Graphical representation of the adaptations which occurred in the liver 
during each of the phases of liver complex III/IV inhibition. A) Phase one. B) Phase 
two. 





Phase one of the adaptations started at one percent inhibition and continued until 
sixty-one percent inhibition. ATP production in the liver was immediately 
supplemented by an increase in glycolysis which continued to increase throughout 
phase one (Figure 3.1a, Figure 3.2a). The pathway reached maximum flux at 
thirteen percent inhibition which was maintained for the rest of the inhibition levels. 
The produced pyruvate from glycolysis was shuttled into the mitochondrial matrix, 
despite costing PMF, and used to feed the TCA cycle via its production into acetyl-
CoA (Figure 3.1a). This was just one of the adaptations which the system used to 
increase TCA flux and, by proxy of NADH regeneration, enabled the increased 
complex I activity to replace the lost PMF from the complex III/IV inhibition. Glucose 
consumption in the other three non-inhibited organs completely halted during phase 
one, the heart stopped at twenty percent whilst the brain stopped at thirty-three 
percent. The kidney began producing glucose via gluconeogenesis at two percent 
inhibition until twenty percent inhibition where it stopped. Despite being one of the 
major sites for gluconeogenesis in mammals [168], the only other being the liver, this 
was the only time that the gluconeogenesis pathway activated in any of the complex 
inhibition simulations.  
The malate-aspartate shuttle transports electrons indirectly across the inner 
mitochondrial membrane into the mitochondrial matrix (Figure 3.3). The shuttle 
involves two mitochondrial transports; one exchanges 2-oxoglutarate and malate, 
which was used heavily in the complex II inhibition simulations, and the other 
exchanges aspartate and glutamate. The net result of the shuttle is the conversion of 
NADH to NAD+ in the cytosolic compartment of the model and the conversion of 
NAD+ into NADH in the mitochondrial matrix. The complete malate-aspartate shuttle 
immediately increased in activity at the beginning of phase one and reached its 
maximum flux at twelve percent which continued throughout phase one and two 
(Figure 3.1a). The malate to oxaloacetate reaction in the mitochondrial matrix 
regenerated mitochondrial NADH as part of the TCA cycle. The pathway activity 
mimicked the behaviour of the pyruvate to acetyl-CoA reaction in the mitochondrial 
matrix as a collective effort to increase the TCA cycle and complex I fluxes to 
supplement the lost PMF. The complete activation of the malate-aspartate shuttle 




was unique to complex III/IV inhibition, behaviour which could be exploited as a 
biomarker for complex III/IV inhibition.  
The required cytosolic NADH to feed the malate-aspartate shuttle was generated by 
the conversion of lactate into pyruvate in the cytosolic compartment (Figure 3.1a), 
with the produced pyruvate being transported into the mitochondrial matrix and fed 
into the TCA cycle. The reaction quickly increased at the start of the phase and 
reached maximum flux which continued throughout the phase. The increased lactate 
consumption caused a dramatic increase in the system lactate import, behaviour 
which would be akin to a decreased level of lactate in a patient’s plasma or liver. The 
metabolomics analysis in the previous section identified a decreased level of lactate 
in the liver of the rats administered the high dose of the complex III inhibitor. The 
simulations therefore support this behaviour as a potential biomarker for moderate 
levels of complex III/IV inhibition. Additional feeding of the malate-aspartate shuttle 
occurred through phenylalanine metabolism which produced malate in the cytosolic 
compartment. The pathway immediately activated and reached maximum flux at the 
start of the phase (Figure 3.1b). Intermediates of the phenylalanine/tyrosine 
metabolism pathway were seen in abundance in the plasma of the rats administered 
the complex III inhibitor analysed in the previous section, highlighting the potential for 
these metabolites as biomarkers for complex III/IV inhibition.  
Despite being a means for additional ATP production and feeding the TCA cycle 
along with regenerating mitochondrial NADH, fatty acid β-oxidation immediately 
decreased in flux throughout phase one (Figure 3.1a). The decreased activity was 
due to the pathway also generating quinones for the quinone pool which are now 
highly unwanted by the model since their only consumption method is inhibited. This 
behaviour is entirely unique to complex III/IV inhibition and could be exploited as a 
biomarker. Fatty acid β-oxidation in the brain slightly increased in flux at the start of 
the phase but gradually decreased throughout the rest of the inhibition levels. In the 
heart and kidney, the fatty acid β-oxidation activity continually decreased throughout 
both phases. The metabolomics analysis in the previous chapter identified a large 
set of fatty acid β-oxidation intermediates accumulated in both the liver and plasma 
with many of the intermediates associated with erroneous activity. The undesirable 
quinone production could be a potential reason for the accumulation of these 




metabolites and further highlights the behaviour as a potentially unique biomarker for 
complex III/IV inhibition.  
The attempt by the model to completely remove quinone production throughout the 
duration of the complex III/IV inhibitions suggests that in vivo there would be an 
abundance of available quinones. Electrons from the quinone pool are known to leak 
out of the inner mitochondrial membrane into the mitochondrial matrix [169], a 
process which is important for signalling [170]. An increased leak of electrons has 
been identified during mitochondrial dysfunction where the increased levels of 
roaming free radicals are known to cause damage to the mitochondria [122]. More 
recently, the increasing levels of free radicals during mitochondrial dysfunction have 
been implicated in altering mitochondrial dynamics during cancer [171]. The 
analyses of the metabolomics dataset in the previous chapter had clear indications 
that the rats administered the complex III inhibitor were under an extremely high 
amount of oxidative stress, and that both cellular and mitochondrial membrane 
conformational changes were occurring. Therefore, the cause for both behaviours 
was most likely caused by the increased leak of abundant quinones in the quinone 
pool caused by complex III/IV inhibition.  
Two amino acid metabolism pathways activated immediately in phase one; 
glutamate and β-alanine (Figure 3.1b). Glutamate metabolism regenerated 
mitochondrial NADH for complex I flux and 2-oxoglutarate which was used to feed 
the import of malate into the mitochondrial matrix as part of the malate-aspartate 
shuttle. β-alanine metabolism fed the TCA cycle via acetyl-CoA and produced both 
mitochondrial NADH and glutamate, which fed glutamate metabolism. During phase 
one in the brain; leucine, isoleucine and valine all completely switch off. Interestingly, 
none of these BCAA metabolism pathways activated at all in the liver during complex 
III/IV inhibition, pathways which were prevalent in the adaptations of both complex I 
and II inhibitions. In the metabolomics, many erroneous intermediates of the BCAA 
pathways were identified in the plasma of the rats administered a complex III 
inhibitor. The BCAA pathways were not activated because of their minor quinone 
production which was undesirable for the model and could be the potential reason 
for the presence of these metabolites, highlighting them as potential complex III/IV 
biomarkers. 





The gradual blockage of the OXPHOS pathway by the inhibition of complex III/IV led 
to the complete halt in fatty acid β-oxidation which marked the start of the phase two 
adaptations (Figure 3.1a, Figure 3.2b). As the final reactions of the OXPHOS 
pathway, the inhibition of complex III/IV also restricted the flux through both complex 
I and II. The start of phase two marked the tipping point in which the inhibition of 
complex III/IV overtook the level of mitochondrial NADH as the rate limiting factor for 
complex I activity necessary for replacing the lost proton motive force. Increased 
TCA flux and mitochondrial NADH regeneration were therefore in less demand, 
which caused the progressive decline in flux of the malate-aspartate shuttle and the 
import and conversion of pyruvate into acetyl-CoA (Figure 3.1a). The decreased 
demand on mitochondrial pyruvate and cytosolic NADH for the malate-aspartate 
shuttle allowed for the reversal of the lactate to pyruvate reaction which was 
necessary to remove the now excess pyruvate in the cytosolic compartment 
Figure 3.3. The series of reactions which constitute the malate-aspartate shuttle, 
transporting electrons indirectly across the inner mitochondrial membrane. 




produced by glycolysis. The produced lactate was exported from both the liver and 
the system.  This behaviour is akin to an accumulation of lactate in the liver or 
plasma of patients, a common feature of known mitochondrial disease which the 
simulations suggest is a biomarker for only high levels of complex III/IV inhibition.  
The reduced flux allowed through complex II prompted the efflux of succinate from 
both the liver and the system to relieve the pressure put onto the TCA cycle by 
circumventing the complex II reaction. The efflux occurred immediately into phase 
two, maximised quickly and remained at its maximum throughout the rest of the 
phase (Figure 3.1a). Similar behaviour occurred during the complex II inhibition 
simulations, although the efflux was almost nine-fold higher during the complex II 
inhibitions. At extremely high levels of complex III/IV inhibition (98%) complex II 
reversed its flux, generating succinate from fumarate which was also effluxed from 
the system to provide additional relief for the TCA cycle and removing quinones from 
the quinone pool produced by complex I activity. The accumulation of succinate may 
therefore be a potential biomarker for high levels of complex III/IV inhibition. 
The final predominant metabolic adaptations which occurred at the start of phase 
two and reached maximum flux instantly were two amino acid metabolism pathways; 
asparagine and arginine/ornithine (Figure 3.1b). Despite declining malate-aspartate 
shuttle activity, asparagine metabolism was activated to produce aspartate to feed 
the shuttle. This behaviour could explain the identified decrease in asparagine within 
the plasma of the rats administered the complex III inhibitor analysed in the previous 
chapter. The metabolism of β-alanine completely halted at the start of phase two and 
was replaced by arginine metabolism in the cytosolic compartment which produced 
ornithine. The ornithine was then transported into the mitochondrial matrix and 
degraded into glutamate, necessary for continued glutamate metabolism. The swap 
from β-alanine metabolism to the arginine/ornithine metabolism pathway was caused 
by the now limited mitochondrial 2-oxoglutarate levels which were instead used in 
the TCA cycle and effluxed as succinate. This behavioural switch could be used as a 
biomarker to differentiate between a lower and higher level of complex III/IV 
inhibition in cases of known complex III/IV inhibition. 




After seventy percent inhibition of liver complex III/IV, all four organs remained in 
phase two and declined in flux until complete inhibition. At complete inhibition, the 
system ATP production flux decreased by 98% of its basal level. 
Rats in the previous chapter were administered a low and high dose of a complex III 
inhibitor, with the lower dose known to be non-lethal and the higher dose known to 
be lethal if the animals were left for greater than four hours. In the high dose rats, 
metabolomics analysis identified decreased lactate in the liver and increased 
succinate and lactate in the plasma, behaviour which would be expected in phase 
two of complex III inhibition, placing the inhibition level above sixty percent. Other 
significant metabolites which suggested the high dose rats were in phase two of the 
simulation adaptations included increased liver glutamate, ornithine and aspartate 
(the product of asparagine metabolism). Meanwhile in the lower dose, metabolomics 
identified no significant difference in any of these metabolites in the liver or plasma 
but did identify increased liver β-alanine, a metabolite whose metabolism pathway 
only activated during phase one and suggested that the low dose rats were 
experiencing less than 60 percent inhibition. The commonalities between the 
metabolomics and the complex III inhibition simulations provided confidence in the 
organism model and showcases the way in which pathway switching can be 
exploited to roughly estimate the level of complex inhibition.  
Having modelled inhibition of complex III/IV for which metabolomics data were 
available, the next simulations modelled inhibition of complex I and II in the liver. 
These simulations should provide a basis in which in vivo studies can be directed to 
explore mitochondrial dysfunction caused by complex I and II inhibition.  
 
3.3.2. Modelling liver mitochondrial complex I inhibition 
Mitochondrial complex I is the first complex of OXPHOS and responsible for 
oxidising NADH, pumping protons across the inner mitochondrial membrane, and 
donating electrons to the quinone pool. Its inhibition is expected to affect all these 
processes. The metabolic adaptations which occurred over the course of complete 
liver complex I inhibition could be separated into three phases. The reactions which 




were identified as important for each of the phases can be seen in Figure 3.4 and a 




During phase one (Figure 3.5a) the system ATP production, the objective function of 
the model, did not decrease in flux, the metabolic adaptations which occurred 
maintained the levels of ATP production across all four organs. The flux through liver 
complex II-IV slightly increased during the phase, whilst ATP synthase slightly 
decreased. The increase in the other complexes of the OXPHOS pathway was 
necessary to generate the proton motive force lost by the complex I inhibition and 
replace the lost electrons in the quinone pool. However, the decrease in ATP 
synthase suggested that this adaptation was not enough to fully maintain basal 
OXPHOS levels. The decrease in ATP production by OXPHOS was met by a slow 
incremental increase in fatty acid β-oxidation over the duration of phase one (Figure 
3.4c). The immediate increase in fatty acid β-oxidation as a first response to 
mitochondrial dysfunction was identified in the metabolomics analysis performed in 
the previous chapter. This behaviour was prevented in the simulations of complex 
III/IV inhibition due to its additional function of producing quinones. However, in vivo 
this behaviour is expected in all forms of mitochondrial dysfunction based on our 
current understanding of metabolism. Therefore, this provided support to the validity 
of the organism model by replicating the behaviour seen in the metabolomics. 
An immediate response to liver complex I inhibition was the rapid decrease in 
glutamine synthesis and the urea cycle, both of which require ATP and ammonia. 
This behaviour suggested that these two pathways are the easiest ATP consumers 
to reduce as an immediate response to complex I inhibition. Glutamine synthesis 
slowly increased over the duration of phase one after its initial drop in flux (Figure 
3.4a), most likely necessary to remove ammonia from the liver, whilst the urea cycle 
steadily decreased, with both pathways completely stopping by the end of phase 
one. This behaviour adds to the list of potential reasons for the decrease in liver 
glutamine levels seen in the metabolomics of mitochondrial dysfunction in the 




previous chapter. Combined, these adaptations managed to maintain basal liver ATP 
levels resulting in a steady system ATP production flux over the duration of phase 
one.  
The only change to amino acid metabolism over the duration of phase one was to 
tyrosine metabolism (Figure 3.4a). Tyrosine is metabolised in the cytosol into 
acetoacetate, a ketone body, and fumarate. The immediate decrease in flux in 
response to complex I inhibition was most likely due to the by-production of ammonia 
from the pathway and linked to the decrease in both the urea cycle and glutamine 
synthesis. The acetoacetate production was necessary for ketogenesis, the ketone 
body was eventually transported into the brain and metabolised. Ketogenesis in the 
liver continued at a steady flux across all three phases of complex I inhibition. The 
fumarate produced was converted into malate and transported into the mitochondrial 
matrix by the oxoglutarate carrier and used to feed the TCA cycle. Tyrosine 
metabolism immediately stopped at the end of phase one, behaviour which could be 
exploited to enable tyrosine intermediates to be used as biomarkers for lower levels 
of complex I inhibition. 
2-Oxoglutarate, also known as α-ketoglutaric acid (α-Kg), is one of the main 
metabolites involved in the TCA cycle which feeds OXPHOS. During the TCA cycle, 
2-oxoglutarate is produced from isocitrate along with either NAD+ or NADP+. The 
production of 2-oxoglurate in the TCA cycle over the duration of phase one 
continually swapped from using NAD+ to NADP+ (Figure 3.4b). This showed the 
incrementally reduced amount of available NAD+ during complex I inhibition, as 
NAD+ is usually produced by the oxidation of NADH at complex I, with the complete 
lack of availability of NAD+ seeming to trigger the start of phase two. An interesting 
way the model tried to circumvent this issue involved the cyclic metabolism and 
transport of alanine and pyruvate.  
In the cytosolic compartment, alanine and 2-oxoglutarate were converted into 
pyruvate and glutamate (Figure 3.4a). The pyruvate was then transported into the 
mitochondrial matrix by the mitochondrial pyruvate transport via proton symport 
[172], which required mitochondrial proton motive force. This mitochondrial pyruvate, 
along with glutamate, was then converted into alanine and 2-oxoglutatrate, with the 
produced alanine transported back into the cytosol, creating a cyclical pathway. The 




net product of this pathway was cytosolic glutamate and mitochondrial matrix 2-
oxoglutarate, which fed the TCA cycle without the need for co-factors. Therefore, 
despite only having a small flux, and thus only generating a small amount of 2-
oxoglutarate, this identified an interesting interaction with alanine and pyruvate 
during complex I inhibition. The cyclical pathway activity slowly decreased in flux 
throughout phase one, most likely due to the increased stress on proton motive force 
but continued into phase two, where it eventually stopped. The ability to feed the 
TCA cycle without the need for co-factors would be an ideal therapeutic to deal with 
complex I inhibition where the NAD+/NADH ratio will be heavily altered. However, 
the dependence of this pathway on the transportation of pyruvate across the inner 
membrane means the pathway could never reach high activity, thus invalidating its 
ability to be supplemented in any way and have any effect on the ratio on a larger 
scale. 





Figure 3.4. Fluxes of important reactions throughout each of the three phases of liver 
complex I inhibition. A-D are the reactions separated based on their flux magnitude. 
 





Figure 3.5. Network representations of the flux profiles for each of the three 
phases of metabolic adaptations for liver complex I inhibition. A) Phase one. 
B) Phase two. C) Phase three. Edges represent reaction fluxes, with yellow 
being low and red being a high flux.  Nodes represent each of the metabolites, 
coloured by their generalized pathway (Table 3.1).  





Phase two (Figure 3.5b) began at twenty percent inhibition until around thirty percent 
inhibition with the cause for the switch in behaviour attributed to the heavily 
perturbed NAD+/NADH ratio. During phase two, liver complex II-IV flux continued to 
slowly increase and eventually reached their maximum half way through. ATP 
synthase flux continued to slowly decrease until complex II-IV reached their 
maximum fluxes, causing the decrease to become much faster. A decrease in ATP 
synthase activity despite a maintained level of OXPHOS activity suggests that the 
reduction in ATP production by ATP synthase was caused by the consumption of 
proton motive force by other reactions, not by its lack of generation by the OXPHOS 
pathway. Reduced activity of these other proton motive force consumption reactions 
would allow restored ATP synthase activity and could be a possible therapeutic 
method. Basal levels of liver ATP production were maintained as fatty acid β-
oxidation continued to slowly increase throughout the phase along with the rapid 
increase in glycolysis, which reached its maximum at the end of the phase (Figure 
3.4c).  
Glycolysis is the conversion of sugars, such as glucose, into pyruvate in the cytosol 
which requires NAD+ and produces ATP in the process. Under regular conditions, 
the pyruvate is transported into the mitochondrial matrix by the pyruvate transporter, 
requiring proton motive force, and used to feed the TCA cycle. However, during 
mitochondrial dysfunction, proton motive force becomes an expensive resource and 
the TCA cycle is disrupted. The excess pyruvate produced from the rapid increase in 
glycolysis during phase two was converted into lactate and exported from the liver, 
and the system (Figure 3.4c). The conversion of pyruvate to lactate also regenerates 
NAD+ from NADH, giving it the additional benefit of being an NAD+ feeder for 
glycolysis. The large system export of lactate is akin to the accumulation of lactate in 
the blood, a hallmark of mitochondrial disease [173]. This result suggests that in the 
case of complex I inhibition, this accumulation may only occur during a small window 
of inhibition levels. Behaviour which could be exploited to roughly estimate the level 
of complex I inhibition in organisms where complex I inhibition is known. 
 




An integral function of complex I activity is the addition of electrons to the quinone 
pool necessary to enable the proton pumping of complex III and IV for proton motive 
force generation. Phase two saw the activation of two different pathways which 
contributed to the quinone pool. Cyclical synthesis and degradation of proline in the 
mitochondrial matrix began at the start of phase two (Figure 3.6) and steadily 
increased throughout the phase, reaching its maximum flux just over half way 
through. This pathway requires NADH and produces NAD+, acting as a replacement 
for complex I by generating mitochondrial NAD+ to feed the necessary TCA cycle 
reactions, albeit in a much lower capacity. The exact carrier responsible for the 
transportation of proline into the mitochondrial matrix has yet to be identified but the 
transportation step is not the limiting factor of proline metabolism in the liver [174]. 
Supplementation of proline could therefore be explored as a potential therapeutic for 
complex I inhibition and proline metabolism intermediates used as biomarkers for 
problems with mitochondrial proton motive force. 
Late on in phase two, the glycerol phosphate shuttle rapidly increased in flux. This 
pathway cyclically converted glycerone phosphate (also known as dihydroxyacetone 
phosphate (DHAP)) into glycerol-3-phosphate, using NADH as a cofactor and 
producing NAD+ in the process (Figure 3.6). The reaction occurs in the cytosolic 
compartment and adds quinones to the quinone pool for OXPHOS activity. The 
increased dependence on NADH for feeding the glycerol-phosphate shuttle forced a 
decline on the conversion of cytosolic pyruvate into lactate and subsequent decline 
in the export of lactate from the system. The glycerol-phosphate shuttle is dependent 
on two enzymes, a cytosolic glycerol-3-phosphate dehydrogenase and a 
mitochondrial membrane bound FAD-dependant glycerol-3-phosphate 
dehydrogenase, the activity of the pathway depends on equimolar proportions of 
both enzymes [175]. Expression levels of these two enzymes are particularly low in 
liver compared to other organs [176]. However, this does not invalidate the presence 
of the pathway in the simulations as the primary focus of flux balance analysis is 
purely qualitative. The rapid activation of the glycerol phosphate shuttle along with 
the halt in system lactate export marked the end of the phase two adaptations, and 
the beginning of phase three. 





The third phase (Figure 3.5c) marked the start of the decline in the system ATP 
production levels, the metabolic adaptations which occurred could no longer 
maintain the basal level of ATP production. The metabolic pathways in the three 
non-inhibited organs began to alter and their complex activity began to decline. The 
brain, being the highest metabolically demanding organ and largest ATP consumer, 
underwent the largest changes. The predominate alteration in the brain was the 
immediate halt of the three branched-chain amino acid (BCAA) metabolism 
pathways along with threonine metabolism, all of which feed the TCA cycle. In 
response to the loss of flux feeding the TCA cycle, fatty acid β-oxidation was 
increased within the brain, although this flux was limited in the model due to the 
known inefficiency of fatty acid β-oxidation in the brain [177]. Fatty acid β-oxidation 
within the heart and kidney slowly declined over the duration of phase three, caused 
by the lowered TCA cycle flux needed to maintain their decreasing complex activity.  
Figure 3.6. Two metabolic pathways that activated during complex I inhibition which 
contributed to the quinone pool; proline synthesis and degradation in the 
mitochondrial matrix and the glycerol phosphate shuttle in the intermembrane space. 




The consumption and conversion of glucose into either pyruvate or serine in all three 
non-inhibited organs had decreased activity over the phase. In the heart and kidney, 
this meant the immediate halt in all activity whilst the brain had a slow decline in 
activity until maximum liver complex I inhibition. The adaptation to glucose 
consumption reflects each organs’ metabolic consumption rate. Fatty-acid β-
oxidation is the more efficient and slower ATP production method whilst glycolysis is 
the faster, less efficient pathway. It is therefore expected that, in times of metabolic 
stress, glycolysis would only be active in the higher metabolically demanding organs 
or organs under stress, such as the brain and liver in this situation. This result adds 
credibility to the choice of objective function by accurately reflecting the expected 
behaviour of glycolysis in human organs put under metabolic stress. 
The organism wide metabolic adaptations and the liver supplementation of the 
quinone pool by the proline cycle and glycerol phosphate shuttle, which both 
remained at maximum flux, enabled the constant maximisation of liver complex II-IV 
over the duration of the phase. However, the start of the phase triggered different 
metabolic adaptations which feed the TCA cycle and subsequent OXPHOS 
complexes. Fatty acid β-oxidation decreased immediately then remained at the same 
reduced rate over the phase. To compensate for the loss of TCA feeding, three 
different amino acid metabolisms were activated; leucine, which fed ketogenesis 
necessary for constant ketone body degradation in the brain, isoleucine and β-
alanine, both of which fed directly into the TCA cycle (Figure 3.4d). The third BCAA 
metabolism pathway, valine metabolism, did not activate, which was the only BCAA 
metabolite found accumulated in the liver of rats with drug-induced mitochondrial 
dysfunction studied in the previous chapter. This suggests that during complex I 
inhibition there was an affinity towards isoleucine metabolism instead of valine 
metabolism, despite both feeding into the same point of the TCA cycle. The 
metabolomics study identified metabolites found in each of the three activated amino 
acid pathways; both leucine and isoleucine intermediates were found in abundance 
whilst β-alanine accumulated in the liver. All these pathways mark the start of phase 
three and could therefore be potential biomarkers for high levels of complex I 
mitochondrial dysfunction. The activation of these specific metabolism pathways 
could be exploited as a biomarker for high levels of complex I inhibition. 




The glycerol phosphate shuttle reaching maximum flux triggered the swap into phase 
three. Phase three began with the reversal of the cytosolic pyruvate into lactate 
reaction, necessary to regenerate NAD+ into NADH in the cytosolic compartment to 
feed the glycerol phosphate shuttle. In accordance, the system lactate export, akin to 
lactate accumulation in the blood, was stopped and returned to basal import levels. 
The overall behaviour of the pyruvate to lactate reaction over the course of complex I 
inhibition makes lactate level monitoring an interesting prospect for complex I 
inhibition. The complete reversal of the reaction creates an inflection point that 
should be noticeable in the blood making it an ideal biomarker. 
Maximum flux of glycolysis, along with the conversion of lactate into pyruvate in the 
cytosolic compartment, caused a large availability of pyruvate in the cytosol. For the 
first time throughout the whole of the complex I inhibition levels, pyruvate was 
transported into the mitochondrial matrix and converted into acetyl-CoA to replace 
the lost feeding of the TCA cycle by decreased fatty acid β-oxidation. In both the 
cytosolic compartment and the mitochondrial matrix, excess pyruvate was converted 
into alanine and 2-oxoglutarate. The cytosolic 2-oxoglutarate was transported into 
the matrix by one half of the malate-aspartate shuttle which, along with the 
mitochondrial 2-oxoglutrate, feed both the TCA cycle and the newly increased BCAA 
metabolism pathways of isoleucine and leucine. The alanine produced in both 
compartments was simply exported by the liver and the system (Figure 3.4d). This 
Figure 3.7. The chain of pathways which activated in phase three of liver complex I 
inhibition, the final adaptations which generated NAD+ in the mitochondrial matrix. 




behaviour, and the cyclical alanine-pyruvate activity which occurred during phase 
one and two, highlights alanine as a particularly critical metabolite for complex I 
inhibition. Similar to lactate, the inflection point on the transportation of alanine in the 
system highlights the monitoring of alanine levels as a potential biomarker for 
varying levels of complex I inhibition.   
The final pathway which activated to regenerate mitochondrial NAD+ was the glycine 
cleavage system (Figure 3.7). The system ultimately converted mitochondrial serine 
into glycine, generating NAD+ from NADH in the process. The pathway was 
continually active throughout all three phases but saw an immediate increase in 
activity as soon as phase three began (Figure 3.4d). The increased demand on 
serine was met by the activation of histidine metabolism which fed directly into serine 
synthesis via the synthesis of 5,10-methenyltetrahydrofolate (5,10-MTHF). Cytosolic 
serine was then transported into the mitochondrial matrix and entered the glycine 
cleavage system. The resulting glycine was then transported out and used to 
generate more cytosolic serine, creating a cyclical pathway. Ammonia produced 
during histidine metabolism was transported into the mitochondrial matrix, requiring 
proton motive force, and used up during the glycine cleavage system, creating a net 
ammonia neutral reaction at the cost of proton motive force. Intermediates of 
histidine metabolism were seen in the plasma of the rats suffering from mitochondrial 
dysfunction analysed in the previous chapter, as was the accumulation of serine in 
the liver. The behaviour of these pathways’ sheds light on potential reasons why 
these were seen and identified both as potential biomarkers for high inhibition 
complex I inhibition. 
After forty percent inhibition of liver complex I, all four organs remained in phase 
three and declined in flux until complete inhibition. At complete inhibition, the system 
ATP production flux decreased by 26% of its basal level.  
 
 





Figure 3.8. A) The activation points of each amino acid metabolism pathway from 
zero to complete inhibition of liver complex II which maximised in flux upon 
activation. Blue for pathways which occur in the mitochondrial matrix, red for those in 
the cytosolic compartment. B/C) Fluxes of important reactions throughout each of 
the three phases of liver complex II inhibition. 
 




3.3.3. Modelling liver mitochondrial complex II inhibition 
Mitochondrial complex II is part of both the OXPHOS and TCA pathways, and its 
inhibition is expected to affect both. Multiple amino acid metabolism pathways can 
be used to feed the TCA cycle such as glutaminolysis, the conversion of glutamine 
into 2-oxoglutarate. Many of the adaptations which occurred during complex II 
inhibition were the activation of various amino acid metabolism pathways, their point 
of activation over the course of the complex I inhibition simulations are shown in 
Figure 3.8a. Once activated, all these pathways immediately reached maximum flux 
and maintained their flux throughout the rest of the complex II inhibition simulations. 
The fluxes of other reactions which were identified as important metabolic 
adaptations during complex II inhibition are shown in Figure 3.8 and were separated 
into three different phases.  
 
Phase one 
Phase one began at one percent inhibition and ran until around twenty five percent 
inhibition. During this phase, the system ATP production level was maintained, 
suggesting adequate adaptations to cope with the increased stress. The activity of 
the liver OXPHOS pathway maintained its basal level with ATP production 
immediately supplemented by glycolysis which slowly increased over the phase and 
eventually reached its maximum (Figure 3.8b). The spike in cytosolic pyruvate levels 
from glycolysis was paired with its conversion into lactate, preferred over its import 
into the mitochondrial matrix which costs proton motive force (Figure 3.8c). Similar 
behaviour was seen during the complex I inhibition simulations once glycolysis 
began. However, unlike the complex I inhibition simulations, the lactate did not get 
exported out of the system. Instead, the lactate was used to feed the other organs, 
which convert it back into pyruvate to feed their own TCA cycles. Therefore, this 
pathway activity would not create an accumulation of lactate in the plasma of 
organisms with low levels of complex II inhibition but may cause increased levels of 
lactate in the liver.  




One of the important functions of a complete TCA cycle is the regeneration of 
mitochondrial NADH from NAD+ that is necessary for complex I activity. As one of 
the reactions of the TCA cycle, complex II inhibition caused a blockage in the cycle 
making it necessary to find alternate ways to regenerate NADH. Valine metabolism 
was the first reaction activated which fulfilled this role (Figure 3.8a). Additionally, 
valine metabolism generates a small amount of quinones for the quinone pool and 
feeds the TCA cycle (Figure 3.8). At three percent inhibition, the pathway switched 
on and immediately reached maximum flux. This showed a contrast to the complex I 
inhibition simulations where valine metabolism never activated, highlighting the 
different amino acid metabolism affinities of the system to different complex 
inhibitions. Valine metabolism intermediates could therefore be used to differentiate 
between mitochondrial dysfunction caused by complex II inhibition.  
The supplementation of the TCA cycle by valine metabolism and the blockage 
caused by the inhibition of complex II necessitated the efflux of succinate, an 
intermediate of the TCA cycle and complex II reaction (Figure 3.8b). Succinate was 
exported from both the mitochondrial matrix and system, akin to an accumulation of 
succinate in the blood (Figure 3.9). Over the duration of all three phases of complex 
II inhibition, succinate export from the system continued with a steadily increased 
efflux during phase one and two, where it reached its maximum. The accumulation of 
succinate has been seen in vitro when cells are given known complex II inhibitors 
[178,179]. In addition, an increased level of succinate has been proposed as a 
diagnostic marker for cancers which have altered complex II activity [180]. Therefore, 
an increase in succinate levels could be used as a biomarker for complex II inhibition 
with the fold-change increase being representative of the inhibition level at lower 
levels of inhibition.  
The loss of complex II activity caused a decrease in quinone production for the 
quinone pool. In addition to valine metabolism activation, the glycerol phosphate 
shuttle was also activated to supplement the quinone pool at the same complex II 
inhibition level (Figure 3.8b). The pathway steadily increased in flux throughout 
phase one and reached its maximum flux at the end of the phase. The pathway 
activated much earlier than during complex I inhibition and increased much slower. 
This highlights a different affinity for the major quinone generation pathways in 




complex II inhibition when compared to complex I, caused by the difference in 
secondary issues related to their inhibitions. Early detection of glycerol phosphate 
shuttle intermediates could therefore be used to differentiate complex II inhibition. 
Further into the phase at around seventeen percent inhibition, isoleucine metabolism 
activated in the mitochondrial matrix (Figure 3.8a). The pathway fulfilled a similar 
function to valine metabolism by feeding the TCA cycle, regenerating mitochondrial 
NADH and contributing a small amount of quinones to the quinone pool (Figure 3.9). 
An increase in valine and isoleucine metabolism put an increased demand on 
mitochondrial 2-oxoglutarate, required for the first steps in both pathways. 
Throughout the complex II inhibition phases, mitochondrial 2-oxoglutarate levels 
were supplemented by the conversion of pyruvate into alanine and 2-oxoglutratate, 
with the excess alanine produced transported back into the cytosolic compartment. 
This put increased demand on the transportation of cytosolic pyruvate into the 
mitochondrial matrix. Combined with the growing cytosolic NADH demands of the 
glycerol phosphate shuttle when isoleucine metabolism activated, and the increased 
demand for pyruvate to feed the TCA cycle, caused a slow decrease in lactate 
production from cytosolic pyruvate. Interestingly, the feeding of the TCA cycle by 
pyruvate in the mitochondrial matrix was done exclusively by its conversion into 
oxaloacetate during phase one instead of its regular conversion into acetyl-CoA, 
despite this reaction costing ATP. This was because the levels of mitochondrial 
oxaloacetate became the limiting factor in TCA cycle flux due to the blockage caused 
by complex II.   
 
Phase two 
Phase two began at twenty five percent inhibition and lasted until around thirty seven 
percent inhibition of complex II. The adaptations during this phase still managed to 
cope with the added stress, maintaining the basal level of system ATP production. 
The complexes in the liver, except for complex II, slowly increased in flux during the 
phase and reached their maximum flux just before the swap into the third phase. 
With glycolysis reaching its maximum flux, the adaptations during phase two focused 
on increasing OXPHOS activity and relieving the blockage in the TCA cycle. 




Additional ATP was produced by the steady increase in fatty acid β-oxidation which 
maxed out just over half way through the phase (Figure 3.8b). The blocked TCA 
cycle caused the system to prefer maximising glycolysis first over fatty acid β-
oxidation as the pathway occurred in the cytosolic compartment and could produce 
ATP without interacting with the TCA cycle. The opposite behaviour occurred during 
complex I inhibition, where fatty acid β-oxidation was the first pathway to reach 
maximum flux, behaviour which could be used to differentiate complex II inhibition in 
vivo.  
The trigger for swapping into phase two was the activation of the production of 
cytosolic malate from oxaloacetate which required cytosolic NADH (Figure 3.10). 
The steady increased demand on cytosolic NADH caused the decline of the glycerol 
phosphate shuttle over the duration of phase two which completely stopped by the 
end of the phase (Figure 3.8b). The produced cytosolic malate was transported into 
the mitochondrial matrix by the mitochondrial citrate carrier, which exchanged 
mitochondrial citrate for cytosolic malate (Figure 3.9) [181]. The mitochondrial malate 
then entered the TCA cycle where it regenerated mitochondrial NADH. The eventual 
product of the imported malate was mitochondrial citrate as part of the natural 
progression of the TCA cycle which was used to import more cytosolic malate via the 
citrate carrier. Combined with the increased efflux of succinate from the 
mitochondrial matrix, the behaviour allowed greater flux in the TCA cycle by acting 
as a bypass around the inhibited complex II reaction of the TCA cycle. The increased 
TCA flux regenerated more mitochondrial NADH resulting in the slow increase in 
OXPHOS activity seen throughout the phase. Cytosolic malate levels were 
immediately supplemented by the activation of phenylalanine metabolism and 
asparagine metabolism in the cytosolic compartment (Figure 3.8a, Figure 3.10). 
Intermediates of both these pathways were found decreased in the plasma of the 
rats studied in the metabolomics data set. 
The exported citrate was then combined with CoA in the cytosolic compartment to 
generate acetyl-CoA and oxaloacetate, closing the loop to create a cyclical pathway 
for feeding the TCA cycle (Figure 3.10). The cytosolic acetyl-CoA then degraded into 
CoA, creating a net neutral use of cytosolic CoA, and acetate which was exported 
from the liver and system. The flux through all the pathways involved in this cycle 




rapidly increased throughout phase two and continued to increase in phase three. 
The rapid efflux of acetate in this manner would cause the accumulation of acetate in 
patients with complex II dysfunction, although this has not been identified in any 
previous studies. An alternative clinical phenotype for this cyclical pathway would be 
the accumulation of either acetyl-CoA in the liver or citrate in the blood with the 
production of acetate either not active or rate limited. Nevertheless, this behaviour 
highlighted three different metabolites which could be used as biomarkers for 
identifying the circumvention of the TCA cycle using the citrate carrier, caused by a 
blockage in the TCA cycle or complex II inhibition. The rats studied in the previous 
chapter had an increased level of citrate in their blood.  
Additional cytosolic citrate, used in the production of oxaloacetate, was generated 
using reductive carboxylation which immediately activated and reached its maximum 
flux once phase two started (Figure 3.8c), converting cytosolic 2-oxoglutarate into 
citrate. The increased demand on 2-oxoglutarate was fulfilled by the conversion of 
cytosolic pyruvate into alanine and 2-oxoglutarate (Figure 3.10), which continued 
throughout the phase (Figure 3.8c). This was a reversal of the basal directionality of 
the pathway which throughout phase one was converting alanine into pyruvate. 
Figure 3.9. The metabolic adaptations in the mitochondrial matrix which fed the TCA 
cycle over the course of zero to complete inhibition of liver complex II. 




Paired with this reaction in phase one was the synthesis of glutamine which was 
being used to remove excess cytosolic glutamate produced as a by-product of the 
alanine to pyruvate conversion (Figure 3.8c). The synthesis of glutamine therefore 
completely stopped during phase two after the steady increase in alanine production. 
The alanine produced in the cytosolic compartment of the liver during phase two was 
exported from both the liver and the system. Clinically this would present itself as an 
accumulation of alanine in the plasma during complex II inhibition, albeit only for the 
small window of inhibition represented by phase two.  
 
Further cytosolic NADH regeneration to feed malate production began at the start of 
phase two using the conversion of lactate into pyruvate (Figure 3.10). The flux 
steadily increased during the phase and eventually reached its maximum towards 
the end of the phase (Figure 3.8c). The constant consumption of lactate caused an 
increase in the system import of lactate which would be equivalent to a lactate 
deficiency in the plasma. A decrease in liver lactate level was identified in the rats 
with known mitochondrial dysfunction studied in the previous chapter. The overall 
Figure 3.10. The metabolic adaptations in the FBA model cytosolic compartment 
which fed the production of malate over the course of zero to complete inhibition of 
liver complex II to facilitate the malate-citrate exchange feeding the TCA cycle. 




behaviour of the pyruvate-lactate pathway over the course of the complex II inhibition 
simulations identified lactate as a potentially useful biomarker. The rapid increase in 
production, subsequently followed by a steady increase in the reverse reaction would 
be expected to cause a detectable change in plasma levels over the course of 
varying complex II inhibition levels, allowing for a rough estimate of an organism’s 
level of complex II inhibition. 
The final two metabolic adaptations which occurred during phase two were the 
activation and immediate maximisation of serine biosynthesis and lysine metabolism. 
Serine biosynthesis in the cytosolic compartment was used to generate cytosolic 
NADH necessary to fuel malate production (Figure 3.10). Lysine metabolism in the 
mitochondrial matrix fulfilled a similar role to the two BCAA metabolism pathways 
already active in the mitochondrial matrix, it regenerated mitochondrial NADH for 
complex I activity, fed the TCA cycle via acetyl-CoA and generated a small amount 
of quinones which were added to the quinone pool (Figure 3.9).  
 
Phase three 
The switch into phase three began at around thirty seven percent inhibition, triggered 
by the return to the basal directionality of the alanine to pyruvate reaction in the 
cytosolic compartment due to increased demand on pyruvate to feed the TCA cycle. 
System ATP production levels began to decline for the first time in the complex II 
inhibition simulations along with a decrease in complex activity of the non-inhibited 
organs. In the heart and kidneys, all glucose consumption completely stopped whilst 
in the brain, leucine, isoleucine, valine and threonine metabolism stopped which was 
met by a slight increase in fatty acid β-oxidation. All these adaptations were the 
same adaptations seen in the complex I inhibitions, just at a slightly higher inhibition 
level. Liver OXPHOS activity slowly decreased over the duration of the phase. Liver 
ATP synthase activity rapidly decreased at a higher rate than the other complexes 
due to a necessary increased import of pyruvate into the mitochondrial matrix to feed 
the TCA cycle which, for the first time, was via its conversion into acetyl-CoA.  




The activity of the alanine to pyruvate reaction in the cytosolic compartment during 
phase three was much higher than its basal level which occurred during phase one 
(Figure 3.8c). This activity was matched by an increased system and liver import of 
alanine which would most likely be seen clinically as a change in alanine levels in 
both the liver and blood. The other metabolite for this reaction was cytosolic 2-
oxoglutarate, putting a much higher demand on the metabolite. In response, the 
system immediately activated and maximised cysteine metabolism (Figure 3.8a). 
Further into the phase, and the last adaptation which occurred in the liver for 
complex II inhibition, was the activation of methionine metabolism which 
supplemented cysteine metabolism and cytosolic 2-oxoglutarate production 
necessary for both alanine and asparagine/aspartate metabolism (Figure 3.10).  
The other three metabolic adaptations which occurred during this phase were all 
amino acid metabolism pathways. In the cytosolic compartment, tryptophan 
metabolism was activated immediately into the phase which was used to regenerate 
cytosolic NADH for the continued activity of the malate-citrate exchange (Figure 
3.8a), the cyclical pathway seen in phase two which continued its activity throughout 
the whole of phase three (Figure 3.10). The final steps of tryptophan metabolism 
occurred in the mitochondrial matrix which shares the same final reactions as lysine 
metabolism, both of which fed the TCA cycle and produced a small amount of 
quinones for the quinone pool. At the same inhibition level, β-alanine metabolism 
was activated in the mitochondrial matrix which regenerated mitochondrial NADH 
and fed the TCA cycle via acetyl-CoA (Figure 3.9). The penultimate pathway to 
activate was histidine metabolism in the cytosolic compartment, paired with an 
increase in the glycine cleavage system to ensure the pathway was ammonia neutral 
(Figure 3.8c). Histidine metabolism was used to ultimately produce cytosolic serine 
for cytosolic NADH regeneration (Figure 3.10).  
A plethora of the amino acid pathways which activated throughout the complex II 
inhibition simulations were not present in the complex I and III/IV simulations. In fact, 
complex I had its own unique amino acid pathway activated, leucine metabolism. 
Figure 3.8a represents the ordered affinity of the system for each of the different 
amino acid metabolisms which switch on during progressively higher complex II 
inhibition in the liver. Therefore, the monitoring of intermediates within each of these 




pathways could act as multiple biomarkers for identifying the level of complex II 
inhibition present in an organism. For example, identifying an increased activity in 
both valine and asparagine metabolism, but not tryptophan metabolism within an 
organism would indicate an inhibition level of less than thirty seven percent and 
place them in phase two of adaptations.  
After fifty percent inhibition of liver complex II, all four organs remained in phase 
three and declined in flux until complete inhibition. At complete inhibition, the system 
ATP production flux decreased by 61% of its basal level. 
 
3.4. Conclusion 
The simulations of all the complex inhibitions in the liver highlighted an obvious 
difference in the ability of the system to adapt to each complex inhibition and their 
subsequent lethality. Complete inhibition of complex I reduced the basal level of 
system ATP production by a quarter, whilst complex III/IV inhibition reduced the 
production to almost zero. Being the first step in the pathway and having no other 
interactors, complex I inhibition had multiple adaptations which counteracted the lost 
function and managed to maintain basal levels of ATP production until twenty five 
percent inhibition. Complex II inhibition caused a larger number of adaptations than 
complex I activity which primarily aimed to fix the blockage in the TCA cycle caused 
by lost complex II activity. The adaptations maintained the basal ATP production 
level until thirty seven percent inhibition but ultimately resulted in a sixty percent 
decrease in system ATP production once completely inhibited. Complex III/IV 
inhibition, being the last stage in the OXPHOS pathway and having no other 
interactors, had the smallest number of adaptations and caused the most drastic 
decrease in system ATP production levels at complete inhibition. The system had no 
means to avoid the complex III/IV inhibition and the reduced ability to safely remove 
quinones from the quinone pool restricted the possible adaptations causing the 
system ATP production to begin reducing as early as one percent inhibition. 
Complex III/IV inhibition is markedly more lethal to a system than complex I & II 
inhibition.  




The unique behaviour of the two primary ATP production replacement pathways, 
glycolysis and fatty acid β-oxidation, over the duration of each complex inhibition 
highlights a simple mechanism for identifying which complex is inhibited in cases of 
known mitochondrial dysfunction during drug development. Complex I inhibition saw 
an increase in fatty acid β-oxidation as a first response, followed by an increase in 
glycolysis paired with a drop in fatty acid β-oxidation. Complex II inhibition saw the 
rapid increase in glycolysis as a first response followed by a slow increase in fatty 
acid β-oxidation. Finally, complex III/IV saw a rapid increase in glycolysis as a first 
response with a decline and complete halt of fatty acid β-oxidation. Therefore, the 
monitoring of these two pathways over various drug concentration levels would 
enable the identification of the complex being inhibited by the drug, a theory which 
should be explored in future experimentation.  
The simulations also identified many other pathways and behaviours which were 
unique to each complex inhibition that could be used to differentiate between 
different types of mitochondrial dysfunction caused by complex inhibition. Complex I 
inhibition can be identified by its drastically increased activity of proline cycling and 
the glycerol phosphate shuttle to replace the lost quinone production, along with the 
increase in a small set of amino acids at relatively high levels of inhibition. Complex 
II had a unique efflux of succinate and increased malate-citrate exchange creating 
an extended TCA cycle to avoid the complex II reaction. In addition, complex II 
inhibition had a plethora of amino acid metabolism pathways which activated at 
different inhibition levels, giving the ability to estimate a complex II inhibition level 
based on which pathways were switched on or off. Finally, complex III/IV had a 
unique increase in the complete malate-aspartate shuttle along with a drastic 
avoidance in quinone production which the metabolomics suggests could be causing 
the accumulation of biomarkers which indicate erroneous activity of pathways that 
generate quinones as a by-product, such as BCAA metabolism and fatty acid β-
oxidation.  
Other particularly interesting results of the simulations point to two specific 
metabolites which had particularly dynamic behaviour; alanine and lactate. Alanine is 
closely related to pyruvate and had highly dynamic behaviour in both complex I and 
II inhibition where it swapped from being consumed to produced, behaviour which 




would be ideal in estimating a precise complex inhibition level. Lactate accumulation 
is a known symptom of mitochondrial dysfunction however, these simulations 
suggest that the case may not be as simple as believed. The metabolite, which also 
has a close relationship with pyruvate, swapped behaviour from consumption to 
production during all three complex inhibition simulations, highlighting it as an 
interesting prospect as a biomarker for identifying both the type of complex inhibition 
and an estimated inhibition level.  
The organism model used for the simulations used constraints based on qualitatively 
adapted values taken from measurements in cardiomyocytes. Although these are 
expected to be within reasonable bound of the true values for each of the different 
organs, they can be massively improved upon. As a result, the discussed 
adaptations are of a qualitative nature, the different phases of adaptations may occur 
at different inhibition levels in vivo and may occur during a different inhibition window 
than identified in the simulations. Future studies focused on measuring each organ 
import/export rate of the various metabolites used in the model would improve 
simulation accuracy and allow for greater confidence in precise inhibition levels and 
phase duration windows. Further simulations of different types of mitochondrial 
dysfunction using the organism model, such as inhibiting complexes in a different 
organ or inhibiting multiple complexes at once, should also be performed in the 
future. These simulations would build on the results of this study by creating a larger 
basis in which unique and shared behaviours can be identified, allowing for the 
identification of biomarker which could confidently differentiate between types of 































  Predicting mitochondrial localisation 
 
4.1. Introduction 
4.1.1. Mitochondrial protein localization  
Advancements in next generation sequencing over the last decade has led to the 
increased knowledge of the human genome with almost 21,000 gold-standard 
reviewed human putative protein-coding genes listed in the UniProt database [182]. 
Less than nine hundred of these are confidently localised in mitochondria with an 
additional six hundred predicted, but currently unknown [28]. The critical functions of 
the mitochondria and their involvement in serious human diseases makes the set of 
unknown proteins an important piece of knowledge. The set of proteins could 
contain the missing link in allowing us to generate therapeutics for multiple diseases 
such as Alzheimer’s disease. Many experimental attempts have been made to 
complete the mitochondrial proteome. 
The most common experimental technique involves using mass spectrometry, and 
many large-scale studies have been done using multiple tissues in a range of 
species [183–185]. The process involves fractioning the mitochondria from cells and 
putting the protein contents of the mitochondria through a mass spectrometer using 
the latest technology, such as liquid chromatography or tandem mass spectrometry. 
The mass spectrometer identifies which proteins are present in the mitochondria 
resulting in binary data sets where each protein is labelled as either present or 
absent. The main problem with the technique is contamination resulting from either 
human error or difficulties in fractioning the mitochondria from the cell, leading to 




proteins being incorrectly annotated as mitochondrially localised, e.g. keratin which 
is commonly transferred from the environment [186].  
Alternative experimental techniques for identifying mitochondrial proteins involve 
imaging complete cells and tracking protein localisation. The experiments are 
performed by tagging a protein of interest with another protein that has fluorescent 
properties making it visible under a confocal microscope, which allows for the 
tracking of protein localisation in the cell. The tagging is done by either anti-body 
staining [187] or by addition of the green fluorescent protein (GFP) sequence to a 
proteins’ coding region, known as GFP tagging [188]. The major drawback to both 
techniques is that a single experiment must be done for each protein making it time 
consuming. There is also a chance that the tagging of the protein can interfere with 
the biology and cause an incorrect result.  
The large proportion of known mitochondrial proteins are nuclear encoded and 
require an N-terminal mitochondrial targeting sequence (MTS) for the protein to be 
transported into the mitochondrial matrix [189]. Computational efforts to predict 
mitochondrial protein localisation have been focused on identifying the presence of 
an MTS for any protein. There have been many different programs which use 
varying techniques and input data to generate a single score for each protein which 
represents the probability of the presence of an MTS. The most recent is MitoFates 
which uses machine learning [33], the other popular programs are iPSORT [190], 
TargetP [191] and MitoProt [192].  
Despite the abundance of different experimental and computation attempts to 
identify the unknown mitochondrial proteins, there is currently no single study which 
is widely accepted as the complete mitochondrial proteome although MitoCarta2 is 
regarded as mostly complete. Multiple different databases have been created which 
aim to collect various data sets into a single place to help with cross-referencing the 
data sets on a single protein. MitoMiner [29] contains the most comprehensive set of 
both experimental and computational mitochondrial protein localisation data sets 
including fifty different mass spectrometry studies, ten different GFP studies, the 
four popular MTS prediction programs and the large-scale immunofluorescent study 
completed by the Human Protein Atlas [187]. MitoMiner references each protein on 
a gene level and therefore also contains all gene information stored in the gene 




ontology (GO) database including GO annotation’s on protein localisation [32]. 
MitoMiner makes cross-referencing the data sets a much simpler task, but the 
process of identifying whether a protein is localised to the mitochondria remains a 
difficult task. Many of the data sets contradict each other and there is no method for 
identifying the most reliable data set without reading each publication, which is 
extremely time consuming.  
 
4.1.2. Consolidating experimental and computational efforts to predict 
mitochondrial localisation 
When making a judgement on whether a protein is part of the mitochondrial 
proteome, consolidating the large amount of different mitochondrial protein 
localisation data sets into a single entity would be vastly better than trying to cross-
reference the often-conflicting data sets. Many previous attempts have been made 
to create a single mitochondrial proteome, with MitoCarta being the most widely 
accepted [37]. However, the study used only a small subset of the currently 
available data sets with a relatively simple computational analysis method, a 
Bayesian classifier. Advances in technology over last decade has seen drastic 
improvement in machine learning capabilities and availability. Packages for 
performing machine learning are widely available and continually supported e.g. 
scikit-learn [97] and Tensorflow [193]. 
Support vector machines (SVM) is a supervised machine learning technique 
generally used for binary classification problems. Using a set of samples known to 
belong to each of the classification groups, called the training set, the method 
constructs a hyperplane (or set of hyperplanes) in the input variable space which 
best separates the two classification groups with the largest margin (Figure 4.1). 
Samples of unknown classification can then be assigned to one of the two classes 
using the generated hyperplane(s). When combined with Platt scaling, SVMs can 
provide probabilistic class outputs [194]. In the case of mitochondrial protein 
localisation, this would translate into each protein in the human proteome being 
assigned a value between zero and one, representing the probability that the protein 
is localised in the mitochondria. During the training process, the importance of data 




sets which have a low amount of classification power are gradually reduced. This 
means that the final assigned probability will not be majorly affected by any data 
sets which are lower quality and removes the need to personally read and evaluate 
each data set. In addition, machine learning methods benefit from having a large 
amount of input data. All these factors make SVMs the ideal machine learning 
method for consolidating the vast amount of experimental and computation datasets 
which try to predict protein mitochondrial localisation into a single, easier to 
understand entity.  
 
4.1.3. Chapter summary 
In this chapter, I describe the method for generating and training a support vector 
machine for predicting protein mitochondrial localisation using a manually curated 
training set. I outline the iterative tuning process used to generate the input data 
array and subsequent SVM optimal parameters. The final model generated is then 
evaluated for overfitting and used to identify novel mitochondrially localised proteins. 
Figure 4.1. An example of the optimal hyperplane which separates the two 
classes in a two-dimensional variable input space.  





4.2.1. Mitochondrial protein localisation data source collection 
MitoMiner was used as the primary source for collecting mitochondrial protein 
localisation data sources. The data sources included in the database have already 
been manually read and checked for any technical flaws. A total of forty-nine 
different data sources were collected from MitoMiner (Table 4.1). Thirty-seven 
different mass spectrometry mitochondrial protein localisation studies were selected 
which included a wide variety of different mammalian tissue types [37,183–185,195–
227]. An additional large-scale proteomic study using HeLa cells was also selected 
[31]. The complete set of GFP tagging studies found in MitoMiner were selected, a 
total of ten studies ranging from mammalian cells to yeast [36,183,188,209,228–
233], along with one large-scale immunofluorescence study conducted by the 
Human Protein Atlas [187]. The final experimental data source selected was a single 
study which used the enrichment of the CLUH gene, a cytosolic mRNA which 
specifically binds to a subset of mRNAs encoding mitochondrial proteins, to identify 
mitochondrial proteins [234]. Four different MTS programs were used to predict MTS 
on all proteins across four different species; human, mouse, rat and zebra fish 
[33,190–192]. Homologue cross-referencing across all the different species used in 
the various data sources was handled by MitoMiner which uses Ensembl Compara 
[235]. Gene ontology localisation annotations were also taken from MitoMiner for 
every protein [32]. Two additional studies were collected from outside of MitoMiner 
which both identified specific species homologs to human proteins, one study for 
homologs in Rickettsia [37] and one study for Monocercomonoides [236]. Rickettsia 
homologs were selected as the species is thought to be the most closely related 
species to the proto-mitochondria. Therefore, its homologs are potentially 
mitochondrial. In contrast, Monocercomonoides homologs are potentially non-
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Table 4.1. The data sources collected and used to generate features for the 
input data array.  




4.2.2. Training set definition  
The complete set of proteins selected for the positive training set, the known 
mitochondrially localised proteins, and the negative training set, the known non-
mitochondrially localised proteins, can be found in Supplementary File 4.1. The two 
sets were generated and manually curated by Dr. Anthony Smith and Dr. Alan 
Robinson based on in-depth database and literature reviews. The positive training 
set contained a total of 1,184 proteins whilst the negative training set contained 
1,336 proteins. The set of known mitochondrial proteins (<900 proteins) was 
expanded upon to generate the positive training set. As part of the iterative process 
of training an SVM model, proteins which were predicted as mitochondrially 
localised by a fully trained SVM model were manually literature reviewed. If 
published evidence for their mitochondrial localisation was found, the proteins were 
added to the positive training set and the whole SVM training pipeline was re-run. 
 
4.2.3. SVM parameter searching and model selection 
All support vector machine modelling was performed using Python [92] and the 
‘scikitlearn’ package [97]. The SVM models were generated using a radial basis 
function (RBF) kernel. The RBF kernel was the optimal choice as it is one of the 
most flexible kernels available for SVMs and allows for infinitely complex models. 
The kernel has also been proven to have universally high generalization ability 
[237]. All the features in the input data array were normalized to a mean of one and 
standard deviation of zero before all SVM model generation. To ensure the best 
choice of kernel parameters C and γ, iterative grid searching was performed using a 
course to fine approach, starting with a large interval for both parameters and 
iteratively reducing the intervals until the best parameters were identified. A large 
parameter space for C and γ between 0.001 and 10.00 was explored to identify the 
best possible model using the area under the receiver operating characteristic curve 
(AUROC) as the metric for measuring model performance. The receiver operating 
characteristic (ROC) curve is a plot used to illustrate the performance of a 
classification model by exploring the false positive rate and true positive rate of a 
model over a variable discrimination threshold. The area under this curve represents 




the degree of separability in the model, giving a numeric representation of how well 
the model can distinguish between the two classes with a value of one being perfect 
distinguishability. Forty SVM models were generated for each pairwise value for C 
and γ, their mean AUROC was used as the pairwise parameter performance metric.  
 
4.2.4. SVM feature and input data array creation 
The input data array which was used in the final SVM model consisted of fifty-seven 
different columns of information, known as features. The conversion of the data 
sources into features and the creation of the final data array was an iterative 
process. The entire parameter grid searching process was performed on many 
different iterations of the input data array producing many SVM models which were 
evaluated for performance based on their grid searching AUROC scores and 
training set accuracies. Additional feature selection was done on each of the input 
data array iterations using recursive feature elimination on an SVM model generated 
with a linear kernel, features which performed poorly were ultimately edited or 
removed from the final data array.  
Multiple different types of feature were generated and explored using the MTS data 
sources. This included using all four programs and each species as a separate 
feature for a total of sixteen features and using the mean MTS score for each 
program across all four species for a total of four features. The best performing, and 
the feature used in the final input data array, was the average score over all four 
programs and all four species. The single feature was a continuous value between 
zero and one representing the likelihood of the protein having an MTS based on four 
different prediction programs across all known homologs in human, mouse, rat and 
zebra fish. MTS were calculated across four different species as mitochondrial 
proteins, and their MTS, are expected to be conserved across vertebrates. If a 
protein MTS is predicted for only one or two species, the result was most likely a 
false positive.  
The mass spectrometry data sources were all converted into binary features 
representing the presence or absence of the protein in the mitochondrial fraction 




analysed in the study. Studies which analysed more than one tissue type were 
found to generate better models when summed together into a single integer feature 
rather than separated out by tissue type into multiple binary features. Additional 
features were created by summing together all binary features of the same tissue 
type across all the mass spectrometry data sources. A single integer feature was 
generated in this fashion for placenta, brain, skeletal muscle, liver, kidney and heart. 
A total of forty-three features were generated from the thirty-seven mass 
spectrometry data sources and used in the final input data array, a mixture of binary 
and integer features used in the training of the final SVM model.  
A single feature was generated using the data contained in the COMPARTMENTS 
database [238]. In the database, each piece of evidence supporting either 
mitochondrial or non-mitochondrial localisation of a protein was assigned a 
confidence score. These values were collected and the difference between these 
two values were calculated and used to generate the ‘compartments knowledge 
difference’ feature where a positive score indicated mitochondrial localisation. An 
additional feature was generated by Dr. Alan Robinson, labelled ‘Community 
mitochondrial ratio’, which measured the ratio of proteins that were mitochondrially 
localised in each protein’s set of direct protein-protein interactors’. The protein-
protein interaction information was collected from the STRING database [239]. 
Eleven binary features were generated from the remaining seven data sources. Two 
features were generated from the collection of GFP studies, one feature for the 
collection of mammalian GFP studies and one for the yeast. The GFP studies for 
each of these two species were combined into a single binary protein presence or 
absence feature. Four binary features were generated from the HPA 
immunofluorescence study based on the HPA annotation of protein localisation to 
the mitochondrial compartment, the non-mitochondrial compartment, not detected 
and the cytoplasm. Two binary features were generated from the HeLa proteomics 
study based on the studies’ protein annotation of mitochondrial or non-
mitochondrial. A single binary feature was generated from the CLUH enrichment 
study based on whether a protein’s mRNA had been determined to bind to CLUH 
during the study. The final two binary features were generated using the homolog 




studies in Rickettisa and Monocercomonoides based on a protein’s presence or 
absence of an identified homolog within the species. 
Other types of mitochondrial protein localisation data sources were explored 
including data sets produced using microarray gene expression [240] and ribosome 
profiling [241], but these provided no additional classification power and were 
therefore filtered out during the iterative SVM model creation process. The final fifty-
seven feature data array resulted in the best model performance and was used to 
generate the SVM model for the mitochondrial protein localisation predictions. 
Hierarchical clustering of the training set over the final input data array and T-
distributed Stochastic Neighbor Embedding (t-SNE) [242] plots of the final data array 
were both generated using R. 
 
4.2.5. SVM model validation 
Model validation to check and prevent for overfitting was performed throughout the 
iterative feature selection and grid searching process. Before every iteration of grid 
searching, twenty percent of the training set was randomly selected and placed into 
a held-out validation set with the remaining eighty percent used to train the SVM 
model. During the training process, randomly selected stratified 10-fold cross-
validation was employed to avoid overfitting. The accuracy of the fully-trained SVM 
model on the held-out validation set was continually compared to the CV accuracy 
of the model to ensure no overfitting occurred. For each grid searching interval and 
randomly selected held-out validation set, the remaining training set was split into 
randomly selected folds (Figure 4.2). Eight SVM models were generated for a single 
training-validation set split, each using a different randomised stratified 10-fold 
cross-validation. Five different randomly selected held-out validation sets were 
generated for each grid searching interval, resulting in a total of forty models 
generated for each grid searching interval. All these steps were to ensure that 
overfitting was not present, and that the models fully explored the complete training 
set.  




Model validation of the final SVM model produced using the optimal parameters was 
performed by producing learning curves. Learning curves plot the AUROC error of 
both the CV and the complete training set against the size of the training set. The 
curve shows how model performance changes as the training set size increases, 
giving an insight into the bias-variance trade-off occurring in the model. Learning 
curves were generated using one-hundred different SVM models generated using 
the optimal parameters, each with different randomly split stratified 10-fold cross-
validation. In addition, overfitting was checked in the final model by calculating held-
out validation accuracies and CV accuracies of the SVM model using optimal 
parameters over a thousand different randomised training-validation set splits. 
 
4.2.6. Input data array feature exploration 
The classification power of each of the features used to create the final SVM model 
was investigated using extreme gradient boosted decision trees. In combination with 
the positive and negative training sets, extreme gradient boosted decision trees 
were generated in R using the ‘xgboost’ package [243]. Parameter searching was 
performed using random grid searching to identify the best parameters based on 
decision tree accuracy. Using the best parameters, one thousand extreme gradient 
boosted decision trees were generated, and each features importance value was 
collected. The feature importance average over all replicates was used as the metric 
for evaluating overall feature classification power between the positive and negative 
training sets in the SVM input data array. 
 
 





Figure 4.2. An illustration of the random shuffling and splitting of the training set 
during the grid searching process.  
Figure 4.3. A) Hierarchical clustering of the training set samples over the SVM input 
data array of each protein (column) of the positive or negative training sets, and with 
each feature (row) scaled to mean zero and standard deviation of one. B) t-SNE plot of 
the training set and input SVM data array with perplexity = 10. 





4.3.1. Training set clustering over the input variable space 
Hierarchical clustering of the training set over the input data set showed that the two 
classes were separable (Figure 4.3a). The positive training set clustered into three 
distinct clusters which were differentiable from the negative training by a large 
subset of features which were much higher in the positive set. The subset of 
features included various binary presence or absence features, such as the mass 
spectrometry studies, which were much higher in the known mitochondrial genes 
than the known non-mitochondrial genes. The t-SNE plot of the training set over the 
input array further supports the fact that the classes are clearly separable (Figure 
4.3b), the two classes showed large regions of clear separation in the plot.  
 
4.3.2. SVM parameter searching using coarse-to-fine grid searching 
The grid searching for optimal parameters showed that the overall choice of 
parameter did not have an overwhelming effect on model performance with only a 
ten percent difference in the minimum and maximum AUROC scores seen (Figure 
4.4). The gamma parameter for tuning the RBF kernel had the largest effect on 
model performance with smaller values producing the best performing models. A 
gamma value of 0.0015 was selected as the optimal parameter based on producing 
high performing models on a consistent basis over the SVM model replicates 
generated as part of the grid parameter searching process. The C parameter for 
tuning the SVM margin had a much smaller effect on model performance, 
irrespective of the value of gamma. The selection of C parameter was set at a value 
of 2.5 which was selected as a middle ground value. The value was large enough to 
ensure a small SVM margin such that there was minimal risk of overfitting, whilst 
being small enough to adequately punish miss-classification and ensure consistently 
high performing models when paired with the optimal gamma value. 





4.3.3. Evaluation of the final SVM model  
The learning curves produced for the final SVM model showed that cross-validation 
error consistently improved with increased training set size for almost the entire 
process of increasing the training set size incrementally (Figure 4.5a). The final 
AUROC error for the cross-validation set eventually reached the low error rate of 
two percent. As the training set size increased, the training set error and cross-
validation error consistently converge to a very similar value, with less than half a 
percent difference between the final AUROC error values. The cross-validation set 
accuracy and validation set across the thousand randomly split replicates were both 
relatively consistent with the sets averaging 92% and 92.2% accuracy respectively 
(Figure 4.5b). The breakdown of the validation set accuracies into the positive and 
negative set accuracies showed a distinct difference in the class accuracies. The 
negative set averaged 98.9% accuracy with a markedly smaller variance than the 
positive set accuracies which averaged 84.7% accuracy.  
Figure 4.4. A 3-D plot showing the results of the coarse-to-fine grid searching for 
tuning the SVM model. 





4.3.4. SVM input feature importance using gradient boosted decision trees 
The extreme gradient boosted decision trees identified the COMPARTMENTS 
annotation feature as the most important feature for classification by a large margin. 
As such, a second iteration of decision trees were generated with the annotation 
feature removed to generate more accurate results for the rest of the feature list 
(Figure 4.6). The subsequent trees identified four features as highly important; 
protein MTS mean score, MitoCarta presence or absence, the protein-protein 
interaction feature which studied protein interaction clusters and the proteomics 
HeLa subcellular localisation study. After these top four features, there was a 
noticeable drop in mean importance score with the second group of important 
features including the HPA large-scale immunofluorescent study, the study on 
presence or absence of a Rickettsia homolog and a large set of mass spectrometry 
studies. At the bottom of the list of important features was a large set of mass 
spectrometry studies, the study on the presence or absence of a 
Monocercomonoides sp. homolog, the CLUH enrichment study and both the 
mammal and yeast GFP feature. For the training set proteins, each of the important 
Figure 4.5. A) Learning curve results using the optimal parameterSVM model averaged 
over 100 replicates. B) Accuracies of a thousand replicate SVM models generated using 
randomly split training sets with optimal parameters. 




features were plotted against their final predicted probability for being 
mitochondrially localised (Figure 4.7).  
 
4.3.5. SVM model mitochondrial localisation probability predictions 
Upon training the SVM model using the optimal parameters, training set and input 
data array, the trained SVM model was then used to generate a probability for all 
known human proteins which indicated their likelihood of being mitochondrially 
localized. The full breakdown of each proteins predicted probability can be 
downloaded at http://www.mrc-mbu.cam.ac.uk/impi, the list of novel predicted 
mitochondrial proteins can be found in Appendix II. Of the proteins that belonged to 
the positive training set, 106 of these were incorrectly classified as they were 
assigned a probability of less than 0.5 (Figure 4.8). In the negative training set, a 
total of 51 proteins were incorrectly classified with a probability greater than or equal 
to 0.5 with eleven of these assigned a probability of greater than or equal to 0.8. 
From the remaining 18,893 known human proteins which were not used in the 
training set, a total of 1,474 proteins were classified as mitochondrially localized with 
a probability of greater than or equal to 0.5 with 442 of these having been assigned 
a value greater than or equal to 0.8.  





Figure 4.6. The mean importance score for each of the features within the final SVM 
input data array calculated using extreme gradient boosted decision trees. Mass 
spectrometry studies are denoted by their PMID, whilst the combined tissue-specific 
mass spectrometry features are denoted by MS <Organ>. 





Figure 4.7. Plots of the training set proteins individual feature values against their 
predicted probability of mitochondrial localisation. Scatter plots have been fitted 
with a generalized linear model. The MitoCarta graph x-axis represents the 
number of experiments in which a protein was identified as mitochondrial during 
the study. 









Figure 4.8. A) The predicted mitochondrial localisation probabilities of the proteins 
belonging to the positive and negative training sets. B) Histogram’s of the predicted 
mitochondrial localisation probabilities of the other 18,893 known human proteins 
which were not included in either training set.  





4.4.1. Validation of the final SVM model 
The performance of any machine learning model is entirely limited by the quality of 
the input data array and the selection of the training set, the training set must be 
representative of the two classes and be separable in the input variable space. The 
t-SNE plot and hierarchical clustering of the training set confirmed that this was true 
for the generated input array and selected training set (Figure 4.3). Both methods 
vastly simplified the fifty-six-dimensional input array and managed to clearly 
separate the two classes. This highlighted the viability of the input array and training 
sets for use in more complex algorithms such as SVMs using the RBF kernel. The 
slight overlap of the training sets in the t-SNE plot, and presence of sparsely spread 
out positive training set samples within the negative training set clusters in the 
hierarchical clustering, indicated the presence of potential positive set outliers which 
could negatively affect model performance. However, as the training set was 
manually curated, these were experimentally confirmed mitochondrially localised 
proteins, not outliers, and were therefore kept in the positive training set to ensure 
complete representation of mitochondrially localised proteins within the training set. 
To ensure that the entirety of the positive training set was considered within the 
training process, including those that clustered with the negative set, the iterative 
random splitting described in Figure 4.2 was performed for many replicates during 
the grid searching process.  
The complete representation of mitochondrially localised proteins within the training 
set and the performed grid searching method was employed to prevent overfitting. 
The final model showed no sign of having overfitting, also known as high variance, 
based on the results of the learning curves and repeated held-out test set 
accuracies (Figure 4.5). In the presence of overfitting the training set error would 
remain extremely low whilst the cross-validation error would not improve resulting in 
a large difference in error rate. Both the training and cross-validation curves 
continually converged and eventually ended with only a small difference in error 
rates, an indicator that overfitting was unlikely. A large difference in held-out 
validation accuracy and cross-validation accuracy would have been seen if the 
model had been overfit to the training set. Many replicate SVM models were 




generated using randomly selected held-out validation sets to ensure that all training 
set samples were included in the held-out validation sets to improve the reliability of 
the accuracies. Only a 0.2% difference was seen in the average accuracy of the 
cross-validation set compared to the held-out validation sets with both having a 
relatively small variance, further indicating that the model did not suffer from having 
high variance.  
The flip side of a model overfitting is the model underfitting, also known as high bias, 
in which the algorithm fails to identify important aspects of the input variable space 
for the classes. An obvious indicator for underfitting would be a high overall error 
rate for both the training and cross-validation sets which was not present in this 
study. Additionally, the gradient of the learning curve for both the cross-validation 
and training sets would not gradually decrease until almost zero, which is precisely 
the behaviour present in the model learning curves. Both clearly show that the 
model did not suffer from having high bias. Combined, these results indicate that the 
final model had a good balance in the bias/variance trade-off and did not suffer from 
either under or overfitting. 
The extreme gradient boosted decision trees identified six features which would be 
expected to have a large amount of classification power in the final SVM model; 
three continuous, two binary and one sum of binary variables (Figure 4.6). The plots 
showed that none of these features singularly dominate the SVM probability 
predictions (Figure 4.7). In each of the features, both positive and negative training 
set samples are almost entirely classified correctly using a 0.5 probability threshold, 
irrespective of a single feature value. For example, using the generalized linear 
model as an indicator, positive training set samples with both a low and high MTS 
mean score are predicted to have a probability over 0.7. The predictions are 
therefore not being made by the algorithm overfitting to a single feature but by a 
combination of multiple features. This result supports the fact that no overfitting 
occurred in the model and gives confidence to the choice of SVM model kernel, 
tuning process and selected parameters. 
 




4.4.2. Mitochondrial proteome predictions of the final SVM model 
The average held-out validation set accuracy of 92.2% is the generalisation 
accuracy of the final model, the expected accuracy on the prediction of 
mitochondrial localisation for a completely unknown protein (Figure 4.5b). The large 
difference in the average validation accuracy between the positive and negative 
training set samples, and the difference in variance of the accuracies over the 
replicates for each set, identifies a potential way for increasing the model accuracy. 
The lower validation accuracy of the positive training set samples, and larger 
variance over the replicates, would most likely have been caused by the positive 
training set samples which were seen overlapping with the negative training set 
samples in the t-SNE plot, and those which clustered with the negative set in 
hierarchical clustering. By removing these samples, a higher positive set validation 
accuracy would most likely occur, but this would come at the cost of removing 
confirmed mitochondrially localised proteins and reduce the positive set 
representation of mitochondrially localised proteins. As such, and due to the already 
high generalisation accuracy of the final model, the positive training set was not 
altered. The difference in each training set validation accuracy identified a much 
higher model specificity than sensitivity i.e. proteins that are predicted to be non-
mitochondrially localised (predicted probability less than or equal to 0.5) can be 
taken with very high confidence but those which are predicted to be mitochondrially 
localised (predicted probability greater than 0.5) should not be taken as absolutely 
certified.  
In the case of identifying mitochondrially localised proteins, having a higher 
specificity is much more desirable than a high sensitivity. Outside of the two used 
training sets, the human proteome consists of 18,893 proteins which must be 
investigated when trying to identify novel mitochondrially localised proteins. The final 
model predicted that only 1,474 of these proteins had a probability of being 
mitochondrially localised, leaving 17,419 proteins predicted non-mitochondrial 
which, due to the hyper specificity of the model, can be taken with high confidence. 
In cases where novel mitochondrially localised proteins need to be identified, such 
as for the investigation of serious mitochondrial diseases, the list of potential 
proteins can therefore be confidently reduced to 1,474 proteins. For defining a 




mitochondrial proteome with confidence, based on the probability predictions of the 
final SVM model, the hyper specificity means that utilizing a higher probability 
threshold for class assignment would be beneficial.  
Using a probability threshold value of 0.8 instead of the default 0.5, the number of 
false positives from the training set was reduced from 51 to just eleven out of the 
1,336 proteins belonging to the negative training set (Figure 4.8). This new threshold 
value was selected solely for defining a referenceable mitochondrial proteome and 
was selected based on manually evaluating predicted proteins at various probability 
values on their evidence of protein localisation, their protein function and in-depth 
literature reviews. Using a probability threshold of 0.8 identified 442 predicted 
mitochondrially localised proteins from the 18,893 unknown human proteins. 
Combined with the known mitochondrial proteins used in the positive training set, 
generated a predicted mitochondrial proteome of 1,626 proteins, a number close to 
the expected 1,500 proteins of the mitochondrial proteome. The remaining 1,032 
proteins which were assigned a probability between 0.5 and 0.8 should still be 
considered when trying to investigate novel mitochondrial proteins as the proteins 
still show some evidence for being mitochondrially localised, just at a lower 
confidence level.  
 
4.5. Conclusion 
The final SVM model generated using the created input data array along with the 
training set performed very well and showed no sign of over or underfitting the data, 
with a generalisation accuracy of 92.2%. The model predicted 1,474 proteins to 
have adequate evidence to suggest mitochondrial localisation, with 442 having very 
high evidence. Therefore, the SVM model identified 442 novel mitochondrially 
localised proteins with high confidence, generating a predicted mitochondrial 
proteome of 1,626 proteins. The predicted proteome is currently being used in an 
NGS analysis pipeline within the MRC Mitochondrial Biology Unit for diagnosing 















  Predicting mitochondrial disease  
 
5.1. Introduction 
5.1.1. Genetic causes of mitochondrial disease 
The complex function of the mitochondria and its highly interconnected network of 
pathways leads to mitochondrial diseases having many different clinical phenotypes. 
Patients with mitochondrial disease caused by in-born errors often present with 
unique clinical phenotypes which are often difficult to associate with the precise 
cause of the disease. For example, patients with a mutation in the mitochondrial 
citrin transporter, SLC25A13, can present with neonatal intrahepatic cholestasis or 
adult onset hepatic disease, neither of which have an obvious correlation to citrin 
transportation across the mitochondrial matrix [244]. As mitochondria have their own 
DNA, called mitochondrial DNA (mtDNA), mitochondrial disease can be caused by 
mutations in either the mtDNA or nuclear DNA (nDNA).  
In humans, mtDNA are small circular DNA present in the mitochondrial matrix which 
are fully defined and encode for thirty-seven genes [27]. In humans the mitochondrial 
genome is entirely maternally inherited [245]. The mutation rate of the mitochondrial 
genome is much higher than the nuclear genome, believed to be related to the 
oxidative stress caused by OXPHOS within the mitochondrial matrix [246]. However, 
in a study of patients with pathogenic mtDNA point mutations, de novo mutations 
were common but showed low reoccurrence in future generations [247]. The 
presentation and clinical phenotype of mitochondrial diseases caused by mtDNA 
mutation are complicated by mitochondrial heteroplasmy, the proportion of wild-type 
mtDNA in the mitochondrial population compared to the mutant mtDNA. 
Chapter 5  Predicting mitochondrial disease 
120 
 
Heteroplasmy of mutant mtDNA must exceed a threshold before mitochondrial 
diseases manifest themselves in patients [46], with a higher proportion of mutant 
mtDNA having been associated with more severe symptoms [248]. Cases of 
mitochondrial disease caused by mutations in mtDNA have been estimated at 9.6 
cases per one-hundred thousand people [249]. Examples of mtDNA mutations which 
result in mitochondrial disease include mutations to complex subunits such as 
MTND1 and MTCO1 for complex I and IV respectively [250]. 
The human nuclear genome shows Mendelian inheritance and encodes for around 
21,000 proteins. There are 1,184 known proteins which belong to the mitochondrial 
proteome with an extra 442 predicted to localise to the mitochondria by the support 
vector machine trained in the previous chapter. The much larger library of possible 
nuclear encoded proteins causing mitochondrial disease makes diagnosis of nuclear 
causing mitochondrial diseases a more difficult process than diagnosing those 
caused by a mutation in the mtDNA. Cases of mitochondrial disease caused by 
mutations in nDNA have been estimated at 2.9 cases per one-hundred thousand 
people [249]. Examples of nDNA mutations which result in mitochondrial disease 
include mutations to the nuclear encoded respiratory complex subunits, such as 
NDUFS1 for complex I, and complex assembly factors such as SURF1 for complex 
IV [250,251].  
 
5.1.2. Diagnosis of mitochondrial disease by next generation sequencing 
Genetic screening for mitochondrial disease is the primary method for identifying and 
diagnosing mitochondrial disease. As mtDNA is relatively small, any patient with a 
suspected mitochondrial disease—especially if a family history suggests maternal 
inheritance—will have their mitochondrial genome sequenced first, generally using 
next generation sequencing (NGS) [252]. If the mtDNA lacks a plausible pathogenic 
variant, the patient will have their nuclear genome sequenced by either targeted 
NGS [253], the sequencing of a selected panel of genes, whole exome sequencing 
by NGS [254] or whole genome sequencing by NGS [255]. Recent studies have 
highlighted whole exome sequencing as the superior method for diagnosing 
mitochondrial diseases [255–257]. The sequence data collected from suspected 
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mitochondrial disease patients is then put through a pipeline such as the Genome 
Analysis Toolkit (GATK) [258]. The pipeline compares a patient’s genome with a 
reference genome and identifies all the mutations present in a patient, known as 
variant calling. Studies on the genetics of the human population shows that all 
humans carry an abundance of rare variants [259,260]. Therefore, each patient 
usually has hundreds of variants in the genes belonging to the mitochondrial 
proteome which must be filtered through in order to identify the disease-causing 
variant. When possible, family members are usually put through a similar pipeline to 
enable additional filtering of a patient’s variant list. 
Initial screening of the potential variants is done by comparison to the already known 
mitochondrial disease genes. The Online Mendelian Inheritance in Man (OMIM) 
database stores information regarding all human disease genes and their 
publications [261]. For mitochondrial diseases specifically, a manually curated and 
constantly maintained list of mitochondrial disease genes has been generated by a 
group at Washington University [262]. Variants which occur in one of the 344 known 
mitochondrial disease genes are then filtered by their rarity in the population. The 
Exome Aggregation Consortium (ExAC) database contains whole exome sequences 
from 60,000 healthy individuals and their known variants which allows for each 
variants rarity within the population to be calculated [263]. Variants in known 
mitochondrial disease genes which are rare within the population (<0.001%) are 
most likely to be the cause for disease. In cases where these variants do not exist, 
patients are left with a huge list of variants which may contain the disease-causing 
variant. This list must be manually investigated which is extremely time consuming 
and often almost impossible to filter. 
Large-scale studies on the diagnosis of mitochondrial diseases using sequencing 
identified only a 50% success rate [264,265]. Novel dominant disease-causing 
variants (those which are caused by a single mutation in one allele) are particularly 
difficult to distinguish from non-pathogenic variants in genes not associated with a 
dominant disease, unless the sequences of both parents are known. Furthermore, 
some diseases may be caused or exacerbated by the compound effect of multiple 
mutated genes leading to different penetrance [266]. Thus, the list of single allele 
variants is usually huge for each patient. The largest hurdle in diagnoses of patients 
Chapter 5  Predicting mitochondrial disease 
122 
 
with mitochondrial disease is this inability to identify candidate disease-causing 
genes from a patient’s list of variants which can be experimentally studied and 
verified.   
 
5.1.3. Computational methods for identifying disease genes 
Experimental procedures for identifying disease-causing genes are extremely costly 
and time consuming. Reducing the list of potential disease-causing variants in a 
patient to a smaller set of potential candidate genes using computational methods 
would enable a more targeted experimental approach and increase the diagnosis 
rate of mitochondrial diseases. The wealth of high quality, manually curated 
databases being created such as Gene Ontology (GO) and UniProt has seen the 
rise in computational methods being explored that can be used in conjuncture with 
sequencing to filter a patient’s list of variants. For example, exploring the functional 
annotation of a protein and linking its potential loss of function to the patient’s 
symptoms [267]. An alternative approach focuses on predicting potential disease 
genes which can be used to improve the screening of a patient’s variants.  
Many computation methods for predicting disease causing genes focus on studying 
the protein-protein interaction network of the human proteome [268,269]. Using 
network analysis, the local information in a protein-protein interaction network can be 
explored and used to quantify the positional importance of a protein within a local 
cluster [270]. Local clusters of the human protein-protein interaction network have 
been shown to fulfil similar cellular functions [271]. Within these clusters, disease 
genes have been shown to segregate at the edge of clusters and avoid highly 
connected areas [272]. In addition, disease genes have been shown to have a high 
propensity to interact with each other, forming disease-related clusters of proteins 
[272]. A method for predicting disease genes using this theorem involves comparing 
the interactors of a protein to those of a known disease gene for similarity [273,274]. 
The global features of the human protein-protein interaction network such as its 
topology have also been explored to predict disease genes. A study which used all 
known disease genes in OMIM showed that human disease genes had a larger 
number of interactors, had a shorter distance to other disease genes and shared 
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more common interactors to other disease genes than genes which had no disease 
association [275]. These theorems identify a potential method for predicting 
mitochondrial disease genes using the human protein-protein interaction network 
which has not yet been explored. 
The increased availability in high throughput gene expression data has seen the 
increase in studies trying to utilize these data sets in identifying disease genes. The 
recent discovery of a tissue-specific gene thought to be a major contributor to type 2 
diabetes portrays the importance of studying tissue-specific expression when 
considering disease genes [276]. In general, disease genes have been identified as 
overexpressed in tissues with the highest pathology but the relationship between 
tissue specific expression of a gene and the tissue pathology was not the same for 
all diseases [277]. In addition, the upregulation of disease genes in their affected 
tissues has higher association with autosomal dominant diseases compared to 
recessive [278]. The tissue-specificity of mitochondria due to variable tissue energy 
demands highlights the importance of exploring tissue-specific expression when 
trying to predict mitochondrial disease genes and may be a potential way to improve 
dominant disease gene identification. 
For mitochondrial disease genes specifically, a recent study has identified a link 
between mitochondrial gene evolution and their association with disease [279]. The 
study identified that the known mitochondrial disease genes were more likely to have 
orthologue’s in a wider set of evolutionary taxa than those which are currently not 
associated with disease. In addition, the origin of the known mitochondrial disease 
genes was more likely to be early in evolutionary history, before the evolution of 
eukaryotes, than those which are currently not associated with a disease. These 
findings suggest that using a gene’s evolutionary history could be a method for 
identifying novel mitochondrial disease genes. 
 
5.1.4. Neural networks for predicting mitochondrial disease genes 
With the rise of machine learning over the last few years, there has been many 
attempts to use machine learning with different data sources to try and predict 
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disease genes in hopes of developing a method for precision medicine [280]. A 
random forest classifier was trained using protein function similarities to try and 
predict autism spectrum disorder genes. The functional similarities of every protein 
were assessed using their GO annotations and protein-protein interactors. The 
model had moderate success with a reported AUROC of 0.8 [281]. There has also 
been an attempt to predict Parkinson’s disease genes which was done by training a 
support vector machine using only protein-protein interaction network information. 
The SVM was trained on protein positional importance in the human protein-protein 
interaction network which was quantified using random walks across the network. 
The model also had moderate success with a reported AUROC of 0.73 [282]. Tissue 
expression data has also been used as a feature of machine learning, it was 
exclusively used to train a random forest classifier to diagnose cancer [283]. The 
classifier managed to distinguish each of the cancerous tissues from their healthy 
counterparts.  
Only a single attempt has been made to use machine learning to specifically predict 
mitochondrial disease genes [284]. The study used a broad range of data sets for 
training which included protein ortholog and gene expression data. However, the 
purpose of the machine learning algorithm was to predict protein function as an 
inference for mitochondrial localisation. The identification of disease genes was then 
done after experimental verification of a patient’s disease locus. Candidate 
prioritization of variants was done by assessing the predicted mitochondrial 
localisation score of the genes known to be around the disease locus. The method 
did not directly address the issue of predicting mitochondrial disease genes and is 
built around experimental data which requires a large amount of time and cost 
investment. 
Most machine learning models trained for disease gene prediction used relatively 
simple machine learning algorithms such as support vector machines and random 
forests. Neural networks are a supervised machine learning algorithm which can be 
trained for classification problems [285]. The networks are made up of multiple 
connected layers of nodes, called neurons, which train in an iterative manner like 
other supervised machine learning algorithms. However, neural network structure 
can be manipulated by changing the number of layers and nodes in the network 
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which allows for more complex relationships between the inputs to be identified and 
used for classification, known as deep learning. The final output of a neural network 
for each input is a vector of class assignment scores which can be used to assign a 
class to each input. A recent study which tried to predict disease genes used a deep 
belief net, a class of neural network [286]. The neural network was trained using GO 
annotation data and a latent representation of the human protein-protein interaction 
network. The model had a reported AUROC of 0.97, much higher than the machine 
learning models generated in a similar manner which used simpler machine learning 
methods. This highlights the potential for using a neural network for predicting 
mitochondria disease genes using the theories on mitochondrial disease genes 
mentioned in the previous section. Neural networks could be trained using the same 
input information for predicting disease association and disease type, such as 
dominant or recessive. These neural networks would provide a score for disease 
association, and for potential disease type, which could be used to prioritize a 
patient’s variants for experimental investigation and greatly improving the diagnosis 
rate of mitochondrial diseases.  
 
5.1.5. Chapter summary 
In this chapter, I discuss the process of collecting and analysing features which can 
be used to differentiate known mitochondrial disease genes from suspected non-
disease mitochondrial genes. I describe the complete training process of two neural 
networks using the complete set of features as the input data array, one network for 
binary classification of disease or non-disease, and one for multiclass classification 
of non-disease, recessive disease, dominant disease or other disease. I then 
examine the trained networks for over-fitting and evaluate their performance on the 
training set. The final trained neural networks are then used to predict novel 
mitochondrial disease genes, the resulting predictions are compared between the 
two networks and investigated.  
 
 




5.2.1. The mitochondrial disease gene training set 
The previous chapter identified an extended mitochondrial proteome of 1,626 
proteins, each of which has the potential for being a mitochondrial disease gene. The 
predicted proteome was therefore the test set for both the trained neural networks, 
the set of proteins which were eventually put through the trained neural networks to 
generate novel predicted mitochondrial disease genes. The set of 344 known 
mitochondrial disease genes, as defined by the OMIM database and Wash U 
mitochondrial disease gene list, were used as the positive training set for both neural 
networks. Their disease classification, such as dominant or recessive, were collected 
from MitoMiner and separated into three categories; dominant, recessive and other. 
The other classification group contained all other disease classes such as X-linked 
dominant and X-linked recessive. The positive training set contained 20 dominant 
disease genes, 273 recessive disease genes and 51 other disease genes. The 
negative training set, the set of known non-disease genes, was generated from 
studies on loss of function mutations. Four different population studies identified 214 
genes in the predicted proteome which had rare (<1% minor allele frequency) loss of 
function (LoF) homozygote mutations present in healthy individuals [263,287-288], 
i.e. both alleles are expected to be non-functional. As these LoF mutations were 
present in healthy individuals, their likelihood of causing disease is extremely low, 
making them the best choice for ‘known’ non-disease genes. The negative test set 
was therefore made up of 214 genes which were used to train both neural networks. 
The set of genes used in the positive training set, along with their disease 
association, and the negative training set can be found in Supplementary File 5.1.  
 
5.2.2. Mitochondrial disease gene neural network input data array creation 
The complete data input array used to train both neural networks can be found in 
Supplementary File 5.2. Seven input array features were generated using a human 
protein-protein interaction network (Table 5.1). The protein-protein interaction 
network was created by combining protein interaction data from multiple databases, 
each of which were themselves a combination of many different databases; 
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inBioMap [290], ConsensusPathDB [291], mentha [292], Integrated Interactions 
Database (IID) [293] and STRING [239]. The inBioMap and STRING databases 
include confidence scores with each of their protein-protein interactions indicating 
the level of confidence in the evidence supporting the interaction. For inBioMap 
interactions, only those with a mean confidence interval greater than 0.1 were 
included whilst only the interactions with a score greater than 0.9 from the STRING 
database were included. The combined protein-protein interaction network consisted 
of 20,408 nodes (proteins) with 1,148,406 edges (interactions). All network 
exploration and the calculation of the network metrics which were used as features 
were generated in R using the ‘igraph’ package [294], unless stated otherwise.  
Five different features were generated using the complete protein-protein interaction 
network. For each of the predicted mitochondrial proteome proteins their number of 
interactors (degree), clustering co-efficient (transitivity), number of shortest paths 
through the protein (betweenness centrality), and number of interactions required to 
completely disconnect the protein from each of the known mitochondrial disease 
genes (edge connectivity) were calculated. The edge connectivity of a protein to all 
known mitochondrial disease genes was averaged and used as a single feature, the 
other four metrics were each used to generate their own single features. The final 
feature generated using the complete protein-protein interaction network involved the 
use of self-avoiding random walks which were completed using custom scripts in 
MATLAB. For each protein in the complete interaction network, five hundred self-
avoiding random walks of length 1 to 10 were completed. Using the known start and 
end point of the complete set of random walks over the network, outward 
accessibility as described by Travençolo et. al [295] was calculated. Outward 
accessibility is a network metric which quantifies the positional importance of each 
protein in the network by evaluating the accessibility of each node in the network 
with respect to all other nodes. A single feature in the input data array was generated 
using each protein’s calculated outward accessibility. 
Two additional protein interaction features were generated using clusters of the 
protein-protein interaction network. Overlapping clustering of the network were 
calculated using overlapping cluster generator (OGC) [296]. For each cluster in 
which a predicted mitochondrial protein was present, the ratio of known 
Chapter 5  Predicting mitochondrial disease 
128 
 
mitochondrial disease proteins vs unclassified mitochondrial proteins was calculated 
and assigned to every predicted mitochondrial protein in that cluster. The average of 
this ratio for each protein was then used to generate a single feature. In addition, for 
each cluster in which a known mitochondrial disease gene was present, the 
structural similarity, a measure of common interactors between two nodes in a 
network, was calculated between the disease gene and all other predicted 
mitochondrial proteins within the cluster. The average of this value for each protein 
was then used to generate a single feature. 
Tissue specific expression of each gene was taken from the Human Protein Atlas 
RNA-Seq study, collected from MitoMiner. The study measured the expression of 
each protein in thirty-seven different tissues, each tissue type was used to generate 
a single feature. The sequence length and protein mass for each protein were 
collected from the UniProt database and used to generate two features. In addition, 
UniProt annotations for protein function and pathway activity were collected for each 
protein. Using the training positive and negative test sets, each of the annotation 
labels were assessed for classification power using χ2 testing. Only two annotations 
showed a significant difference between the positive and negative training sets (p = 
3.10x10-6, p = 0.001105), the ‘acetylation’ and ‘transport’ functional annotations, 
which were used to generate two features. The transport annotation being significant 
was unsurprising due to the impermeability of the inner mitochondrial membrane 
forcing a high importance onto the transportation proteins to ensure regular 
mitochondrial function. A potential reason for the significance of the acetylation 
annotation was that acetylation has been identified as a regulatory mechanism for 
mitochondrial proteins [297,298], dysfunction of which would cause a large disruption 
to regular mitochondrial function.  
Two features were generated using the population genomic study available on the 
ExAC database. The database has its own calculated metric for each gene called 
the probability of being loss-of-function intolerant (pLi) [299], along with z-scores on 
the number of observed vs. expected missense mutations identified in each of the 
genes. Each metric was used to generate a single feature and used in the input data 
array.  
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The final set of twelve features used in the input array was generated using the 
results of the mitochondrial protein evolutionary study [279]. In the study, each 
protein’s homologs were identified across various phylogenetic taxa. Eight different 
features were generated based on the number of homologs found in the eight 
studied taxa for each protein, along with a single feature based on the total number 
of homologs found across all eight taxa for each protein. In addition, a single feature 
was generated using the number of unique taxa in which each protein had identified 
homologs. Finally, a categorical feature was generated for each protein based on the 
protein’s oldest taxa in which a homolog was identified. Each of the eight taxa were 
assigned a value between one and eight as a class assignment which was used to 
generate a single categorical feature. Each of the eight taxa was assigned an 
estimated age since their first evolutionary appearance in millions of years. Using the 
categorical class assignment for each protein, a single feature was generated to 
represent a protein’s estimated age since its first appearance in evolution. 
Exploration of the input data array and training set selection prior to developing the 
neural networks was performed using R. Each of the features created using the 
protein-protein interaction network, and those generated from the evolutionary study, 
were tested for significance over the training sets using Wilcox’s rank sum testing 
[300]. The tissue expression features were explored using hierarchical clustering 
across the training set. The entire input data array was used to train an extreme 
gradient boosted decision tree using the ‘xgboost’ package [243]. Parameter 
searching for the best decision tree was performed by generating three hundred 
randomly initiated gradient boosted decision trees. The best performing parameters 
were then used to generate five thousand replicate gradient boosted decision trees. 
Importance scores for the features were extracted from each replicate and averaged. 
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Table 5.1. The data sources used to generate features for the input data array.  
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5.2.3. Neural network creation, tuning and validation using TensorFlow 
Two neural networks were trained using the same input array and training set with 
TensorFlow in python [193]. One network was generated for binary classification, 
predicting disease or non-disease, whilst the other utilized the positive training set 
split into their disease types. The split positive training set was used to train a neural 
network for multiclass classification, predicting non-disease, dominant disease, 
recessive disease or other disease. To reduce the chance of overfitting and allow for 
accurate evaluation of the neural networks during the tuning process, the training 
data for both networks was split into a training set, validation set and test set. The 
validation and test set each consisted of ten percent of the training set and were 
separated from the training set in a stratified manner (the ratio of positive and 
negative training set samples in each split was kept the same across all of the splits). 
The seed used to split the data into the three sets was kept the same throughout the 
generation of both neural networks to enable comparisons between different 
networks whilst tuning the hyperparameters.  
Training of both neural networks was done using batch gradient descent [301] with 
the Adam optimization algorithm to improve the learning speed [302]. All hidden 
layers used in the network architectures were dense layers, the inputs were batch 
normalized [303] using batch renormalization due to the potentially small batch sizes 
[304]. Drop-out normalization was employed just before the leaky rectified linear unit 
(ReLU) activation function [305,306] of each layer to improve training performance 
and reduce the chance of overfitting [307]. During training the loss was calculated 
using sigmoid with cross entropy for the binary neural network, and softmax with 
cross entropy for the multiclass network. Bias variables were initiated as zero, whilst 
the weights for each neuron were randomly initialised using He initialization [308]. 
Optimal parameters for the network were identified using hyperparameter searching. 
Six different parameters were investigated using randomly selected values between 
specific ranges in a coarse-to-fine grid searching methodology; learning rate of the 
network between 0 and 1.0, batch size of the input size during training between 5 
and 200, the number of nodes in each hidden layer with one variable for each hidden 
layer between 2 and 500, and the drop-out probability for each layer with one 
variable for each layer between 0 and 1.0. In addition, the number of hidden layers in 
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the networks was explored by performing hyperparameter searching across four 
different network architectures; networks with one, two, three and four hidden layers 
were tuned for both classification problems.  
Five hundred replicate neural networks were generated using randomly initialized 
parameters with fifty thousand training epochs. Batches were randomly shuffled for 
each replicate based on their initialized batch size. After a complete set of five 
hundred replicate neural networks were trained, each replicate was evaluated based 
on its validation set accuracy. Parameters which greatly affected model performance 
had their parameter search ranges reduced and another set of five hundred 
replicates were generated for all four network architectures.  For example, the 
learning rate was reduced from between 0 and 1.0 to between 0 and 0.1 after the 
first set of iterations for both the binary and multiclass neural network. The 
hyperparameter searching pipeline was completed three times for a total of one 
thousand five hundred replicates for both the binary and multiclass neural networks.  
Once the optimal neural network architecture and parameters were identified for both 
the binary and multiclass networks, five hundred replicate optimal neural networks 
were trained for each classification problem. Each of the replicates used randomly 
split training, validation and test sets. This was performed to ensure that the seed 
used to split the data in the hyperparameter tuning pipeline was not producing outlier 
accuracies, and that the selected network parameters generated a robust network. 
Both optimal neural networks were then used to generate predictions on the proteins 
which were not used for training, the remaining predicted mitochondrial proteome, 
which can be found in Supplementary File 5.3. The list of novel predicted 
mitochondrial disease genes by both neural networks can be found summarised in 
Appendix III.   
 
 




5.3.1. Separation of the training sets using the input data array features 
Hierarchical clustering of the training set proteins using their expression data can be 
seen in Figure 5.1. The positive training set proteins did not clearly cluster away from 
the negative set training proteins. However, the clade of proteins which showed a 
generally higher level of expression across all the tissues was almost entirely made 
up of the positive training set proteins. The clustering of the tissue types across the 
training set did not generate many meaningful clusters, the tree resulted in many 
small distinct clades which did not group together tissues of similar function. Two 
clades which did separate from the rest included the liver and kidney, and the 
skeletal muscle and heart muscle. All four of these tissues were found significantly 
different between the positive and negative training sets (p < 0.001). 
Figure 5.1. Hierarchical clustering of the training sets over the tissue 
expression features used in the input data array.  























Figure 5.2. Boxplots of the continuous features used in the input data array 
over the training sets, excluding the tissue expression features.   
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Boxplots of the rest of the continuous features generated for the input data array 
from the protein-protein interaction network, evolutionary study and ExAC database 
can be seen in Figure 5.2. Hypothesis testing of each of the features identified only 
four features that were not significantly different (p < 0.001) between the positive and 
negative training sets. These were PPI transitivity (p = 0.665), the number of 
Archaea homologs (p = 0.004), the mass of the protein (p = 0.008) and the sequence 
length of the protein (p = 0.01). For the two ExAC database features, Z-score for 
missense and pLi, both found that disease genes had a higher value than the non-
disease genes. For all the evolutionary study features, a similar relationship was 
found for the disease genes, they had a generally higher value than the non-disease 
genes. For the six other protein-protein interaction network generated features, 
degree, betweenness centrality, average edge connectivity, outward accessibility, 
cluster structural similarity average and cluster mitochondrial disease gene ratio 
average, the value for each of these was also found to be higher among disease 
genes compared to the non-disease genes.  
The complete input array was used to train multiple replicate extreme gradient 
boosted decision trees. The importance score for each of the features was collected 
from each replicate and averaged. Two features had a much higher average score 
than the rest, cluster structural similarity average and cluster mitochondrial disease 
gene ratio average. Histograms showing the distribution of these two feature values 
across the positive and negative training set were generated (Figure 5.3). In addition, 
histograms showing the distribution of these two feature values across the proteins 
not used in either training set, the proteins which are not known to be disease or 
non-disease, were generated. The histograms clearly showed the difference in 
feature values between the negative and positive training sets. Figure 5b and 5d 
include vertical lines on the distributions which highlight both the positive and 
negative training set averages. Both histograms highlighted the fact that there was 
only a small subset of the remaining mitochondrial proteome that had feature values 
close to and above the positive training set averages, the large majority had a value 
smaller than the negative set averages.  
A second iteration of the pipeline for training the decision trees was performed after 
the two protein-protein interaction cluster features were removed to get an accurate 
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reflection of the importance scores of the remaining features, the results of which 
can be seen in Figure 5.4. The resulting average importance scores highlighted a 
wide variety of features as good for classification of the training sets. Three of the 
homolog features had a higher importance score than the rest; the homolog numbers 
of each protein in Holozoa and Holomycota, the two oldest taxa explored in the 
study, and the total number of identified homologs across all the taxa. Of the 
remaining protein-protein interaction network features transitivity, the only feature to 
have been found not significantly different, had a low importance average. The two 
ExAC features, Z-score for missense and pLi, had relatively high importance scores, 
as did protein sequence length. The tissue expression features had a huge number 
of tissues that had high importance score where spleen, lymph node, adrenal gland 
and cerebral cortex had particularly high values. The four tissues identified in the 
hierarchical clustering, liver, kidney, heart and skeletal muscle were all given lower 
importance scores, as were all the categorical variables. 
T-SNE plots were generated using the complete input data array and predicted 
mitochondrial proteome. Proteins were labelled based on their training set 
assignments for both the binary and multiclass training sets (Figure 5.5). The 
positive and negative training sets used for the binary network showed good 
separation with many regions clearly belonging to only one training set. The t-SNE 
plot also identified multiple overlapping regions which were not unexpected as the 
input array was drastically reduced in dimensionality to only two dimensions. The 
recessive diseases made up most of the positive training set as seen in Figure 5b. 
All three of the disease types were spread among the t-SNE plot which suggested a 
high amount of intergroup variance, with the dominant diseases having the highest 
amount of variance despite only having twenty samples. The ‘other’ diseases had a 
small set of clusters of proteins whilst the recessive diseases were extremely similar 
to the positive set used to train the binary network, as expected due to the recessive 













Figure 5.3. A) Histogram of the positive and negative training set cluster 
mitochondrial disease ratio average values B) Histogram of the remaining 
mitochondrial proteome cluster mitochondrial disease ratio average values, with lines 
indicating the negative (red) and positive (blue) training set averages. C) Histogram of 
the positive and negative training set cluster structural similarity average values D) 
Histogram of the remaining mitochondrial proteome cluster structural similarity 
average values, with lines indicating the negative (red) and positive (blue) training set 
averages. 























Figure 5.4. Average importance scores of the input array features when used to train 
extreme gradient boosted decision trees. Features are coloured by their means of 
collections; Red – PPI network, Yellow – Tissue expression, Blue – Evolutionary study, 
Green – Sequence information and ExAC, Grey – Annotations. ‘Phylostrata’ features 
are the one-hot representation of a proteins phylostrata of evolutionary origin. 























Figure 5.5. t-SNE plots of the positive and negative training sets using the complete input 
data array. A) Plots of the positive and negative training set used to train the binary neural 
network. B) Plots of the positive training set split into the three disease types which were 
used to train the multiclass neural network. 























Figure 5.6. The network architecture of the multiclass neural network 
created in TensorFlow. 
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5.3.2. Training and validation of the neural networks after hyperparameter 
searching 
Hyperparameter searching of the two neural networks identified the optimal 
hyperparameter values and network architectures for both the binary and multiclass 
classifications. Figure 5.6 shows the network architecture for the multiclass network 
using four hidden layers, the binary neural network used a similar structure but with 
only two hidden layers. The final binary neural network was trained using the 
following optimal hyperparameters; learning rate = 0.026, batch size = 7, number of 
neurons in the first hidden layer = 35, number of neurons in the second hidden layer 
= 281, drop-out probability on the first hidden layer = 0.51 and drop-out probability on 
the second hidden layer = 0.85. The final multiclass neural network was trained 
using the following optimal hyperparameters; learning rate = 0.032, batch size = 21, 
number of neurons in the first hidden layer = 48, number of neurons in the second 
hidden layer = 15, number of neurons in the third hidden layer = 10, number of 
neurons in the fourth hidden layer = 63,  drop-out probability on the first hidden layer 
= 0.76, drop-out probability on the second hidden layer = 0.60,  drop-out probability 
on the third hidden layer = 0.48 and drop-out probability on the fourth hidden layer = 
0.87. 
The accuracies over the duration of training for the final optimal neural networks are 
shown in Figure 5.7. Throughout the duration of the training process, both neural 
networks showed a consistent improvement in both the training set and validation set 
accuracies. The final validation set accuracy for the binary neural network was 
97.32% with a training accuracy of 95.51%. The validation loss of the binary network 
at the point of early stopping was 0.248, whilst the training loss was 0.133. The 
precision of the binary network was 0.953, the recall 0.936 and F1-score 0.944. The 
final validation set accuracy for the multiclass neural network was 82.14% with a 
training accuracy of 90.12%. The validation loss of the multiclass network was 0.935 
whilst the training loss was 0.313. The precision and recall values for each of the 
classes in the multiclass network can be seen in Table 5.2. The average precision 
value for the network was 0.639 and average recall 0.580 giving an F1-score of 
0.608. The generalization accuracy of the final binary neural network was 90.18%, 
whilst the multiclass neural network was 81.25% 
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The breakdown of the disease class values for the positive training set proteins and 
the non-disease class value for the negative training set proteins assigned by the 
final binary neural network are shown in Figure 5.8. The binary network correctly 
classified 322 of the positive training set as disease genes, with 288 of those being 
assigned a value greater than or equal to 0.75, leaving 22 incorrectly classified as 
non-disease (Table 5.3). For the negative training set, 198 proteins were correctly 
assigned with 171 of these having a high class score (>= 0.75), leaving 16 proteins 
that were incorrectly classified. The breakdown of the final multiclass assignment 
scores for each of the training proteins belonging to the four classes are shown in 
Figure 5.9, each training protein has only been shown with their respective class 
value i.e. recessive training proteins are only shown in the recessive class score 
histogram. The multiclass network correctly assigned 207 of the non-disease 
proteins with 203 of these having a non-disease value greater than or equal to 0.5, 
leaving 7 incorrectly classified which were all assigned as recessive disease (Table 
5.4). The recessive training set had 256 correctly identified, leaving 17 incorrect, with 
246 of these having a high recessive class value (>= 0.5). The incorrectly classified 
proteins had 15 assigned as non-disease whilst two were assigned as other disease. 
In the dominant disease training set, none of the proteins were correctly classified as 
dominant. Instead, 15 of the dominant diseases were assigned as recessive, two as 
non-disease and 3 as other disease. The other disease set contained 21 correctly 
classified proteins with 18 of these having a high other disease class value (>= 0.5). 
The 30 incorrectly classified other disease genes had 22 assigned as recessive, 7 as 
non-disease and one as dominant. 
The accuracies of the fully trained replicate network generated using the optimal 
hyperparameters and network architecture for both the binary and multiclass 
networks are shown in Figure 5.10. The binary neural network achieved an average 
validation accuracy of 93.45% with an average training accuracy of 90.10%. The 
multiclass neural network achieved an average validation accuracy of 83.99% with 
an average training accuracy of 86.43%.  
 
 





























 Non-disease Recessive Dominant Other 
Precision 0.896 0.853 0 0.808 
Recall 0.967 0.938 0 0.412 
 Predicted 
Disease Non Disease 
Actual Disease 322 22 
Non Disease 16 198 
 Predicted 




Non disease 207 7 0 0 
Recessive 15 256 0 2 
Dominant 2 15 0 3 
Other 7 22 1 21 
Figure 5.7. Training of both the binary and multiclass neural networks over the duration of 
the training epochs. A) Binary neural network. B) Multiclass neural network 
Table 5.2. The precision and recall values of the multiclass neural network for each 
of the classes. 
Table 5.3. Truth table for the training sets predicted using the binary neural network 
Table 5.4. Truth table for the training sets predicted using the multiclass neural 
network 




Figure 5.8. Histograms of disease class values assigned to the positive training set and 
non-disease class values assigned to the negative training set by the binary network. 
Figure 5.9. Histograms of the four class values assigned to each of the proteins 
belonging to each of the specific class training proteins using the multiclass 
neural network. 











5.3.3. Predictions on the remaining predicted mitochondrial proteome using 
the trained neural networks 
The remaining 1,067 proteins belonging to the predicted mitochondrial proteome 
which were not used in any of the training sets were fed through both the binary and 
multiclass neural networks to generate predictions to identify novel disease causing. 
The final binary neural network assigned 422 as disease genes with 330 of these 
having a disease class score greater than or equal to 0.75, and 184 having a score 
greater than or equal to 0.99 (Figure 5.11). The remaining 645 proteins were 
assigned to the non-disease class, with only 82 of these having a disease class 
score greater than or equal to 0.3 and only 5 having a disease score greater than 
0.5.   
The multiclass neural network assigned 733 proteins as non-disease, with 722 of 
these having a non-disease class value of greater than or equal to 0.5 and 683 
having a score greater than or equal to 0.75. The remaining proteins were assigned 
as follows; 232 recessive disease, 92 other disease and 10 dominant disease. The 
set of recessive genes contained 191 genes assigned a recessive class score 
greater than or equal to 0.5 with 113 of those having a score greater than or equal to 
0.75. The set of ‘other’ disease genes contained 71 genes assigned an ‘other’ 
disease class score greater than or equal to 0.5 with 38 of those having a score 
Figure 5.10. Training and validation set accuracies of 500 replicate optimal neural 
networks generated using random training set splits A) Binary neural network. B) 
Multiclass neural network. 
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greater than or equal to 0.9. The predicted dominant disease genes contained only 
two genes with a dominant class score greater than or equal to 0.5. 
By summing together the class assignment scores of the three disease types used in 
the multiclass neural network, a disease class score was calculated for each protein 
based on the multiclass neural network predictions. The disease class value for each 
protein assigned by both the binary and multiclass networks were plotted on the t-
SNE plot generated using the compete input array (Figure 5.13). The disease scores 
from both networks show a similar distribution around the t-SNE plot, showing a 
similarity in their predicted disease vs. predicted non-disease assignments. The two 
neural networks agree upon 304 proteins being predicted as disease-causing, and 
615 proteins as non-disease causing (Figure 5.14). The binary network assigned 118 
proteins as disease-causing which were assigned as non-disease in the multiclass 
network, whilst the multiclass network assigned only 30 proteins as disease-causing 
which were assigned as non-disease by the binary neural network. 
 
 
Figure 5.11. Histogram of the disease class values assigned to the remaining 
mitochondrial proteome using the binary neural network. Those predicted as 
disease-causing are green, with the predicted non-disease in purple.  

















Figure 5.12. Histograms of the disease class values assigned to the remaining 
mitochondrial proteome using the multiclass neural network. Only proteins which were 
assigned to each of the three classes are shown in their respective histogram. 
Figure 5.13. The predicted disease values for the remaining mitochondrial 
proteome from both the multiclass and binary neural networks overlaid onto the 
input data array t-SNE plot. 













Figure 5.14. Scatter plot of the predicted disease and non-disease values of the 
binary and multiclass neural networks. In blue are the proteins that are predicted as 
the same class by both networks, whilst red are predicted by just one of the 
networks. A) Predicted disease genes. B) Predicted non-disease genes. 




5.4.1. Properties of mitochondrial disease genes 
Hierarchical clustering of the tissue expression features across the entire training set 
shows that using tissue expression data alone is not enough to clearly differentiate 
the known mitochondrial disease genes from the negative training set (Figure 5.1). 
The result is not unexpected as the set of known mitochondrial disease genes 
contains many different functional types of protein which are known to have 
consistently different expression profiles across all tissues in humans. For example, 
the known disease genes contain ribosomes, which are known to have consistently 
high expression in humans, and transporters, which have a consistently lower 
expression in humans. However, the right clade of the clustered training proteins 
does indicate that highly expressed proteins may have a higher propensity to be 
disease genes. Highly expressed proteins have been shown to evolve at a much 
slower rate than those which have lower expression [309]. Slower evolution of a 
protein leads to greater conservation of the protein among species akin to a form of 
evolutionary pressure usually put on important proteins. The importance of these 
genes thus identifies a potential explanation for why the highly expressed proteins 
have an increased likelihood of being disease-causing genes.  
When clustering tissue specific expression across any set of human genes, it would 
be expected that tissues of a similar functional role, such as the set of hormone 
producing tissues, would cluster together. The hierarchical clustering of the tissues 
across the training set did not follow this pattern in most cases, the tree consisted of 
mostly small, disorganised clades. This highlights that in most tissues, both the 
disease and non-disease genes have highly variable tissue specific expression 
profiles. The exception to this can be seen by the clustering of the liver and kidney, 
and the skeletal muscle and heart, into distinct clades separated from the rest of the 
tree. These four tissues are some of the most energetically demanding tissues in 
humans and facilitate many integral metabolic functions such as producing urea in 
the liver and kidneys. These tissues are also the most affected tissues during 
mitochondrial disease and are regularly studied when investigating mitochondrial 
dysfunction. This clustering behaviour, and the fact that all four of these tissues were 
identified as significantly different between the positive and negative training sets, 
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identifies these four tissues as having the potential to predict mitochondrial disease 
genes. Since the disease genes showed a consistently higher expression across all 
the tissues using hierarchical clustering, which was a relatively simple method for 
separating the training sets, the complete set of tissue expression features were 
used in the training of both neural networks. 
Four of the continuous features generated were not found to be significantly different 
between the two training sets using a very conservative p-value threshold of p = 
0.001. However, if a more lenient threshold value were selected such as p = 0.05, 
only one of these would remain not significant, PPI transitivity.  The near significant 
difference of protein sequence length and mass identifies that the known disease 
proteins are on average much smaller proteins than the negative training proteins 
(Figure 5.2). In a study in yeast, highly expressed proteins were identified to be 
generally smaller proteins [310]. This identifies a potential link between disease 
genes having generally higher expression and being smaller. The pLi ExAC 
database feature identified that the known disease genes have on average a higher 
pLi score which was expected as the sole purpose of the metric is to identify genes 
which are intolerant to loss-of-function variants. However, the large variance seen in 
both the training sets shows that this value is not entirely dependable as many of the 
known disease genes had low pLi values, whilst many of the negative training set 
had high pLi values. The known disease genes also had higher Z-score for missense 
than the negative training set. This meant that based on the ExAC population study, 
the disease genes had fewer observed variants than would be expected in the 
healthy population i.e. the disease proteins had a higher intolerance to variation. This 
suggests that the disease genes have undergone a high amount of evolutionary 
pressure and are therefore proteins of importance that, once disrupted, lead to 
disease. 
The complete set of protein-protein interaction features, including the one which was 
not significantly different, identified many network features of the known 
mitochondrial disease genes which mostly agree with theorems on the entire set of 
known human disease genes. The degree feature showed that the known 
mitochondrial disease genes had on average more interactors than the negative 
training proteins, a theorem which had previously been shown for all known human 
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disease genes [275]. The set of known mitochondrial disease genes generally 
clustered together, highlighted by the cluster disease ratio average feature, and 
within the clusters the disease genes on average shared more similar interactors 
with other known disease genes than the negative training set, shown by the cluster 
structural similarity average. Both theorems are consistent among all known human 
disease genes [275, 272]. In addition, the average edge connectivity feature 
suggests that the mitochondrial disease genes are generally more highly connected 
to the other known disease genes than the negative training set. The positional 
importance of the known mitochondrial disease genes is shown by the betweenness 
centrality and outward accessibility feature. The mitochondrial disease genes had on 
average higher betweenness centrality and outward accessibility which identifies that 
the known disease proteins are placed in highly positionally important locations 
within the network (e.g. as the only protein which connects two clusters generating a 
choke point in which many pathways must go through), a theorem which was proven 
for all known human disease genes [272]. The only contradiction to current theorems 
of all known human disease genes comes from the lack of significant difference in 
the transitivity feature. Human disease genes have been shown on average to avoid 
highly connected areas [272]. The highly variable and non-significant difference in 
the transitivity between the positive and negative training sets identified that this is 
not necessarily true for the known mitochondrial disease genes.  
The features generated using the evolutionary study showed the exact same results 
reported in the study [279]. The known mitochondrial disease genes had on average 
a much higher total number of homologs than the negative training set. In addition, 
the homologs of the known disease genes were identified among more unique taxa 
than the homologs of the negative training set. The known disease genes had 
significantly more homologs than the negative training set across all the taxa studied, 
but the difference was much larger in the older taxa. In general, these results 
suggest that the known mitochondrial disease genes originated much earlier in 
evolutionary history and have been conserved across eukaryote evolution at a 
greater rate than the negative training set proteins. This result implies a higher 
importance of the known mitochondrial disease genes than the negative training set. 
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Based on training set significant differences, almost all the continuous features could 
be used individually to predict a genes’ disease status. However, using only one of 
the features for predictions would vastly oversimplify the problem of predicting 
mitochondrial disease. The use of a complex algorithm such as a neural network 
allows for the identification of complex relationships between all the features for 
predicting disease and would lead to a much high confidence in the predictions. The 
linear separability of the training sets using each of the continuous features 
highlights each features viability for use in training a neural network for classification 
of disease genes. Therefore, the complete set of continuous features were used in 
the training of both neural networks. Despite being not significantly different between 
the positive and negative training sets, the transitivity feature was included in the 
training process as hypothesis testing is only a simple means for identifying 
separability and does not disqualify the feature from containing useful information 
when used in conjunction with other features within a more complex algorithm for 
classification. 
  
5.4.2. Viability of the input data array for training the neural networks 
The first iteration of gradient boosted decision trees identified the two protein-protein 
interaction cluster features as the two best features for classification of the positive 
and negative training sets by a huge margin. As the gap in average importance 
score between these two features and the rest was so great, the features needed to 
be investigated further to see if the high classification power assigned by the 
decision trees was justified in both a machine learning and biological viewpoint. If the 
assignment was entirely justified, it needs to be ensured that the two features would 
not have a huge effect on the training and final predictions of the neural network as 
the purpose of the network is to identify complex relationships between the complete 
set of input features and not to overfit to two features. 
The distribution of the two feature values across the positive and negative training 
sets clearly justified why the two features were assigned a high classification power 
by the decision trees from a machine learning viewpoint (Figure 5.3). In the complete 
clustered protein-protein interaction network which was used to calculate the two 
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features, the average cluster size of any cluster which had at least one mitochondrial 
protein was 25, each of which contained on average 4 mitochondrial proteins. The 
average ‘cluster mito disease ratio average’ value for the negative training set was 
0.11, whilst the positive training set was 0.57. Based on the average of 4 
mitochondrial genes per cluster, the known mitochondrial disease genes therefore 
clustered with 2.2 other known disease genes on average, whilst the negative 
training proteins only clustered with 0.4 known disease genes on average. 
Therefore, the known mitochondrial disease genes clustered with a substantially 
larger number of known disease genes than the negative training proteins, which 
rarely clustered with a single known disease gene. Given a protein of unknown 
disease association, if the protein were to cluster with a large proportion of known 
mitochondrial disease genes, from a biological viewpoint it would not be 
unreasonable to assign the protein a high probability of being disease-causing.  
The ‘average cluster structural similarity average’ for the negative training set was 
0.19, whilst the positive training set was 0.67. This means that the known 
mitochondrial disease genes share 67% of the same interactors on average with all 
other known disease genes within their clusters, whilst the negative training proteins 
only shared 19% of the same interactors as the known disease genes within their 
clusters. This indicated that within the clusters, the known mitochondrial disease 
genes were positionally close to each other, whilst any negative training set protein 
which clustered with at least one known disease gene was positionally distant from 
the disease gene(s). Given a protein of unknown disease association, if the protein 
were to cluster with at least one known disease gene and shared many of the same 
interactors within the cluster it would be biologically reasonable to assign a high 
association for disease to the protein. These arguments show that the assigned high 
importance score to these two features by the decision trees was entirely justified 
and would be expected in the neural network. 
The variance in the distribution of the two feature values for the training sets was 
reasonably large, particularly for the positive training sets. In combination with the 
regularisation methods used in the training process of the neural network, this 
variance would help prevent the neural network from overfitting to these two 
features. In addition, the distribution of the remaining predicted mitochondrial 
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proteome, the set of proteins which were ultimately predicted on, showed that there 
was only a very small number of proteins which had feature values anywhere near 
the positive training set averages. The high classification power of the features was 
therefore not expected to cause a drastic effect on the final predictions. Both 
features were therefore left in the input data array unchanged and used in the 
training of the neural networks. 
The second iteration of trained extreme gradient boosted decision trees gave a large 
set of features with comparatively high average importance score (Figure 5.4). The 
top scoring set of features contained features collected from many of the different 
data sources which gave support for each of their inclusion in the neural network 
input data array. Tissue expression features were highly favoured among the data 
array, making up six of the top ten features. The tissues which ranked highly did not 
have any obvious links to mitochondrial function and showed no common trend in 
function. Three of the four tissues which stood out in the hierarchical clustering which 
are affected by mitochondrial disease the most, the liver, kidney and skeletal muscle, 
were all assigned low importance scores whilst the heart muscle ranked in the 
middle. This gave support for the inclusion of the complete set of tissue expression 
data as the decision trees identified relationships in unexpected tissues that could be 
used to classify the two training sets. The top ranking feature was the number of 
homologs found in Holozoa collected from the evolutionary study. Two other features 
from the study also ranked relatively highly, the total number of homologs and the 
number of homologs in Holomycota. Holozoa and Holomycota were the two oldest 
taxa examined in the evolutionary study which further highlights the theory that 
mitochondrial disease genes are much older and more conserved than the negative 
training set genes. The only remaining protein-protein interaction feature which was 
assigned a low importance score was the only non-significant feature, protein 
transitivity, which made the result unsurprising. The entire set of categorical 
variables were included in the decision tree training array, but they were all assigned 
extremely low importance scores. This was most likely due to the decision tree 
method rather than a reflection of their classification power as decision trees are 
highly prone to overfitting, causing the algorithm to prefer the continuous variables 
rather than the categorical.  
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The t-SNE plot of the input data array and training set proteins showed good 
separation of the positive and negative training sets (Figure 5.5). The plot contained 
distinct regions for each of the training sets which showed that the input data array 
contained enough valid information to be able to classify mitochondrial disease 
genes with a good degree of accuracy. The plot did contain regions where the two 
training sets overlapped which identified that a subset of the positive and negative 
training sets were similar across the input data array and highlights the complexity of 
the classification problem. The t-SNE plot of the separated positive training set into 
the three disease classes highlights the high intergroup variance in all three of the 
classes. The high variance of the dominant diseases and the large overlap in the 
positions of the dominant disease genes with the recessive disease genes reflects 
the difficulty in differentiating the dominant from recessive disease genes. 
Compounded by the fact that there is currently only a small set of known dominant 
mitochondrial disease genes, these factors indicate that the training of the multiclass 
neural network for predicting dominant diseases would most likely be extremely 
difficult. 
Overall, each feature showed good separation of the two training sets based on 
hypothesis testing and the combined input data array separated the training sets well 
on the t-SNE plot. The complex nature of the problem and the combination of linearly 
separable features was the perfect scenario for use in a complex machine learning 
algorithm, such as a feed-forward neural network. Therefore, the input data array 
and training sets were used to train the binary neural network, predicting disease or 
non-disease, and the multiclass neural network, predicting non-disease, recessive, 
dominant or ‘other’ disease. The added complexity of the separated positive training 
set meant that the multiclass neural network was expected to perform badly on the 
dominant disease genes but was explored due to the lack of current means to 
diagnose dominant diseases and the importance to do so. 
 
5.4.3. Machine learning success of the final trained neural networks 
The end goal of both neural networks was to generate disease association scores for 
each protein in the predicted mitochondrial proteome, giving a means to filter through 
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a patient’s list of variants to find the disease-causing variant. The miss-classification 
of a disease gene as non-disease would have severe consequences and would lead 
to a patient receiving no diagnosis. This factor led to the decision to use the 
accuracy of the neural networks as the metric for evaluating network performance, 
instead of the loss value. Early stopping was employed during the final training of the 
neural networks using accuracy as the network performance metric to ensure that 
the networks reached their maximum validation accuracy without excessive training 
epochs to reduce the chance of overfitting. The changes in the training set accuracy 
and validation set accuracy over the duration of the training epochs prior to early 
stopping were also investigated for any signs of overfitting. 
Both neural networks showed a consistent increase in the training and validation set 
accuracies across their complete set of training epochs (Figure 5.7). In addition, the 
final validation and training set accuracies showed only a small difference of around 
5% for both neural networks. Similarly, the final validation and training set loss had 
only a small difference at the point of early stopping for both networks. The 
multiclass neural network performed worse than the binary network as expected, 
with the training accuracy constantly higher than the validation accuracy during 
training and at the point of early stopping, a potential sign of underfitting. The 
multiclass neural network showing signs of underfitting was an expected result as 
the dominant disease genes had such a large ingroup variance and small training set 
size. The average accuracies of the replicate neural networks are similar to the 
recorded final neural network accuracies (Figure 5.10) which highlights the 
robustness of the neural network hyperparameters and architecture to the 
randomised training set splits. This combined set of results suggests that all the 
methods used to regularize the neural network, such as drop-out and batch 
normalization, were working correctly and that neither network had any obvious 
overfitting. 
The miss-classification of a known disease gene as non-disease is a greater 
problem when diagnosing a patient than the reverse situation. This identifies that a 
high recall is the most importance metric for both neural networks. The binary neural 
network achieved a high value for all the network performance metrics along with a 
high generalization accuracy. The network showed no sign of overfitting and was 
Chapter 5  Predicting mitochondrial disease 
157 
 
therefore successfully trained for classification of mitochondrial disease genes. The 
network assigned very high (≥0.75) class values to 89% of the correctly assigned 
known mitochondrial disease genes (Figure 5.8), and 86% of the correctly assigned 
negative training set proteins. Therefore, the binary neural network had extremely 
high confidence in the vast majority of its class assignments which gives confidence 
in the predicted class values, particularly for those assigned a high value.  
The multiclass neural network had mixed success across the groups based on the 
network performance metrics but managed to attain a reasonable generalization 
accuracy (Table 5.2). The negative training set and recessive disease training set 
achieved good precision and high recall values. The overall network performance 
metrics were dragged down by the network’s performance on the dominant and 
‘other’ disease training set. The domain disease training set was particularly bad with 
not even a single gene correctly predicted as dominant, a result which was expected 
as the training set was small and had a large amount of ingroup variance. The 
multiclass network showed a high preference towards predicting all the known 
disease genes as recessive diseases which caused the recall of the ‘other’ and 
dominant disease training sets to be low. Around 75% of the incorrectly classified 
dominant and ‘other’ disease training set genes were classified as recessive 
diseases. The propensity of the multiclass network to classify all known disease 
genes as recessive was caused by the imbalanced disease training set sizes as 
recessive diseases make up 79% of all known mitochondrial diseases.  
However, 14 of the genes which belonged to the ‘other’ disease training set and one 
gene which belonged to the dominant disease set which were incorrectly classified 
as recessive disease but are in fact X-linked recessive diseases or diseases which 
were found as both dominant and recessive. These predictions by the network are 
therefore technically not incorrect and highlight an improvement which could be 
made to the multiclass network. The ‘other’ disease group contained genes which do 
not clearly fall into the recessive or dominant disease group and were therefore 
separated into their own category as it was unknown whether these genes were 
vastly different across the input data array. The separation of the ‘other’ disease 
group into the recessive and dominant disease group would potentially lead to a 
better performing neural network for classification of disease type as it would reduce 
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the number of trained classes and increase the size of the dominant disease training 
set, although the dominant disease training set would still be small and most likely 
suffer from similar underfitting problems. 
The multiclass neural network assigned 98% of the correctly classified negative, 
96% of the correctly classified recessive and 85% of the correctly classified other 
training set proteins a high class score (≥0.5). The network therefore had a high 
confidence in the class assignment for these three classes (Figure 5.9). Combined 
with the high precision and recall values for the negative training set and recessive 
diseases suggests that the predictions made by the network for these two classes 
have some validity. In fact, the predictions of the multiclass neural network when 
differentiating the known disease genes from the negative training set showed 
similar accuracies to the binary neural network. By combining all three disease 
classes scores to create a single multiclass disease class score and using the 
negative training set, the multiclass neural network achieved a precision of 0.979 
and recall of 0.930 when classifying the known mitochondrial disease genes and the 
negative training set. The multiclass neural network can therefore be used as a 
second reference for predicting gene disease association with the added ability of 
identifying a gene’s similarity to the know recessive genes, offering a potential way to 
identify new dominant disease genes. 
 
5.4.4. Prediction results on the predicted mitochondrial proteome 
The set of known mitochondrial disease genes assigned the highest disease class 
score for both neural networks are shown in Table 5.5, using the sum of the three 
multiclass disease class scores as the multiclass overall disease score.  Both sets of 
genes were extremely similar, containing only the mitochondrial OXPHOS complex 
subunits. When patients are initially screened, these are the exact set of genes that 
are always investigated first and any identified mutation in an OXPHOS complex 
subunit gene is immediately suspected as the disease causing variant. Therefore, 
the identification of these disease genes as the highest disease causing genes out of 
the set of 344 known mitochondrial disease genes was an accurate representation of 
our current understanding of mitochondrial diseases and gave confidence to the 
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predictions of disease association by both networks on the remaining predicted 












The binary network predicted 422 disease associated genes out of the remaining 
1,067 mitochondrial genes, 44% of these were assigned extremely high disease 
class scores similar to the scores assigned to the known disease causing 
mitochondrial complex subunits (Figure 5.11). Within this set of extremely high 
scoring disease associated genes was the set of remaining mitochondrial complex 
subunits which currently have no disease association, such as MT-ND1 and COX6C. 
These subunits would also be used in early screening during the patient diagnosis 
process along with the already known disease associated complex subunits. There 
was also a large set of ribosomes within the extremely high scoring disease genes, 






















Table 5.5. The top ten disease class value genes by both networks which are 
known disease genes. 
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disease causing in a patient due to their fundamental cellular function. Functional 
annotation of the extremely high score disease genes using DAVID [311] identified 
many significantly enriched annotations within the set of genes such as transport (p 
= 1.3x10-3), methylation (p = 8.5x10-5) and apoptosis (p = 1.1x10-3).  
The multiclass neural network predicted 232 recessive disease genes out of the 
remaining mitochondrial genes (Figure 5.12), 82% of these were assigned a high 
recessive class score (≥0.5) with 49% assigned an extremely high score (≥0.75). 
This set of extremely high scoring genes was extremely similar to the set of genes 
assigned a high disease score by the binary neural network, including all of the un-
associated mitochondrial complex subunits such as COX7C and COQ3. Function 
annotation identified many enriched annotations within this set of genes including 
ribosomal proteins (p = 1.9x10-16), transport (p = 1.4x10-4) and aminotransferase (p = 
6.3x10-3). The set of genes assigned a high ‘other’ disease class score (≥0.9) 
contained two mitochondrially encoded OXPHOS complex subunits, MT-ND1 and 
MT-ND4. These were assigned to the ‘other’ disease class as the known 
mitochondrially inherited disease genes, such as MT-COX1, were included in the 
‘other’ disease training set. The highly predicted ‘other’ disease set of genes also 
contained a couple of ribosomes (p = 4.4x10-3) and shared many similar significantly 
enriched annotations with the highly predicted recessive disease set of genes. The 
three mitochondrial genes predicted dominant with a high dominant class score (≥ 
0.5), and low score for all other classes (≤0.4), were RPL18A and RPS8 which are 
both nuclear ribosomes. The nuclear ribosome RPS15A is a known autosomal 
dominant disease-causing gene [312] which is most likely the reason for their 
predictions. The low performance of the multiclass network on the dominant training 
set means that this prediction should not be taken in high confidence but does 
suggest that these genes do not look similar to any of the know recessive genes. 
The distribution of the disease class score predictions for both networks on the t-
SNE plot showed how similar the disease predictions were by the two networks 
(Figure 5.13). The set of genes predicted to be disease associated by both networks 
were also assigned a high disease class score (≥ 0.5) in both networks (Figure 5.14). 
The set of genes predicted to be disease and assigned an extremely high disease 
score (≥0.95) in both networks contained many genes which have already been 
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associated with diseases, including many of the mitochondrial complex subunits and 
the following discussed genes. ACTB has been associated with Baraitser-Winter 
syndrome which has symptoms such as growth problems and seizures [313]. 
YWHAZ has been associated with Popov-Chang syndrome, a neurodevelopmental 
disorder [314]. GNB1 which has been associated with mental retardation, seizures, 
hypotonia and neurodevelopmental problems [315]. CRYAB which has been 
associated with cardiomyopathy and myopathy [316]. All these symptoms have a 
large cross-over with common mitochondrial disease symptoms giving support for 
their prediction as potential mitochondrial disease genes. In addition, two well-known 
viral onco-genes were assigned an extremely high disease score by both networks, 
ATK1 [317] and SRC [318]. Many heat shock proteins, which are chaperone proteins 
and regulators of cellular adaptations to stress, such as HSPA8 and HSPA5 were 
assigned extremely high disease score by both networks. The heat shock protein 
HSPD1 is an already known mitochondrial disease gene [319] which gives support 
for their assignment and highlights these as an interesting family of proteins to 
investigate further. Many ribosomes were also predicted in this set including 
MRPS25 which is the only experimentally confirmed recessive mitochondrial disease 
gene to be identified since the training of both networks [320]. The gene was 
predicted to be disease in the binary network with an assigned disease class score 
of 0.78, and recessive with an assigned recessive class score of 0.72 by the 
multiclass network. Both networks therefore correctly predicted the disease 
association and disease type with relatively high class scores which, although only a 










The features generated for the input data array identified properties of mitochondrial 
disease genes which could be used to linearly separate the known disease genes, 
the positive training set, and the negative training set. Combined into a single data 
array, the features were suitable for use in training a neural network for classification 
of mitochondrial disease with the aim of generating disease association scores for 
every gene in the predicted mitochondrial proteome for use in improving patient 
diagnosis rates. The binary neural network was successfully trained for binary 
classification of disease or non-disease with no sign of overfitting. The multiclass 
neural network showed moderate success but was ultimately limited by the small 
subset of highly variable known dominant diseases. However, the multiclass network 
showed great success in accurately assigning disease or non-disease status to the 
training set, giving it validity in predicting mitochondrial diseases vs non-disease. The 
two networks showed similarity in their predictions with many of the agreed upon 
highly predicted disease genes having already suspected disease associations. The 
networks also accurately predicted the only experimentally verified mitochondrial 
disease gene to be identified since the development and training of the two 
networks, the recessive disease gene MRPS25, a nuclear ribosome. The predicted 
disease association scores are currently being used in an NGS analysis pipeline at 







  Conclusions 
 
6.1. Metabolic adaptations to mitochondrial dysfunction 
The aim of this project was to investigate the metabolic adaptations to mitochondrial 
dysfunction in mammals. The large-scale metabolomics data set analysed in 
Chapter 2 provided the means to begin identifying the metabolic adaptations to 
mitochondrial dysfunction caused by drug-induced mitochondrial complex III 
inhibition.  
The combined analysis of hypothesis testing, support vector machines with recursive 
feature elimination and partial least squared discriminant analysis enabled the 
identification of metabolites found significantly different during mild mitochondrial 
dysfunction in mammals across all three methods. Hypothesis testing was also 
utilized to identify significantly different metabolites during high levels of 
mitochondrial dysfunction, the low biological replicate number prevented the use of 
the more complex analysis methods. The significant metabolites for both mild and 
high levels of mitochondrial dysfunction identified many perturbed pathways and 
metabolites which have important biological functions in relation to mitochondrial 
function and could be used as biomarkers, e.g. Serine. The analysis of the 
metabolomics data set revealed erroneous pathways which were difficult to explain 
based on current understanding of mitochondrial dysfunction. Signs of erroneous 
fatty acid β-oxidation were present in both mild and high levels of mitochondrial 
dysfunction, based on the significance of multiple 3-hydroxy fatty acids, as were 
signs of erroneous branched chain amino acid (BCAA) metabolism based on the 
presence of many hallmarks of known BCAA metabolism in-born diseases.




To investigate the potential causes for many of the identified significant metabolites 
and to provide a means to investigate mitochondrial dysfunction caused by other 
complex inhibitions, a multi-organ model of mitochondrial metabolism was developed 
as described in Chapter 3. The simulations of liver mitochondrial complex III 
inhibition predicted similar behaviour to the adaptations identified in the 
metabolomics data set, supporting its applicability in predicting in vivo outcomes. 
The simulations also provided a potential reasoning for the identified erroneous fatty 
acid β-oxidation and BCAA metabolism in vivo related to their by production of 
quinones, a highly undesirable behaviour in the model under complex III inhibition. 
The simulations of the other complex’s inhibitions identified many pathways which 
could be exploited as unique biomarkers for each type of complex inhibition and 
provide a means in which to estimate the level of inhibition occurring. For example, 
complex I inhibition identified an inflection point in the behaviour of the conversion of 
pyruvate into lactate during only a small window of complex I inhibition levels which, 
if seen in vivo, would make an excellent biomarker and allow for the estimation of the 
complex I inhibition level occurring. 
Future metabolomics studies should be performed on mitochondrial dysfunction 
caused by other types of complex inhibition. By comparing the adaptations occurring 
in vivo to different types of mitochondrial dysfunction with the adaptations identified 
in Chapter 2 would enable the identification of unique high confidence biomarkers of 
complex III inhibition, along with high confidence biomarkers of overall mitochondrial 
dysfunction. In addition, the multi-organ complex inhibition simulations provide a 
means in which to direct future experimentation. Direct testing of the predictions of 
the simulations by targeted assays in vivo would provide higher confidence in the 
model and identify potential biomarkers of mitochondrial dysfunction. Given 
successful predictions, the model could then be used as part of future computational 
studies investigating other types of mitochondrial dysfunction, such as the inhibition 
of specific transport proteins. 
 
 




6.2. Predicting novel mitochondrial disease genes 
The aim of this project was to generate a meaningful way in which a suspected 
mitochondrial disease patient’s variant could be filtered through to prioritize 
candidate disease-causing genes for experimental verification. The necessary 
requirement to filtering variants for mitochondrial disease-causing genes is the 
mitochondrial proteome, which is currently considered incomplete. Therefore, the 
first step to achieving the aim of this project was to expand on the current 
mitochondrial proteome using the vast amounts of published data on mitochondrial 
protein localisation. 
The MitoMiner database contained a wealth of manually curated computational and 
experimental protein localisation data sources. The data sources were used to train 
a support vector machine (SVM) to predict protein mitochondrial localisation as 
described in Chapter 4. The tuned SVM showed no signs of over or underfitting and 
reported a high generalisation accuracy of 92.2%. A total of 442 novel proteins were 
predicted highly likely to be mitochondrially localised which expanded the current 
mitochondrial proteome to 1,626 proteins. These novel proteins can now be used to 
investigate mitochondrial diseases and the predictions on the remaining human 
proteome can be used as a means to evaluate current evidence on each protein’s 
mitochondrial localisation. Future work can continue to improve the predictions by 
including up-to-date data sources in the input array used for training the SVM and by 
updating the protein training sets as new proteins are experimentally verified.  
Having established a predicted mitochondrial proteome, the proteome could then be 
used as the basis in which to investigate predicting novel mitochondrial disease 
associated genes. Two neural networks were trained to predict disease association 
and disease type of each gene in the predicted mitochondrial proteome as described 
in Chapter 5. The neural networks were trained using features generated from 
multiple different types of data including gene tissue expression, protein-protein 
interaction network metrics, population study metrics and gene evolutionary history.  
Both networks showed great success in accurately predicting the disease or non-
disease status of the positive and negative training sets. One of the networks was 
trained for binary classification of disease or non-disease which achieved high 




performance metrics, no sign of overfitting and a generalisation accuracy of 90.18%. 
The second network was trained for multiclass classification of non-disease, 
recessive disease, dominant disease or ‘other’ disease. The network achieved 
reasonable performance metrics but was severely hindered by the dominant 
diseases as there is currently only a small set of known dominant disease genes 
which had a high in-group variance and high similarity to the recessive disease 
genes. The multiclass network had a reasonable generalisation accuracy of 81.25% 
and performed similarly well to the binary neural network when only considering its 
predictions as disease or non-disease i.e. combining the dominant, recessive and 
‘other’ disease predictions into a single disease prediction.  
The two neural networks agreed upon 304 predicted mitochondrial disease-
associated genes within the predicted mitochondrial proteome. This set of proteins, 
and the complete list of predicted disease-association probabilities by both neural 
networks, can be used to filter through a patient’s list of variants for candidate 
disease-causing genes. The predictions by the two neural networks successfully 
predicted the only experimentally verified new mitochondrial disease gene published 
since the training of the networks was completed. 
Future work to improve the networks could be performed by organising the ‘other’ 
disease group into either dominant or recessive which would simplify the multiclass 
classification problem by reducing the number of classes and increase the dominant 
training set size. Generating a feature based on a gene’s chromosome may provide 
a way in which to address the issue of having X-linked diseases separated into 
dominant and recessive. This would also allow for a dummy variable to be generated 
in the same feature for mtDNA diseases, although they would ultimately have to be 
classified as dominant or recessive. The framework for training the neural networks 
has been performed in this project which enables future work to improve upon the 
networks by adding more features to the input training array and updating the 
training sets as new genes are identified. 
 
 




6.3. Thesis summary 
In summary, in this thesis I have begun addressing two major issues related to 
mitochondria in toxicology and mitochondrial diseases. The metabolic adaptations 
identified in the metabolomics study provide the first steps in trying to understand 
mitochondrial dysfunction at a metabolic level which can be built upon greatly by 
future experimental studies. The predictions by the modelling of complex inhibition 
provide a basis for directing future experiments and if proven correct, could provide 
in-silico predictions for multiple other types of mitochondrial dysfunction relevant for 
both toxicology and mitochondrial disease. The predicted mitochondrial proteome 
collates multiple protein localisation data sources into a single, easy to understand 
value and identified many novel mitochondrial proteins which can be used as a basis 
for investigating mitochondrial disease. Predicted disease-association probabilities of 
the predicted mitochondrial proteome provide a means for filtering a patient’s 
variants for candidate disease-causing genes which was a previously difficult and 
time-consuming process. The framework for generating the predictions of protein 
localisation and disease-association has been generated which can be iteratively 
improved upon in future as new information gets published. The predicted 
mitochondrial proteome and disease-association probabilities are currently being 
used in an NGS pipeline for diagnosing mitochondrial disease patient samples in the 
MRC Mitochondrial Biology Unit.  
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Appendix I: The significantly different metabolites during mitochondrial dysfunction 
 












level  q-value 
Fold-
change 
(log2)  Rho 
methionine 0.012281 4.716701 1 -0.31774 9   0.053586 -0.35713   -0.36364 
phenyllactate (PLA) 0.012281 4.511833 1 -1.17226 9   0.173225 -1.31542   -0.24545 
2-piperidinone 0.016477 4.480894 1 -0.78807 9   0.074427 -0.79585   -0.00909 
myo-inositol 0.039745 4.123371 1.142857 -0.63313 9   0.074427 -0.71509   -0.09091 
proline 0.016091 4.223782 1.285714 -0.43809 9   0.029197 -0.5357   -0.37273 
hypotaurine 0.038313 4.081483 1.714286 -0.71258 9   0.271484 -0.48875   0.209091 
3-hydroxybutyrate (BHBA) 0.019786 3.867431 3.714286 1.551293 9   0.275634 1.616223   -0.21818 
adenine 0.06531 3.638111 6.285714 -0.24584 9   0.271492 -0.3231   -0.17273 
methyl glucopyranoside 
(alpha + beta) 0.016091 4.196769 17 -0.67324 9   0.051801 -0.86769   -0.29091 
2-
arachidonoylglycerophosph
oinositol 0.101435 4.047362 2.285714 0.75615 8   0.41663 0.884   0.474891 
arachidate (20:0) 0.071646 3.425517 11.42857 -0.29474 8   0.053586 -0.44116   -0.48182 
N-acetylmethionine 0.06531 3.434251 19 -0.48507 8   0.514613 -0.29037   0.563636 
palmitoleate (16:1n7) 0.016091 3.672584 27 1.260022 8   0.22228 1.692   0.218182 
16-hydroxypalmitate 0.032886 3.539416 49 1.053061 8   0.053586 1.294285   0.218182 
EDTA 0.131449 2.82429 4.571429 -0.2438 7   0.075714 -0.42572   -0.36364 
X - 22145 0.038098 2.355309 5.428571 -1.55032 7   0.559966 -0.26621   -0.06364 
X - 12818 0.016091 2.332899 7.142857 1.762761 7   0.235102 -1.12375   0.287017 
1-arachidonoyl-GPC (20:4) 0.101435 3.28487 8 0.191285 7   0.198426 0.300106   0.318182 
Table 1. Metabolites identified as significantly different in the plasma of the low dose rats after 2 hours. 




(ribothymidine) 0.104472 3.104708 9.714286 -0.24992 7   0.271492 -0.26856   0.2 
X - 21807 0.289481 3.643452 18 -0.69466 7   0.33287 -1.48427   0.063636 
X - 12170 0.140817 3.18102 22 -0.2395 7   0.433223 -0.46481   0.272727 
N-acetylmethionine 
sulfoxide 0.075654 3.312568 30 -1.51633 7   0.910612 0.352762   0.692485 
docosapentaenoate (DPA; 
22:5n3) 0.082798 2.899834 34 0.533395 7   0.151661 0.505238   -0.37273 
gamma-glutamylalanine 0.090656 3.402096 38 -0.49516 7   0.198426 -0.55357   0.072727 
mannose 0.071646 3.04353 42 0.480191 7   0.235102 0.492131   0.036364 
palmitate (16:0) 0.06531 3.36832 61 0.421961 7   0.344006 0.498867   0.027273 
acetoacetate 0.026314 3.38961 70 1.593893 7   0.271492 1.225847   -0.39091 
linolenate (18:3n3 or 3n6) 0.059256 3.051576 93 0.840903 7   0.282601 0.940057   -0.10909 
N-6-trimethyllysine 0.157945 2.55609 21 -0.23009 6   0.095199 -0.40218   -0.7 
glycylleucine 0.136622 2.665973 39 -0.44882 6   0.235102 -0.6707   -0.5 
2-hydroxyoctanoate 0.149108 2.532576 46 -0.29504 6   0.235102 -0.54781   -0.41818 
3-hydroxyisobutyrate 0.104472 3.197991 47 0.613542 6   0.173225 0.782866   0.163636 
cyclo(L-phe-L-pro) 0.136622 2.626884 50 -0.46785 6   0.235102 -0.72262   -0.54545 
mead acid (20:3n9) 0.101435 3.282024 55 0.622016 6   0.282601 0.90717   -0.01818 
cyclo(leu-pro) 0.130397 2.954024 57 -0.65216 6   0.25297 -0.92305   -0.25455 
gamma-glutamylmethionine 0.115773 2.717151 64 -0.35245 6   0.271492 -0.23872   0.2 
pentadecanoate (15:0) 0.101435 2.917625 78 0.232983 6   0.423508 0.242615   -0.19091 
methionine sulfoxide 0.127937 2.586786 83 -0.53665 6   0.146096 -0.70692   -0.44545 
alanine 0.100223 3.082259 87 -0.32146 6   0.235102 -0.42443   -0.03636 
4-guanidinobutanoate 0.149108 2.659812 88 -0.5557 6   0.235102 -0.80016   -0.19091 
mevalonate 0.10294 2.613088 95 -0.71877 6   0.151661 -0.78286   -0.26424 
X - 21477 0.130397 3.003553 98 -0.43229 6   0.238267 -0.7229   -0.29091 
linoleoylcarnitine 0.042254 3.424846 105 0.913708 6   0.306171 0.794623   -0.23636 
linoleate (18:2n6) 0.071646 3.236731 109 0.339975 6   0.410737 0.409442   -0.25455 
X - 17761 0.080138 2.739125 121 -1.70743 6   0.235102 1.390799   0.045455 




(17:1n7) 0.06531 3.043511 140 0.771307 6   0.25297 0.909293   0.009091 
oleoylcarnitine (C18) 0.045427 3.381146 146 1.128206 6   0.25297 1.209401   -0.14545 
myristoleate (14:1n5) 0.082055 2.945635 153 0.934009 6   0.254643 1.247202   -0.01818 
1-methylimidazoleacetate 0.224863 2.41335 15 -0.57356 5   0.306171 -0.73634   0.127273 
2-arachidonoyl-GPC (20:4) 0.230372 2.196027 20 0.22863 5   0.235102 0.470731   0.127273 
12,13-DiHOME 0.196143 2.443693 23 0.658725 5   0.888967 0.097586   -0.33636 
citrate 0.180933 2.101092 25 0.189108 5   0.266965 0.332497   0.309091 
valylglycine 0.162963 2.806258 33 -0.75067 5   0.874827 -0.05203   0.454545 
cinnamate 0.157945 2.559908 45 0.620076 5   0.100037 0.84788   0.223235 
gamma-glutamylleucine 0.157945 2.553039 58 -0.19642 5   0.275634 -0.19415   0.118182 
X - 12411 0.136622 2.205701 65 -1.27729 5   0.514613 -0.48698   0.236364 
X - 12442 0.275997 3.429089 82 -0.27544 5   0.434135 0.912886   -0.29091 
6-oxopiperidine-2-carboxylic 
acid 0.155852 2.583731 91 -0.51494 5   0.198426 -0.54285   0.018182 
margarate (17:0) 0.101435 3.074673 107 0.443718 5   0.474127 0.403184   -0.17273 
dihomolinolenate (20:3n3 or 
3n6) 0.110011 2.542434 136 0.338591 5   0.235102 0.633932   0.363636 
prolylphenylalanine 0.116279 2.733117 174 -0.87806 5   0.238267 -0.91074   -0.08182 
hydroxyproline 0.149108 2.55478 184.4286 -0.20354 5   0.077761 -0.30195   -0.12727 
palmitoylcarnitine (C16) 0.080138 2.782585 222 0.819122 5   0.344006 0.856727   -0.19091 
3-phosphoglycerate 0.17106 2.203112 26 -1.04395 4   0.433223 -0.98014   0.318907 
X - 11612 0.192695 2.202644 29 -0.98315 4   0.598962 0.886768   -0.00909 
X - 20587 0.230372 2.106959 32 -0.43719 4   0.476894 -0.3417   0.145455 
taurine 0.216862 2.127304 48 -0.43243 4   0.39005 -0.25295   0.163636 
2-hydroxydecanoate 0.260669 2.073432 51 -0.50993 4   0.876376 -0.05963   0.390909 
O-sulfo-L-tyrosine 0.180933 2.25161 52 -0.20709 4   0.246507 -0.29772   -0.26364 
trans-urocanate 0.230372 2.079909 54 -0.9032 4   0.235102 -1.0281   -0.19091 
4-hydroxyphenylpyruvate 0.207807 2.169578 67 -0.44139 4   0.33287 -0.44518   -0.05455 
valerylcarnitine (C5) 0.157945 2.206882 77 0.5905 4   0.649001 0.256886   -0.60909 
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glutaroylcarnitine (C5) 0.192695 2.239182 81 -0.4102 4   0.306171 -0.83811   -0.15455 
carnitine 0.213734 2.097068 84 -0.2123 4   0.383026 -0.23868   0.190909 
guanidinoacetate 0.140817 2.486186 119 -0.82213 4   0.236643 -0.74797   0.327273 
4-hydroxyphenylacetyl 
glycine 0.115773 2.245124 124 -1.2259 4   0.235102 -1.28016   0.281818 
2-hydroxybutyrate (AHB) 0.101098 2.471234 171 1.915204 4   0.238267 2.41726   0.063636 
myristoleoylcarnitine 0.115773 2.846017 232 1.017575 4   0.235102 0.689123   -0.37273 
propionylcarnitine (C3) 0.172998 2.351591 104 -0.42765 3   0.306171 -0.43193   0.027273 
imidazole lactate 0.235576 2.184238 111 -0.43323 3   0.250385 -0.75315   -0.24545 
isoleucylglycine 0.197825 2.358543 112 -0.34749 3   0.714922 -0.14921   0.136364 
isovalerylcarnitine (C5) 0.180933 2.324549 115 -0.42579 3   0.334425 -0.64347   -0.01818 
valylisoleucine 0.230372 2.293493 131 -1.06605 3   0.588406 -0.47578   0.428247 
N6-acetyllysine 0.202106 2.116863 133 -0.21729 3   0.235102 -0.23835   0.045455 
acetylcarnitine (C2) 0.230372 2.149902 138 0.229091 3   0.832623 0.112002   -0.42727 
1-stearoyl-GPE (18:0) 0.212485 2.073061 148 0.473404 3   0.25297 0.422346   -0.1 
X - 19561 0.250507 2.028295 152 -0.73699 3   0.787498 -0.2271   0.646927 
arabitol 0.162963 2.166538 157 -0.47475 3   0.44081 -0.24367   0.627273 
erythritol 0.197825 2.245262 161 -0.34628 3   0.235102 -0.30651   0.054545 
guanosine-3',5'-cyclic 
monophosphate (cGMP) 0.17106 2.022258 170 -0.86335 3   0.476894 -0.58956   0.318907 
3-hydroxyoctanoate 0.147763 2.208096 202 0.50055 3   0.283204 0.645093   0.181818 
X - 16975 0.230086 3.18324 285 0.451842 3   0.151661 -1.75537   -0.46364 
myristoylcarnitine 0.130397 2.351944 303 0.862659 3   0.382218 0.893767   -0.1 
X - 21329 0.242788 2.667255 507 4.202287 3   0.238267 0.438453   0.172727 
X - 12730 0.964701 3.747455 526 -0.14115 3   0.074427 -1.92158   0.172727 
X - 12199 0.596603 4.059631 600 0.165925 3   0.124517 -1.26713   -0.49091 
X - 12721 0.649051 3.681763 684 0.370839 3   0.323973 2.109984   0.072727 
docosapentaenoate (n6 
DPA; 22:5n6) 0.360323 2.048139 118 0.380696 2   0.238267 0.703224   0.527273 
X - 12007 0.824183 2.08026 179 0.789352 2   0.271492 -1.26897   0.090909 
     
213 
 
X - 18913 0.64621 2.429116 195 -0.16541 2   0.965822 0.136917   0.272727 
S-methylcysteine 0.180933 2.279775 210 0.332549 2   0.271492 0.246003   -0.31818 
alpha-CEHC 0.252738 2.070855 217 0.903424 2   0.235102 0.83757   0.081818 
10-nonadecenoate (19:1n9) 0.18375 2.371745 235 0.453766 2   0.39005 0.603011   -0.04545 
bilirubin 0.244614 2.072742 248 0.70409 2   0.198426 1.222308   0.182233 
3-hydroxy-3-methylglutarate 0.162963 2.141036 260 0.376772 2   0.665446 0.322947   -0.37273 
X - 12119 0.595042 2.631418 298 0.419286 2   0.679301 0.133615   -0.31818 
stearoylcarnitine (C18) 0.18375 2.231192 305 0.371406 2   0.543047 0.206302   -0.41818 
oleate (18:1n9) 0.157945 2.306246 334 0.72082 2   0.264476 1.019691   0.118182 
X - 17717 0.539094 3.392825 340 -0.32665 2   0.383026 -0.85311   -0.19091 
3-methyl-2-oxovalerate 0.191815 2.224986 350 0.750063 2   0.077761 0.813277   -0.07273 
3-methyl-2-oxobutyrate 0.197825 2.196639 416 0.434204 2   0.202999 0.467792   -0.08182 
X - 21431 0.53788 2.767055 504 0.22514 2   0.319159 -0.3707   0.354545 
X - 17735 0.781855 2.893461 506 0.235801 2   0.28641 0.893997   0.090909 
X - 21788 0.846795 2.72092 617 -0.14051 2   0.514613 -0.24386   0.345455 
X - 12267 0.781855 3.387627 629 0.169936 2   0.235102 -1.49381   -0.21868 
X - 14374 0.89537 2.665028 678 0.066252 2   0.433223 -0.26143   0.3 
X - 21792 0.964701 2.500299 710 -0.00659 2   0.44081 1.079978   -0.43636 
X - 12100 0.942872 2.63647 735 -0.04835 2   0.074427 -0.42887   -0.56364 
X - 15497 0.874481 2.6279 736 -0.20365 2   0.37191 -0.55118   -0.04545 
X - 14473 0.53788 2.085146 213 -0.24891 1   0.282601 -0.48934   -0.31818 
X - 18889 0.497037 2.028188 329 0.400841 1   0.44081 -0.45459   0.218182 
X - 11442 0.846795 2.370804 368 -0.10371 1   0.659974 -0.32787   0.419135 
X - 12450 0.696613 2.350147 390 -0.13254 1   0.36037 0.731951   -0.22727 
X - 21664 0.497037 2.442846 403 -0.10288 1   0.244843 -0.58654   -0.39091 
X - 13846 0.395505 2.373643 431 0.456808 1   0.514613 -0.83665   0.364466 
X - 12329 0.53788 2.191707 466 0.314165 1   0.269616 -1.68029   -0.31818 
X - 17367 0.874481 2.21205 486 0.034349 1   0.832392 0.288984   0.728931 
X - 22776 0.649051 2.19151 539 -0.50085 1   0.251986 -0.71276   0.336364 
     
214 
 
X - 13529 0.516351 2.417909 568 0.428657 1   0.491725 -0.265   0.236364 
































 level  q-value 
Fold-
change 
(log2)  Rho 
mevalonate 0.008585 4.830892 1 -1.02308 9   0.016239 -1.52559   -0.73636 
phenyllactate (PLA) 0.005177 4.675277 1 -1.39605 9   0.275586 -0.74199   0.445455 
prolylphenylalanine 0.008585 4.50887 1.571429 -0.91394 9   0.563829 -0.26221   0.445455 
proline 0.008585 4.578103 2.285714 -0.79517 9   0.331937 -0.45932   -0.14545 
methionine 0.027058 4.26247 3.714286 -0.53796 9   0.240253 -0.33809   -0.01818 
2-piperidinone 0.038463 4.100551 4.428571 -0.98571 9   0.038997 -0.71342   0.490909 
methyl glucopyranoside 
(alpha + beta) 0.008585 4.331417 5.142857 -0.93064 9   0.001606 -1.8482   -0.83636 
5-oxoproline 0.038945 3.768579 5.857143 -0.36824 9   0.050038 -0.46381   -0.37273 
6-oxopiperidine-2-
carboxylic acid 0.01353 4.418407 8.285714 -0.74648 9   0.143395 -0.42963   0.063636 
asparagine 0.038463 3.571622 10.85714 -0.6047 9   0.278137 -0.33996   0.127273 
citrulline 0.045711 3.77694 12.57143 -0.42369 9   0.445176 -0.30306   -0.33636 
alanine 0.038463 3.631242 16 -0.66264 9   0.847245 0.401375   0.272727 
cyclo(L-phe-L-pro) 0.045711 3.516566 16.85714 -0.64695 9   0.019255 -0.98211   -0.65455 
methionine sulfoxide 0.038463 3.953058 18.57143 -0.89021 9   0.096353 -0.94381   -0.35455 
3-hydroxyisobutyrate 0.014541 3.929132 21.14286 0.646173 9   0.11064 1.621229   0.918182 
cyclo(gly-pro) 0.038463 3.978582 23.71429 -0.66893 9   0.121698 -1.06576   -0.54545 
carnitine 0.051665 3.331363 6.571429 -0.3006 8   0.110997 -0.46018   -0.52727 
palmitoylcarnitine (C16) 0.038463 3.166767 10 1.128396 8   0.001606 1.342882   0.118182 
2-aminophenol sulfate 0.051665 3.059837 19.42857 -0.78798 8   0.744624 0.23955   0.781818 
gamma-
glutamylmethionine 0.045711 3.456907 20.28571 -0.69225 8   0.334642 -0.43538   -0.18182 
citrate 0.096009 2.663198 24.71429 0.239368 8   0.180597 0.670165   0.427273 
Table 2. Metabolites identified as significantly different in the plasma of the low dose rats after 4 hours. 
     
216 
 
gamma-glutamylalanine 0.061175 3.507418 36.71429 -0.84102 8   0.772406 0.101651   0 
cyclo(leu-pro) 0.038463 3.618906 37.71429 -1.13978 8   0.094051 -1.44763   -0.42727 
isoleucylisoleucine 0.14027 2.709096 15.14286 -0.91224 7   0.378602 -0.33492   0.454545 
glucuronate 0.127863 2.616944 22.85714 0.288782 7   0.01426 0.60679   0.581818 
X - 14255 0.09157 2.610101 26.71429 -0.66294 7   0.774773 0.114369   0.545455 
4-hydroxyphenylacetyl 
glycine 0.09157 2.760646 27.71429 -1.04693 7   0.576191 -0.33064   0.390909 
butyrylcarnitine (C4) 0.096863 3.093727 30.71429 -0.62131 7   0.649361 -0.17563   0.181818 
1-oleoyl-GPE (18:1) 0.078705 2.998651 32.71429 -0.72807 7   0.724706 -0.07989   0.118182 
mannose 0.048275 3.043504 34.71429 0.376952 7   0.676553 0.171845   -0.24545 
hydroxyproline 0.045711 3.3184 42.71429 -0.50247 7   0.15659 -0.56452   -0.23636 
3-hydroxy-2-
ethylpropionate 0.038945 3.461236 46.71429 0.628257 7   0.16374 0.825209   0.5 
stearoylcarnitine (C18) 0.079384 2.883895 47.71429 0.564088 7   0.028044 0.732195   0.063636 
3-hydroxyoctanoate 0.027058 3.22282 53.71429 0.889034 7   0.050038 1.756323   0.8 
gamma-glutamylglutamine 0.077991 3.275618 55.71429 -0.68925 7   0.232695 -0.70507   -0.18182 
prolylvaline 0.079384 3.298524 61.71429 -0.66211 7   0.050038 -0.95856   -0.36364 
2-hydroxybutyrate (AHB) 0.038463 2.875965 63.71429 2.274393 7   0.002873 3.04252   0.763636 
nicotinamide 0.075434 2.88099 77.71429 0.63424 7   0.043385 1.346819   0.718182 
oleoylcarnitine (C18) 0.038463 3.078122 84.71429 1.298099 7   0.001622 1.526236   0.290909 
3-hydroxysebacate 0.038463 2.890542 87.71429 1.367667 7   0.112933 2.524536   0.454545 
1-linoleoyl-GPE (18:2) 0.094466 2.545834 88.71429 -0.62334 7   0.11736 -0.92943   -0.50909 
3-hydroxylaurate 0.039762 2.792687 94.71429 1.029726 7   0.001606 1.290928   0.336364 
2,3-dihydroxyisovalerate 0.197227 2.658462 17.71429 0.668946 6   0.4568 0.289062   -0.54545 
glutamine 0.101511 3.071818 48.71429 -0.38079 6   0.163124 -0.61918   -0.61818 
N6-succinyladenosine 0.101511 3.062221 59.71429 0.409578 6   0.206133 0.512798   -0.30909 
1-methylimidazoleacetate 0.125229 2.98161 83.71429 -1.11029 6   0.303727 -0.8487   0.054545 
hydroxybutyrylcarnitine 0.039762 2.758099 105.7143 1.733385 6   0.057684 2.492412   0.127273 
guanidinoacetate 0.07128 2.660704 121.7143 -1.09295 6   0.334217 -0.78241   -0.15455 
     
217 
 
ectoine 0.094466 2.749742 160.7143 -0.55147 6   0.218078 -0.89169   -0.28182 
propionylcarnitine (C3) 0.178682 2.2971 22 -0.39652 5   0.269045 1.130749   0.890909 
3-phenylpropionate 
(hydrocinnamate) 0.100991 2.4278 50.71429 -1.28674 5   0.502901 -0.52809   0.563636 
2-hydroxyoctanoate 0.138108 2.35196 51.71429 -0.49828 5   0.13642 -0.3374   0.136364 
3-hydroxy-3-
methylglutarate 0.100754 2.471638 67.71429 0.811809 5   0.180597 1.082757   -0.2 
N-acetyl-aspartyl-
glutamate (NAAG) 0.132539 2.462324 80.71429 -0.46595 5   0.112933 -0.91901   -0.69091 
X - 14473 0.129332 2.874833 102.7143 -1.20539 5   0.266483 -0.60606   -0.13636 
S-methylcysteine 0.132539 2.508794 113.7143 0.397973 5   0.15659 0.508123   0.218182 
myristoylcarnitine 0.078705 2.440547 154.7143 1.12988 5   0.081242 1.777995   0.318182 
3-hydroxybutyrate (BHBA) 0.061585 2.339849 165.7143 1.230862 5   0.061991 1.394567   0.472727 
X - 12730 0.136119 2.838823 182.7143 -1.01004 5   0.391228 -0.99791   0.645455 
X - 12258 0.096635 3.220515 242.7143 -3.36777 5   0.810836 -0.15237   0.909091 
2-aminoheptanoate 0.297553 2.011211 28.71429 0.455332 4   0.787946 -0.14042   -0.80909 
N-(2-furoyl)glycine 0.257692 2.041109 35.71429 1.03268 4   0.75228 0.953227   -0.31818 
4-imidazoleacetate 0.185748 2.472705 52.71429 -0.55443 4   0.613696 -0.15567   0.090909 
indolelactate 0.155651 2.392415 54.71429 -0.56239 4   0.857033 -0.0517   0.590909 
erythritol 0.184191 2.293884 68.71429 -0.28878 4   0.576191 -0.11864   0.236364 
hydroquinone sulfate 0.225735 2.120301 72.71429 -0.78235 4   0.275586 0.851578   0.718182 
urea 0.248103 2.146678 85.71429 0.298033 4   0.160031 0.35482   0.309091 
biotin 0.185748 2.100397 95.71429 0.31421 4   0.190782 0.466264   0 
glycylvaline 0.156157 2.333343 96.71429 -0.49146 4   0.500599 0.321578   0.481818 
alpha-hydroxyisocaproate 0.118973 2.265921 106.7143 -0.76901 4   0.889637 0.028596   0.281818 
X - 14625 0.168659 3.411513 107.7143 -0.6101 4   0.355872 -0.22648   0.127273 
ferulic acid 4-sulfate 0.178682 2.680966 111.7143 -1.02735 4   0.325021 -0.94144   -0.21818 
N-methyl proline 0.137196 2.410764 124.7143 -0.47963 4   0.352533 -0.25599   0.272727 
adrenate (22:4n6) 0.128673 2.463403 129.7143 0.598243 4   0.38749 0.423854   0.154545 
N-acetylisoleucine 0.178682 2.595007 138.7143 1.327927 4   0.047411 2.378513   0.772727 
     
218 
 
3-methyl-2-oxobutyrate 0.149683 2.188749 157.7143 0.657199 4   0.061991 0.809811   -0.00909 
stearoyl-arachidonoyl-
glycerophosphocholine 0.136119 2.368372 166.7143 0.21931 4   0.381855 0.238092   -0.05455 
octadecanedioate (C18) 0.118973 2.313274 195.7143 1.274691 4   0.138318 2.513236   0.436364 
alpha-ketobutyrate 0.094466 2.167743 201.7143 2.105077 4   0.036779 1.926085   0.081818 
myristoleoylcarnitine 0.071265 2.083464 222.7143 1.580603 4   0.160031 2.889215   0.372727 
16-hydroxypalmitate 0.09157 2.043567 229.7143 1.029101 4   0.041954 0.792949   -0.04545 
X - 12119 0.413186 2.466847 60.71429 0.768529 3   0.345229 0.690902   0.009091 
glycerol 0.172584 2.04652 108.7143 0.528179 3   0.799369 0.07492   -0.69091 
N-palmitoyltaurine 0.178682 2.127812 112.7143 0.847167 3   0.02366 1.608063   0.6 
N6-acetyllysine 0.168659 2.172813 114.7143 -0.2058 3   0.929051 -0.00098   0.036364 
N-acetyl-1-methylhistidine 0.208394 2.058227 140.7143 0.520407 3   0.177788 0.529953   -0.03636 
serine 0.18932 2.07686 141.7143 -0.27113 3   0.757872 0.245983   0.1 
sphingomyelin 0.199861 2.301601 147.7143 0.377732 3   0.724706 0.098662   -0.78626 
laurylcarnitine (C12) 0.122089 2.258723 234.7143 0.909095 3   0.11064 2.165485   0.6 
indolebutyrate 0.132539 2.023233 244.7143 1.544192 3   0.161514 1.130501   -0.18182 
X - 12199 0.219754 2.724844 267.7143 0.343264 3   0.481583 0.276295   0.418182 
X - 18886 0.474621 3.574707 274.7143 -0.32743 3   0.012332 1.807576   0.509091 
X - 17761 0.666353 3.830359 283.7143 -0.55439 3   0.106012 1.227942   0.109091 
X - 16975 0.62471 4.373364 588.7143 0.436069 3   0.036779 -2.66541   -0.20957 
X - 12721 0.503013 3.621673 690.7143 0.396174 3   0.213615 3.623974   -0.01818 
spermidine 0.37129 2.016487 125.7143 -0.98018 2   0.195701 -1.55858   -0.73636 
X - 14352 0.491258 2.087236 190.7143 -0.28112 2   0.446721 -0.60666   -0.15455 
palmitate (16:0) 0.168659 2.073408 218.7143 0.443168 2   0.322934 0.194929   -0.29091 
2-aminobutyrate 0.156157 2.032901 240.7143 1.070913 2   0.11736 1.254029   0 
X - 21892 0.503013 3.319036 282.7143 0.383963 2   0.178308 1.329189   0.636364 
X - 17717 0.824218 3.086305 290.7143 -0.23847 2   0.106012 -1.52571   -0.36364 
X - 13835 0.776447 2.80843 359.7143 0.106016 2   0.814244 0.163213   0.181818 
X - 21431 0.328006 3.037525 377.7143 0.442945 2   0.946454 0.011107   0.618182 
     
219 
 
X - 12007 0.682035 3.473447 440.7143 0.659221 2   0.14264 -2.06964   0.127563 
X - 12860 0.928871 2.800688 497.7143 -0.1029 2   0.036779 1.931848   0.536364 
xylitol 0.987065 2.6614 522.7143 -0.07042 2   0.943652 0.023323   0.790909 
X - 14291 0.980162 2.95142 552.7143 0.296201 2   0.194355 -0.22227   0.063636 
X - 14318 0.424411 3.140063 566.7143 0.71463 2   0.245896 -0.50499   0.190909 
X - 17735 0.94223 2.667536 590.7143 -0.05544 2   0.094051 0.77872   0.390909 
X - 18913 0.628189 2.691591 596.7143 -0.16883 2   0.559021 0.385061   0.663636 
X - 12329 0.731265 3.425448 600.7143 0.162866 2   0.827012 0.174065   0.536364 
X - 12267 0.92197 3.353273 644.7143 0.048881 2   0.032394 -3.0761   -0.44039 
X - 21803 0.762902 3.028953 691.7143 0.152671 2   0.707045 0.716417   0.890909 
X - 21295 0.777172 2.506966 731.7143 -0.15771 2   0.902744 0.077049   0.518182 
X - 21353 0.987065 2.578551 740.7143 -0.03502 2   0.008429 1.385294   0.409091 
X - 11441 0.97301 2.562544 778.7143 -0.01306 2   0.11736 -0.97172   -0.51818 
X - 21792 0.375741 2.384679 215.7143 -0.06768 1   0.135949 0.769303   -0.57273 
X - 21729 0.492163 2.482178 231.7143 -0.31958 1   0.994976 0.100088   0.5 
X - 14374 0.814386 2.093024 345.7143 -0.10476 1   0.269045 -0.61909   -0.43636 
X - 12095 0.905322 2.316029 354.7143 -0.04393 1   0.178308 1.407377   0.809091 
X - 12212 0.628189 2.307694 427.7143 0.220189 1   0.951991 0.00571   0.590909 












































level  q-value 
Fold-
change 
(log2)  Rho 
AMP 0.251345 4.647859 1 0.575549 7   0.155969 0.456934   0.036364 
3-hydroxy-3-methylglutarate 0.251345 4.537536 1 1.414274 7   0.131955 1.071386   -0.4 
adenylosuccinate 0.251345 4.040677 1 1.839679 7   0.251481 1.836392   0.255126 
serine 0.321991 5.909512 1 0.353674 6   0.015601 0.681229   0.754545 
pyruvate 0.469938 4.766416 1 -1.3947 6   0.353482 -2.27927   -0.26364 
erythritol 0.484886 4.476072 1 -0.51379 6   0.258664 -0.56683   0.01373 
maltopentaose 0.484886 4.363443 24.57143 -1.29013 6   0.345109 -1.39642   -0.09567 
maltotriose 0.518649 4.352898 16.42857 -1.06904 6   0.109164 -4.97111   -0.7 
gamma-glutamyltryptophan 0.399456 4.206596 1 0.92859 6   0.499991 0.459053   -0.48182 
stearoyl-arachidonoyl-
glycerophosphoinositol 0.484886 4.203953 1 -0.21669 6   0.536955 -0.16925   0.172727 
2-aminophenol sulfate 0.484886 4.102025 2.285714 -0.83889 6   0.962405 0.024839   0.618182 
butyrylcarnitine (C4) 0.321991 4.091793 1 -0.95705 6   0.130422 -1.2094   0.136364 
ribose 1-phosphate 0.484886 4.057763 1 0.327199 6   0.464253 0.256072   0.036364 
guanidinosuccinate 0.469938 4.040342 6.857143 0.719335 6   0.581394 0.421889   -0.26364 
NAD+ 0.37723 4.018621 4.285714 0.670579 6   0.249514 0.545851   -0.00909 
glycerol 3-phosphate (G3P) 0.518649 3.759778 1.285714 0.643599 6   0.248532 0.751303   0.236364 
pregnenolone sulfate 0.510741 3.753985 13.57143 1.718983 6   0.045742 2.583251   0.818182 
gamma-glutamylglutamate 0.484886 3.738857 1 0.556691 6   0.654423 0.49367   -0.11818 
anserine 0.484886 3.738824 1 0.81785 6   0.169926 0.719984   0 
tigloylglycine 0.510741 3.632585 5.142857 0.558072 6   0.054162 1.263174   0.563636 
pregnanolone/allopregnanol
one sulfate 0.484886 3.520798 1 0.942781 6   0.335745 1.307445   0.145455 
Table 3. Metabolites identified as significantly different in the liver of the low dose rats after 4 hours. 
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X - 12101 0.836272 4.276358 58.57143 0.593844 5   0.755883 0.532448   -0.3 
sorbitol 0.484886 3.877457 90.57143 -0.69679 5   0.102996 -1.99862   -0.63636 
formononetin 0.470893 3.73319 37.57143 -1.05423 5   0.783819 -0.0889   0.3 
S-methylcysteine 0.470893 3.577633 32.57143 0.613019 5   0.027878 0.757693   0.309091 
pantethine 0.321991 3.549615 49.57143 1.090461 5   0.166789 1.690908   0.336364 
choline 0.459952 3.527017 26.57143 0.593089 5   0.103076 1.116603   0.672727 
deoxycarnitine 0.484886 3.467673 1.142857 -0.36654 5   0.656033 0.175132   0.590909 
phenyllactate (PLA) 0.484886 3.394419 22.57143 -1.77237 5   0.515439 -1.15963   0.396356 
3-hydroxy-2-ethylpropionate 0.518649 3.341656 10 0.495403 5   0.142458 0.76622   0.536364 
N-acetyl-glucosamine 1-
phosphate 0.484886 3.304682 11.42857 0.313726 5   0.027878 0.366046   0.118182 
1-docosapentaenoyl-GPC 
(22:5n6) 0.484886 3.24286 3.428571 -1.09815 5   0.602806 1.299314   0.564922 
2'-O-methylguanosine 0.484886 3.237808 8.142857 0.556776 5   0.261862 1.165277   0.363636 
2-
linoleoylglycerophosphoinos
itol* 0.57675 3.154069 3.857143 0.789474 5   0.984572 0.192074   -0.3 
ribonate (ribonolactone) 0.585049 3.128943 3 -0.37896 5   0.27445 -0.73493   -0.48182 
alpha-hydroxyisovaleroyl 
carnitine 0.510741 3.094648 2 0.266759 5   0.015601 0.813819   0.918182 
orotate 0.510741 3.070479 5.571429 0.450994 5   0.454171 0.373604   -0.08182 
methyl glucopyranoside 
(alpha + beta) 0.484886 3.030993 6 -0.56832 5   0.126194 -1.37705   -0.69091 
ethylmalonate 0.487825 2.909813 1.428571 -0.84504 5   0.158057 -1.32079   -0.14545 
glycerophosphoethanolamin
e 0.484886 2.786142 10.71429 -0.41272 5   0.093721 -1.15146   -0.54545 
gamma-glutamyltyrosine 0.510741 2.57867 6.428571 0.958499 5   0.253946 1.272921   -0.1 
X - 21861 0.687161 3.960112 126.5714 0.47938 4   0.015601 1.018282   0.481818 
pseudouridine 0.484886 3.345503 27.57143 0.318074 4   0.187311 0.456538   0.372727 
fructose 0.484886 3.282759 68.57143 -0.51918 4   0.075431 -1.67453   -0.53636 
pipecolate 0.484886 3.251177 55.57143 0.525826 4   0.296993 0.530051   0.009091 
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sedoheptulose-7-phosphate 0.321991 3.130161 39.57143 1.272271 4   0.109164 1.98693   0.645455 
2-hydroxypalmitate 0.484886 3.126327 36.57143 0.340515 4   0.877241 -0.0672   -0.52727 
cyclo(leu-pro) 0.598389 3.093743 43.57143 -0.63657 4   0.126194 -1.47636   -0.69091 
daidzein 0.484886 3.093106 67.57143 -0.94926 4   0.976798 0.279671   0.572727 
phosphoenolpyruvate (PEP) 0.484886 3.011915 77.57143 0.558739 4   0.060034 0.795191   0.327273 
UMP 0.484886 3.004034 84.57143 0.718771 4   0.499991 0.505116   -0.02727 
3-hydroxybutyrate (BHBA) 0.484886 2.986459 75.57143 0.546377 4   0.039742 1.020909   0.645455 
beta-alanine 0.484886 2.982172 70.57143 0.389176 4   0.314276 0.913213   0.463636 
2-aminobutyrate 0.485138 2.972555 86.57143 1.074673 4   0.126194 1.261711   -0.09091 
N-acetylglucosamine 6-
phosphate 0.484886 2.938438 34.57143 0.2677 4   0.057727 0.379176   0.354545 
X - 14838 0.734151 2.914205 31.57143 -0.22631 4   0.247931 -1.18429   -0.09091 
N-acetylserine 0.518649 2.888999 72.57143 0.394878 4   0.166789 0.594446   0.309091 
caprylate (8:0) 0.592595 2.807356 28.57143 0.249104 4   0.594081 0.114608   -0.30909 
isobutyrylglycine (C4) 0.592595 2.761467 79.57143 0.87706 4   0.651308 0.921503   0.095672 
palmitoyl-linoleoyl-
glycerophosphocholine 0.531951 2.717766 50.57143 0.266403 4   0.503613 0.174506   -0.53636 
glutaroylcarnitine (C5) 0.597432 2.713239 76.57143 -0.98269 4   0.258664 -1.1943   -0.07273 
gamma-glutamylvaline 0.484886 2.686069 57.57143 -0.97001 4   0.078486 -1.66078   -0.49887 
uridine-3'-monophosphate 
(3'-UMP) 0.592595 2.571951 30.57143 -0.90861 4   0.258664 -1.09788   0.050114 
glycylmethionine 0.518649 2.558059 52.57143 0.295096 4   0.875022 -0.0801   -0.01818 
7-methylguanine 0.592595 2.543879 83.57143 0.194896 4   0.314276 0.484358   0.545455 
naringenin 0.592595 2.457126 18.14286 2.167313 4   0.251481 0.75517   -0.27273 
5-hydroxyindoleacetate 0.594136 2.371931 19.85714 -0.38192 4   0.83664 -0.12133   0.509091 
2-
palmitoleoylglycerophospho
inositol 0.615349 2.367359 1.714286 -0.43467 4   0.474451 -0.36813   0.214124 
stachydrine 0.798062 2.351723 4.714286 0.214314 4   0.65782 -0.17717   -0.54545 
2-palmitoyl-GPE (16:0) 0.728062 2.315985 17.28571 -0.40951 4   0.617505 1.028252   0.436364 




glutamylphenylalanine 0.578435 2.238667 15.71429 0.519822 4   0.598742 0.410353   -0.2 
beta-muricholate 0.839197 2.085134 9.285714 -1.87281 4   0.281735 1.309749   0.581818 
X - 12104 0.960735 5.904875 560.5714 0.067944 3   0.027878 1.515314   0.381818 
X - 21343 0.900806 4.931907 511.5714 -0.16382 3   0.251481 0.245576   -0.43636 
X - 13737 0.839722 4.294123 235.5714 -0.2114 3   0.256536 1.255444   0.390909 
X - 12442 0.689867 4.242108 350.5714 0.552862 3   0.166789 0.654625   0.2 
X - 11979 0.992882 3.764186 663.5714 -0.48265 3   0.126194 1.344173   0.6 
xanthosine 0.959309 3.676239 595.5714 0.084041 3   0.126194 -0.86779   -0.28182 
maltose 0.518649 3.39027 138.5714 -0.6364 3   0.137782 -3.07137   -0.65455 
threonine 0.484886 3.125971 111.5714 0.360546 3   0.014594 0.962483   0.845455 
ferulic acid 4-sulfate 0.510741 2.880105 129.5714 -1.07817 3   0.503613 -1.38788   -0.27273 
cytidine 0.484886 2.84422 161.5714 0.162603 3   0.169926 0.506487   0.572727 
X - 18938 0.801777 2.681402 163.5714 0.370132 3   0.985417 -0.00639   0.472727 
N6-
carbamoylthreonyladenosin
e 0.518649 2.660934 118.5714 0.37195 3   0.06775 0.677222   0.772727 
X - 17246 0.942126 2.652088 143.5714 0.278139 3   0.503613 -0.68233   0.405468 
CMP 0.484886 2.604571 174.5714 1.069898 3   0.007879 1.88241   0.590909 
X - 21755 0.743965 2.599205 181.5714 -1.06348 3   0.023252 0.408708   0.309091 
N-acetylarginine 0.510741 2.554252 136.5714 0.412836 3   0.055289 1.008054   0.818182 
benzoate 0.54495 2.55264 109.5714 0.205229 3   0.949944 -0.02686   -0.60909 
glutamine 0.510741 2.547358 104.5714 -0.26093 3   0.039742 -0.72482   -0.79091 
dihydrokaempferol 0.532138 2.498276 38.57143 3.233653 3   0.186444 1.07412   -0.24545 
5-hydroxytryptophol 0.518649 2.491922 29.57143 -0.49425 3   0.406778 -0.42535   0.2 
glycyltyrosine 0.518649 2.371132 56.57143 0.305277 3   0.822352 -0.09339   -0.01818 
phosphate 0.531951 2.359067 74.57143 0.088451 3   0.919087 0.045273   0.327273 
N-acetylaspartate (NAA) 0.57675 2.285455 45.57143 -0.84202 3   0.207473 -1.05378   -0.32727 
glycerophosphorylcholine 
(GPC) 0.518649 2.27612 80.57143 -0.56697 3   0.057727 -1.37749   -0.57273 
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UDP-galactose 0.551652 2.170553 96.57143 0.569762 3   0.609184 -0.40655   -0.58182 
2-hydroxyhippurate 
(salicylurate) 0.828417 2.167493 65.57143 1.284875 3   0.533898 1.024062   -0.24715 
4-imidazoleacetate 0.757001 2.101049 48.57143 -0.39225 3   0.362345 -0.69866   -0.13636 
X - 22768 0.484886 2.035546 99.57143 -1.31353 3   0.54833 1.62861   0.290909 
xanthine 0.782978 2.00367 87.57143 0.348489 3   0.354236 0.207761   0.427273 
X - 21353 0.942126 3.401222 454.5714 -0.16207 2   0.845096 0.109469   -0.48182 
xylitol 0.998209 3.248118 376.5714 -0.31138 2   0.251172 -1.30637   -0.52727 
X - 16944 0.896415 3.179174 783.5714 0.196922 2   0.327855 0.517264   0 
X - 12125 0.998209 3.172699 265.5714 0.037449 2   0.093721 0.83474   0.709091 
X - 12695 0.959309 3.027875 795.5714 0.305551 2   0.09595 0.994052   0.818182 
X - 17694 0.998209 3.000108 624.5714 -0.09377 2   0.542518 0.744688   -0.15597 
X - 11576 0.900806 2.912117 390.5714 -0.03535 2   0.241714 0.545387   0.018182 
X - 12689 0.900806 2.897862 707.5714 0.133537 2   0.521991 -0.23952   0.209091 
X - 14961 0.959607 2.859556 453.5714 -0.05858 2   0.231762 -1.36676   -0.60909 
X - 11360 0.782978 2.777293 366.5714 -0.30814 2   0.280395 -1.25456   -0.35455 
trigonelline (N'-
methylnicotinate) 0.510741 2.528682 204.5714 -0.35254 2   0.253946 -1.12385   -0.55455 
CDP-ethanolamine 0.510741 2.416931 130.5714 0.63547 2   0.674133 0.469107   0.118182 
alpha-ketoglutarate 0.510741 2.348807 188.5714 -0.61884 2   0.093721 -1.03308   -0.07273 
5-dodecenoate (12:1n7) 0.54495 2.340059 128.5714 0.546371 2   0.258664 1.35749   0.436364 
guanosine 0.54495 2.327632 122.5714 0.208094 2   0.899078 -0.02414   -0.02727 
oleic ethanolamide 0.55335 2.110588 180.5714 0.354897 2   0.542518 0.325099   -0.07273 
myristoleoylcarnitine 0.592595 2.100654 168.5714 -0.63677 2   0.109164 -1.21696   -0.43636 
glutathione, reduced (GSH) 0.592595 2.016793 125.5714 -0.2155 2   0.015601 -1.1759   -0.66364 
mannose 0.592595 2.395832 242.5714 -0.41458 1   0.057727 -1.79364   -0.55455 
X - 12860 0.896415 2.385132 330.5714 0.191399 1   0.241389 -1.30728   -0.05455 
androsterone sulfate 0.599334 2.342602 316.5714 0.685294 1   0.027878 1.617424   0.827273 
X - 22162 0.950879 2.306493 219.5714 -0.46876 1   0.917436 0.081696   -0.21818 
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X - 17709 0.998209 2.306 317.5714 -0.71005 1   0.057727 1.224718   0.536364 
X - 22585 0.7363 2.303402 809.5714 -0.30763 1   0.231762 -1.28963   0.281133 
hexadecanedioate (C16) 0.484886 2.258314 249.5714 0.586457 1   0.101606 1.155971   0.827273 
valine 0.531951 2.194454 202.5714 0.193278 1   0.131955 0.334574   0.627273 
X - 21444 0.896415 2.176711 208.5714 0.274327 1   0.123197 -2.48539   -0.62244 
X - 21607 0.518649 2.158387 395.5714 -0.863 1   0.542518 0.304174   -0.43636 
alanine 0.549772 2.145709 215.5714 -0.13299 1   0.549773 0.316233   0.6 
glucose 0.597432 2.128497 261.5714 -0.30598 1   0.126194 -1.64074   -0.6 
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Appendix II: The novel predicted mitochondrial proteins 
Gene ID Symbol Probability   Gene ID Symbol Probability 
ENSG00000177150 FAM210A 1   ENSG00000165443 PHYHIPL 0.921197 
ENSG00000184857 TMEM186 1   ENSG00000112208 BAG2 0.920945 
ENSG00000137274 BPHL 1   ENSG00000205002 AARD 0.920675 
ENSG00000157326 DHRS4 1   ENSG00000126947 ARMCX1 0.920409 
ENSG00000050426 LETMD1 1   ENSG00000206052 DOK6 0.919912 
ENSG00000172992 DCAKD 1   ENSG00000100422 CERK 0.919119 
ENSG00000130748 TMEM160 1   ENSG00000089597 GANAB 0.91765 
ENSG00000142444 C19orf52 1   ENSG00000257727 CNPY2 0.916305 
ENSG00000159348 CYB5R1 1   ENSG00000166199 ALKBH3 0.915694 
ENSG00000160439 RDH13 1   ENSG00000072133 RPS6KA6 0.914952 
ENSG00000130349 C6orf203 1   ENSG00000148730 EIF4EBP2 0.914561 
ENSG00000168393 DTYMK 1   ENSG00000131379 C3orf20 0.91412 
ENSG00000161558 TMEM143 1   ENSG00000105135 ILVBL 0.911377 
ENSG00000178096 BOLA1 1   ENSG00000084733 RAB10 0.910815 
ENSG00000173137 ADCK5 1   ENSG00000134824 FADS2 0.910214 
ENSG00000180011 ZADH2 1   ENSG00000174444 RPL4 0.910017 
ENSG00000116096 SPR 1   ENSG00000184840 TMED9 0.909878 
ENSG00000156398 SFXN2 1   ENSG00000147403 RPL10 0.909084 
ENSG00000184227 ACOT1 1   ENSG00000186591 UBE2H 0.908941 
ENSG00000114021 NIT2 1   ENSG00000111647 UHRF1BP1L 0.90814 
ENSG00000117528 ABCD3 1   ENSG00000159374 M1AP 0.908099 
ENSG00000164241 C5orf63 1   ENSG00000189283 FHIT 0.906965 
ENSG00000165792 METTL17 1   ENSG00000114942 EEF1B2 0.906159 
ENSG00000063761 ADCK1 1   ENSG00000105193 RPS16 0.906126 
ENSG00000165028 NIPSNAP3B 1   ENSG00000135046 ANXA1 0.906087 
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ENSG00000205544 TMEM256 1   ENSG00000255154 RPP14 0.905946 
ENSG00000164040 PGRMC2 1   ENSG00000124614 RPS10 0.905404 
ENSG00000100714 MTHFD1 1   ENSG00000114573 ATP6V1A 0.904648 
ENSG00000114735 HEMK1 0.999999   ENSG00000124207 CSE1L 0.903871 
ENSG00000204394 VARS 0.999999   ENSG00000250317 SMIM20 0.903199 
ENSG00000100445 SDR39U1 0.999999   ENSG00000105640 RPL18A 0.90169 
ENSG00000120992 LYPLA1 0.999999   ENSG00000204628 GNB2L1 0.900423 
ENSG00000122378 FAM213A 0.999999   ENSG00000152904 GGPS1 0.899981 
ENSG00000008394 MGST1 0.999998   ENSG00000134285 FKBP11 0.89986 
ENSG00000164924 YWHAZ 0.999997   ENSG00000162496 DHRS3 0.89904 
ENSG00000163866 SMIM12 0.999997   ENSG00000165152 TMEM246 0.898951 
ENSG00000163607 GTPBP8 0.999997   ENSG00000140798 ABCC12 0.898718 
ENSG00000112304 ACOT13 0.999996   ENSG00000156482 RPL30 0.896773 
ENSG00000147592 LACTB2 0.999996   ENSG00000179869 ABCA13 0.896169 
ENSG00000231500 RPS18 0.999996   ENSG00000133121 STARD13 0.895773 
ENSG00000133597 ADCK2 0.999995   ENSG00000163617 KIAA1407 0.895589 
ENSG00000180488 FAM73A 0.999995   ENSG00000068784 SRBD1 0.895386 
ENSG00000167004 PDIA3 0.999994   ENSG00000244694 PTCHD4 0.894809 
ENSG00000165233 C9orf89 0.999994   ENSG00000138760 SCARB2 0.894471 
ENSG00000167264 DUS2 0.999992   ENSG00000166133 RPUSD2 0.893829 
ENSG00000197746 PSAP 0.99999   ENSG00000183891 TTC32 0.893413 
ENSG00000157379 DHRS1 0.99999   ENSG00000075035 WSCD2 0.893262 
ENSG00000139990 DCAF5 0.999989   ENSG00000183569 SERHL2 0.892904 
ENSG00000117450 PRDX1 0.999987   ENSG00000124194 GDAP1L1 0.891744 
ENSG00000186603 HPDL 0.999984   ENSG00000203859 HSD3B2 0.891547 
ENSG00000067225 PKM 0.999983   ENSG00000006451 RALA 0.890808 
ENSG00000204564 C6orf136 0.999983   ENSG00000127526 SLC35E1 0.890049 
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ENSG00000170634 ACYP2 0.997425   ENSG00000147604 RPL7 0.889564 
ENSG00000060971 ACAA1 0.997353   ENSG00000113643 RARS 0.889308 
ENSG00000204237 OXLD1 0.996793   ENSG00000100030 MAPK1 0.887955 
ENSG00000150787 PTS 0.99677   ENSG00000068097 HEATR6 0.887185 
ENSG00000254402 LRRC24 0.996748   ENSG00000141338 ABCA8 0.887132 
ENSG00000110011 DNAJC4 0.996745   ENSG00000174903 RAB1B 0.887105 
ENSG00000170889 RPS9 0.996552   ENSG00000186314 PRELID2 0.887088 
ENSG00000089157 RPLP0 0.996277   ENSG00000122406 RPL5 0.886808 
ENSG00000168273 SMIM4 0.995782   ENSG00000129151 BBOX1 0.886556 
ENSG00000166598 HSP90B1 0.995767   ENSG00000244038 DDOST 0.886205 
ENSG00000205707 LYRM5 0.995506   ENSG00000197959 DNM3 0.885691 
ENSG00000109971 HSPA8 0.995223   ENSG00000039560 RAI14 0.884775 
ENSG00000132570 PCBD2 0.995045   ENSG00000025708 TYMP 0.88475 
ENSG00000198755 RPL10A 0.994871   ENSG00000099977 DDT 0.884512 
ENSG00000160752 FDPS 0.994764   ENSG00000155890 TRIM42 0.88284 
ENSG00000172270 BSG 0.994757   ENSG00000114383 TUSC2 0.882763 
ENSG00000073169 SELO 0.994729   ENSG00000117016 RIMS3 0.882585 
ENSG00000026025 VIM 0.994312   ENSG00000063177 RPL18 0.882197 
ENSG00000142168 SOD1 0.993291   ENSG00000142459 EVI5L 0.882088 
ENSG00000168569 TMEM223 0.992672   ENSG00000211456 SACM1L 0.881837 
ENSG00000101166 SLMO2 0.992441   ENSG00000071082 RPL31 0.881441 
ENSG00000161016 RPL8 0.992206   ENSG00000215301 DDX3X 0.879846 
ENSG00000184524 CEND1 0.992131   ENSG00000077157 PPP1R12B 0.879218 
ENSG00000224877 C17orf89 0.992103   ENSG00000164645 C7orf62 0.878521 
ENSG00000170791 CHCHD7 0.992001   ENSG00000093010 COMT 0.876406 
ENSG00000084207 GSTP1 0.991264   ENSG00000130707 ASS1 0.876376 
ENSG00000110719 TCIRG1 0.991186   ENSG00000092841 MYL6 0.876238 
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ENSG00000154258 ABCA9 0.99081   ENSG00000161203 AP2M1 0.876179 
ENSG00000100316 RPL3 0.990524   ENSG00000166833 NAV2 0.875443 
ENSG00000159596 TMEM69 0.990339   ENSG00000239672 NME1 0.874996 
ENSG00000186081 KRT5 0.990305   ENSG00000080824 HSP90AA1 0.874615 
ENSG00000179988 PSTK 0.99006   ENSG00000174177 CTU2 0.87374 
ENSG00000006125 AP2B1 0.989959   ENSG00000067560 RHOA 0.872881 
ENSG00000160883 HK3 0.989361   ENSG00000140284 SLC27A2 0.872674 
ENSG00000204427 ABHD16A 0.989176   ENSG00000204653 ASPDH 0.871421 
ENSG00000198650 TAT 0.989152   ENSG00000167641 PPP1R14A 0.871216 
ENSG00000184992 BRI3BP 0.988635   ENSG00000128245 YWHAH 0.870473 
ENSG00000118363 SPCS2 0.988624   ENSG00000104059 FAM189A1 0.870027 
ENSG00000011052 NME2 0.988411   ENSG00000186298 PPP1CC 0.869349 
ENSG00000110917 MLEC 0.988314   ENSG00000277791 PSMB3 0.86901 
ENSG00000164398 ACSL6 0.988295   ENSG00000170921 TANC2 0.868841 
ENSG00000102794 IRG1 0.988192   ENSG00000116337 AMPD2 0.868054 
ENSG00000165553 NGB 0.98798   ENSG00000188343 FAM92A1 0.867584 
ENSG00000149428 HYOU1 0.987872   ENSG00000186051 TAL2 0.86729 
ENSG00000111640 GAPDH 0.98779   ENSG00000112514 CUTA 0.866533 
ENSG00000136628 EPRS 0.98777   ENSG00000100364 KIAA0930 0.866479 
ENSG00000135362 PRR5L 0.987471   ENSG00000065060 UHRF1BP1 0.865823 
ENSG00000127948 POR 0.986887   ENSG00000127452 FBXL12 0.86544 
ENSG00000109475 RPL34 0.986424   ENSG00000198610 AKR1C4 0.86419 
ENSG00000197157 SND1 0.985957   ENSG00000146350 TBC1D32 0.863969 
ENSG00000196230 TUBB 0.985616   ENSG00000138101 DTNB 0.861792 
ENSG00000047230 CTPS2 0.985431   ENSG00000085662 AKR1B1 0.861765 
ENSG00000132763 MMACHC 0.985112   ENSG00000188483 IER5L 0.861742 
ENSG00000096384 HSP90AB1 0.984982   ENSG00000130734 ATG4D 0.861304 
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ENSG00000100596 SPTLC2 0.98497   ENSG00000144369 FAM171B 0.860189 
ENSG00000162398 C1orf177 0.984928   ENSG00000197045 GMFB 0.859941 
ENSG00000167815 PRDX2 0.984792   ENSG00000075785 RAB7A 0.85919 
ENSG00000119917 IFIT3 0.983932   ENSG00000197226 TBC1D9B 0.858618 
ENSG00000119943 PYROXD2 0.983685   ENSG00000131370 SH3BP5 0.857403 
ENSG00000172482 AGXT 0.983442   ENSG00000197006 METTL9 0.857143 
ENSG00000074800 ENO1 0.983232   ENSG00000080371 RAB21 0.856143 
ENSG00000185386 MAPK11 0.982913   ENSG00000122203 KIAA1191 0.85566 
ENSG00000108828 VAT1 0.982846   ENSG00000118520 ARG1 0.854239 
ENSG00000182899 RPL35A 0.982816   ENSG00000117592 PRDX6 0.853315 
ENSG00000164978 NUDT2 0.982691   ENSG00000244187 TMEM141 0.853132 
ENSG00000164587 RPS14 0.981636   ENSG00000109046 WSB1 0.853024 
ENSG00000134419 RPS15A 0.980925   ENSG00000182718 ANXA2 0.852473 
ENSG00000240857 RDH14 0.980504   ENSG00000162927 PUS10 0.851334 
ENSG00000137038 TMEM261 0.979148   ENSG00000106772 PRUNE2 0.851187 
ENSG00000181915 ADO 0.978351   ENSG00000138801 PAPSS1 0.84898 
ENSG00000103502 CDIPT 0.978048   ENSG00000135821 GLUL 0.848464 
ENSG00000166348 USP54 0.977858   ENSG00000124786 SLC35B3 0.847544 
ENSG00000166347 CYB5A 0.977237   ENSG00000173540 GMPPB 0.846092 
ENSG00000111669 TPI1 0.975584   ENSG00000130589 HELZ2 0.846053 
ENSG00000167654 ATCAY 0.97504   ENSG00000104412 EMC2 0.845244 
ENSG00000148343 FAM73B 0.974711   ENSG00000125691 RPL23 0.845114 
ENSG00000197043 ANXA6 0.974328   ENSG00000105784 RUNDC3B 0.843567 
ENSG00000143554 SLC27A3 0.973068   ENSG00000140280 LYSMD2 0.842684 
ENSG00000103254 FAM173A 0.973064   ENSG00000088320 REM1 0.842581 
ENSG00000164163 ABCE1 0.972959   ENSG00000139438 FAM222A 0.842521 
ENSG00000166340 TPP1 0.972858   ENSG00000086289 EPDR1 0.842086 
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ENSG00000041988 THAP3 0.972778   ENSG00000167996 FTH1 0.842018 
ENSG00000141367 CLTC 0.972258   ENSG00000074755 ZZEF1 0.841716 
ENSG00000177600 RPLP2 0.971742   ENSG00000105726 ATP13A1 0.840398 
ENSG00000133687 TMTC1 0.970902   ENSG00000166329 CCDC182 0.839901 
ENSG00000135002 RFK 0.970585   ENSG00000119771 KLHL29 0.83976 
ENSG00000033050 ABCF2 0.969855   ENSG00000089127 OAS1 0.839752 
ENSG00000138363 ATIC 0.96947   ENSG00000144713 RPL32 0.839209 
ENSG00000106436 MYL10 0.966689   ENSG00000120705 ETF1 0.838718 
ENSG00000101152 DNAJC5 0.966505   ENSG00000120697 ALG5 0.838158 
ENSG00000232859 LYRM9 0.966441   ENSG00000184867 ARMCX2 0.838031 
ENSG00000135116 HRK 0.966428   ENSG00000105372 RPS19 0.837808 
ENSG00000134308 YWHAQ 0.966381   ENSG00000157999 ANKRD61 0.836447 
ENSG00000087086 FTL 0.965572   ENSG00000111790 FGFR1OP2 0.83632 
ENSG00000115275 MOGS 0.964986   ENSG00000196872 KIAA1211L 0.835759 
ENSG00000110497 AMBRA1 0.964499   ENSG00000125844 RRBP1 0.834867 
ENSG00000101337 TM9SF4 0.963812   ENSG00000162777 DENND2D 0.83473 
ENSG00000122884 P4HA1 0.963555   ENSG00000165661 QSOX2 0.834581 
ENSG00000067177 PHKA1 0.963552   ENSG00000167645 YIF1B 0.834465 
ENSG00000171097 CCBL1 0.962574   ENSG00000107099 DOCK8 0.830902 
ENSG00000072274 TFRC 0.962385   ENSG00000158792 SPATA2L 0.830852 
ENSG00000101473 ACOT8 0.961463   ENSG00000135624 CCT7 0.830115 
ENSG00000173681 CXorf23 0.961209   ENSG00000115464 USP34 0.829579 
ENSG00000165632 TAF3 0.960227   ENSG00000214827 MTCP1 0.829559 
ENSG00000074695 LMAN1 0.959058   ENSG00000196743 GM2A 0.829065 
ENSG00000213593 TMX2 0.958735   ENSG00000131149 GSE1 0.82884 
ENSG00000036448 MYOM2 0.958655   ENSG00000102882 MAPK3 0.828612 
ENSG00000164488 DACT2 0.957867   ENSG00000119285 HEATR1 0.828596 
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ENSG00000177692 DNAJC28 0.957604   ENSG00000167552 TUBA1A 0.828343 
ENSG00000142937 RPS8 0.957554   ENSG00000136682 CBWD2 0.827447 
ENSG00000254772 EEF1G 0.957049   ENSG00000143353 LYPLAL1 0.826878 
ENSG00000221886 ZBED8 0.956369   ENSG00000156510 HKDC1 0.826857 
ENSG00000117480 FAAH 0.956036   ENSG00000066739 ATG2B 0.826703 
ENSG00000086061 DNAJA1 0.954798   ENSG00000174021 GNG5 0.825851 
ENSG00000153982 GDPD1 0.954667   ENSG00000250067 YJEFN3 0.825764 
ENSG00000166794 PPIB 0.95432   ENSG00000078369 GNB1 0.825535 
ENSG00000160285 LSS 0.95339   ENSG00000109846 CRYAB 0.825319 
ENSG00000111906 HDDC2 0.952805   ENSG00000168765 GSTM4 0.824858 
ENSG00000188738 FSIP2 0.951657   ENSG00000182774 RPS17 0.82484 
ENSG00000141391 SLMO1 0.951298   ENSG00000141401 IMPA2 0.824746 
ENSG00000186150 UBL4B 0.950763   ENSG00000137198 GMPR 0.824092 
ENSG00000213719 CLIC1 0.95005   ENSG00000204311 DFNB59 0.82355 
ENSG00000162032 SPSB3 0.949877   ENSG00000132530 XAF1 0.822391 
ENSG00000140107 SLC25A47 0.949552   ENSG00000155792 DEPTOR 0.821959 
ENSG00000100612 DHRS7 0.949288   ENSG00000139641 ESYT1 0.821331 
ENSG00000104723 TUSC3 0.949219   ENSG00000156958 GALK2 0.821226 
ENSG00000167588 GPD1 0.94754   ENSG00000007516 BAIAP3 0.820643 
ENSG00000120265 PCMT1 0.947407   ENSG00000116151 MORN1 0.820643 
ENSG00000151640 DPYSL4 0.947395   ENSG00000100991 TRPC4AP 0.820107 
ENSG00000101986 ABCD1 0.946485   ENSG00000137968 SLC44A5 0.820083 
ENSG00000072110 ACTN1 0.945643   ENSG00000099797 TECR 0.819986 
ENSG00000060982 BCAT1 0.945034   ENSG00000117114 ADGRL2 0.818956 
ENSG00000179933 C14orf119 0.944973   ENSG00000135632 SMYD5 0.818744 
ENSG00000074696 HACD3 0.944727   ENSG00000215712 TMEM242 0.818363 
ENSG00000198682 PAPSS2 0.943718   ENSG00000124164 VAPB 0.818098 
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ENSG00000170899 GSTA4 0.943117   ENSG00000173486 FKBP2 0.817939 
ENSG00000171433 GLOD5 0.942852   ENSG00000162813 BPNT1 0.817677 
ENSG00000134884 ARGLU1 0.942776   ENSG00000215845 TSTD1 0.817497 
ENSG00000104763 ASAH1 0.942583   ENSG00000182676 PPP1R27 0.817361 
ENSG00000118705 RPN2 0.941903   ENSG00000138413 IDH1 0.816266 
ENSG00000109511 ANXA10 0.941382   ENSG00000114857 NKTR 0.8151 
ENSG00000134108 ARL8B 0.938531   ENSG00000130304 SLC27A1 0.814207 
ENSG00000182712 CMC4 0.938398   ENSG00000225921 NOL7 0.81392 
ENSG00000163902 RPN1 0.938157   ENSG00000179314 WSCD1 0.813711 
ENSG00000106346 USP42 0.93783   ENSG00000164124 TMEM144 0.813297 
ENSG00000178927 C17orf62 0.93639   ENSG00000107518 ATRNL1 0.812071 
ENSG00000180879 SSR4 0.936366   ENSG00000144867 SRPRB 0.811645 
ENSG00000103512 NOMO1 0.935814   ENSG00000114374 USP9Y 0.8115 
ENSG00000109016 DHRS7B 0.934397   ENSG00000163596 ICA1L 0.811444 
ENSG00000139324 TMTC3 0.934224   ENSG00000124374 PAIP2B 0.811163 
ENSG00000164327 RICTOR 0.933976   ENSG00000125170 DOK4 0.81105 
ENSG00000132781 MUTYH 0.932636   ENSG00000065413 ANKRD44 0.810462 
ENSG00000137700 SLC37A4 0.932539   ENSG00000154229 PRKCA 0.810284 
ENSG00000139644 TMBIM6 0.932427   ENSG00000153721 CNKSR3 0.810249 
ENSG00000118492 ADGB 0.931948   ENSG00000187862 TTC24 0.808903 
ENSG00000114993 RTKN 0.931436   ENSG00000148225 WDR31 0.808847 
ENSG00000170348 TMED10 0.930374   ENSG00000148057 IDNK 0.808832 
ENSG00000137393 RNF144B 0.930291   ENSG00000130255 RPL36 0.808065 
ENSG00000108953 YWHAE 0.929957   ENSG00000167526 RPL13 0.80798 
ENSG00000127314 RAP1B 0.929554   ENSG00000167658 EEF2 0.807083 
ENSG00000133878 DUSP26 0.92887   ENSG00000154124 OTULIN 0.807051 
ENSG00000146731 CCT6A 0.928632   ENSG00000116685 KIAA2013 0.804838 
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ENSG00000176894 PXMP2 0.928023   ENSG00000162755 KLHDC9 0.804455 
ENSG00000177889 UBE2N 0.925532   ENSG00000110700 RPS13 0.803322 
ENSG00000089009 RPL6 0.925493   ENSG00000168904 LRRC28 0.803098 
ENSG00000180891 CUEDC1 0.924334   ENSG00000109270 LAMTOR3 0.802992 
ENSG00000142544 CTU1 0.924172   ENSG00000136854 STXBP1 0.801646 
ENSG00000088854 C20orf194 0.923799   ENSG00000109436 TBC1D9 0.801477 


































     
237 
 
Appendix III: The novel predicted mitochondrial disease genes  
UniProt Symbol Binary disease Multiclass disease sum Multiclass recessive Multiclass dominant Multiclass other 
P36873 PPP1CC 1 0.999999931 1.16E-11 0.002197631 0.9978023 
P40763 STAT3 1 0.99999996 1.11E-14 0.00025596 0.999744 
Q02878 RPL6 1 0.98887971 0.01626507 0.31585544 0.6567592 
P12931 SRC 1 0.999999953 7.12E-20 3.65E-06 0.9999963 
P26439 HSD3B2 1 0.999999888 2.19E-08 0.007930366 0.9920695 
P15121 AKR1B1 1 0.999999958 1.16E-09 0.002607157 0.9973928 
P36578 RPL4 1 0.998887185 0.04452034 0.121593095 0.83277375 
P62910 RPL32 1 0.999991453 0.000800151 0.024261972 0.97492933 
Q9Y4K3 TRAF6 1 0.999999999 4.75E-23 3.59E-07 0.99999964 
P62829 RPL23 1 0.999985204 0.004582717 0.020134687 0.9752678 
P62899 RPL31 1 0.99999999 0.000790893 4.64E-06 0.99920446 
P31749 AKT1 1 1.000000036 1.05E-25 3.64E-08 1 
P04406 GAPDH 1 0.999999951 2.40E-08 0.000953777 0.99904615 
P62888 RPL30 1 0.999999915 0.001594319 0.000552396 0.9978532 
P08238 HSP90AB1 1 1 1.21E-31 1.91E-10 1 
P08670 VIM 1 0.999999966 6.99E-15 2.58E-05 0.99997413 
P63104 YWHAZ 1 1 0 7.78E-13 1 
P07900 HSP90AA1 1 1 0 7.27E-16 1 
P62873 GNB1 1 1 0 1.42E-17 1 
P03886 MT-ND1 1 1.000000008 2.32E-19 7.71E-09 1 
P03905 MT-ND4 1 1 0 1.42E-24 1 
P62258 YWHAE 1 1 0 0 1 
P23396 RPS3 1 0.991243486 0.005228526 0.34348196 0.642533 
P11142 HSPA8 1 1.000000031 3.29E-16 1.41E-05 0.99998593 
P11021 HSPA5 1 0.999999971 2.21E-14 0.000206021 0.99979395 
P60709 ACTB 1 1 4.01E-26 1.20E-11 1 
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P39019 RPS19 1 0.999838986 3.28E-05 0.12615493 0.8736513 
P02511 CRYAB 1 0.99910665 0.16285683 0.06690952 0.7693403 
P27361 MAPK3 1 0.999999917 7.63E-10 0.009924866 0.99007505 
Q92731 ESR2 1 0.999999862 9.21E-10 0.010534761 0.9894651 
Q9Y3U8 RPL36 1 0.99781079 0.0065518 0.24068935 0.75056964 
P13196 ALAS1 1 0.97037526 0.06133436 0.3179493 0.5910916 
P17612 PRKACA 1 0.999999932 2.01E-09 0.00866673 0.9913332 
P02792 FTL 1 1 0 1.34E-27 1 
P28482 MAPK1 0.999999999 0.999999984 3.34E-11 0.001600544 0.99839944 
P17252 PRKCA 0.999999996 0.999999569 7.40E-09 0.014845562 0.985154 
P46783 RPS10 0.999999987 0.995875641 0.000533121 0.34329182 0.6520507 
P10109 FDX1 0.99999977 0.90154841 0.2342498 0.26630494 0.40099367 
Q02156 PRKCE 0.999999645 0.999277559 2.10E-05 0.22561006 0.7736465 
P61764 STXBP1 0.999999614 0.97201257 0.07328749 0.30121058 0.5975145 
P02794 FTH1 0.999999594 1.000000014 0.005375701 1.39E-08 0.9946243 
P06493 CDK1 0.999999009 0.999999969 1.19E-09 0.005060668 0.9949393 
P62277 RPS13 0.999998684 0.990720631 0.019664261 0.30100527 0.6700511 
P62263 RPS14 0.999998589 0.985545378 0.010100848 0.36621773 0.6092268 
P61978 HNRNPK 0.999993521 0.999999581 2.77E-08 0.012584304 0.98741525 
P27348 YWHAQ 0.999992721 0.999996872 1.42E-07 0.03330363 0.9666931 
P38646 HSPA9 0.999983355 0.998883981 0.000517401 0.21728358 0.781083 
P34897 SHMT2 0.999933338 0.99261569 0.00064801 0.37570363 0.61626405 
P16220 CREB1 0.999932412 0.999922956 5.93E-06 0.109651975 0.89026505 
P31689 DNAJA1 0.999931593 0.91712475 0.2576459 0.24717715 0.4123017 
P61088 UBE2N 0.99990959 0.999985302 1.77E-06 0.054590233 0.9453933 
P32119 PRDX2 0.999908121 0.90732227 0.15450673 0.31131312 0.44150242 
P27469 G0S2 0.99990395 0.999693785 0.001688285 0.1457992 0.8522063 
P37840 SNCA 0.999883605 0.998998074 0.001011364 0.21501401 0.7829727 
P05388 RPLP0 0.999880692 0.997934177 0.001234627 0.26085025 0.7358493 
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P61586 RHOA 0.99976098 0.999999894 8.35E-09 0.006734735 0.99326515 
P60660 MYL6 0.999697851 0.999949612 0.006963168 0.035640184 0.95734626 
O00571 DDX3X 0.999668441 0.97624079 0.05099383 0.31261766 0.6126293 
Q96CW1 AP2M1 0.99966822 0.999316248 0.000661518 0.18863103 0.8100237 
P35613 BSG 0.999633348 0.92004317 0.08476377 0.3630782 0.4722012 
Q04917 YWHAH 0.99963223 0.999999942 7.64E-09 0.005168035 0.9948319 
P05387 RPLP2 0.999547902 0.99714983 0.0102467 0.24321783 0.7436853 
Q06124 PTPN11 0.999521063 0.999545487 5.44E-05 0.18428978 0.8152013 
O95298 NDUFC2 0.998808565 0.81023782 0.26111388 0.2582412 0.29088274 
P05089 ARG1 0.997750352 0.9516774 0.2563116 0.22497137 0.47039443 
P29353 SHC1 0.995722921 0.99711991 0.00040873 0.30066308 0.6960481 
P07437 TUBB 0.994621972 0.999918515 6.96E-06 0.109323055 0.8905885 
P40227 CCT6A 0.994405989 0.84761175 0.23256433 0.27412495 0.34092247 
Q00610 CLTC 0.993574403 0.997411383 0.003226503 0.23527408 0.7589108 
P17302 GJA1 0.991859889 0.987213823 0.007487823 0.3655512 0.6141748 
Q71U36 TUBA1A 0.98968188 0.999999947 5.43E-08 0.003102692 0.9968972 
O75438 NDUFB1 0.989455788 0.94440108 0.33612338 0.2018933 0.4063844 
O75394 MRPL33 0.985481657 0.89929885 0.10834575 0.35172117 0.43923193 
P63010 AP2B1 0.976522491 0.80763483 0.2553246 0.25797287 0.29433736 
P20336 RAB3A 0.968940329 0.999345566 6.32E-05 0.21154806 0.7877343 
P09874 PARP1 0.968900796 0.89460482 0.24892785 0.25588205 0.38979492 
Q13617 CUL2 0.954469458 0.991829652 0.002598552 0.3534712 0.6357599 
Q9NUB1 ACSS1 0.942897711 0.88279531 0.25409317 0.25925747 0.36944467 
Q9Y230 RUVBL2 0.920219249 0.982312106 0.012544926 0.36720082 0.60256636 
Q02978 SLC25A11 0.903637399 0.7898282 0.24266653 0.26638642 0.28077525 
P14618 PKM 0.901668171 0.999738359 0.000156629 0.13741288 0.86216885 
P09912 IFI6 0.87805275 0.93937254 0.10498691 0.32700288 0.50738275 
P40305 IFI27 0.862024921 0.977367819 0.018280359 0.37190232 0.58718514 
P07203 GPX1 0.653971244 0.90615803 0.12520048 0.33284873 0.44810882 
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Q9NR31 SAR1A 0.630566157 0.92588316 0.08430742 0.35803857 0.48353717 
Q02543 RPL18A 1 0.978703884 5.41E-08 0.63445306 0.34425077 
P62241 RPS8 1 0.634337954 1.63E-06 0.5517032 0.08263312 
Q3ZCQ8 TIMM50 0.999067678 0.73682338 0.19814903 0.2809093 0.25776505 
P30044 PRDX5 0.994719528 0.75822708 0.1388764 0.32947758 0.2898731 
Q9HCE7 SMURF1 0.878981221 0.586300558 0.006126368 0.44373107 0.13644312 
P27824 CANX 0.839058218 0.612611943 0.022769403 0.4203245 0.16951804 
P12236 SLC25A6 0.790992624 0.69991874 0.08530321 0.36749893 0.2471166 
O75323 GBAS 0.720103105 0.76596453 0.17177685 0.30557305 0.28861463 
P06576 ATP5B 1 0.964643006 0.5645618 0.111708686 0.28837252 
P18124 RPL7 1 0.998495747 0.49877954 0.046401337 0.45331487 
P49207 RPL34 1 0.995886034 0.6135136 0.056968864 0.32540357 
P20674 COX5A 0.999999999 0.970462341 0.90011185 0.020452961 0.04989753 
Q9UII2 ATPIF1 0.999999968 0.997853578 0.9844714 0.001937657 0.011444521 
O14561 NDUFAB1 0.999999935 0.992212318 0.95897776 0.006914065 0.026320493 
Q16718 NDUFA5 0.99999987 0.988687222 0.9562464 0.007690964 0.024749858 
P18077 RPL35A 0.999999856 0.999856757 0.96011597 0.000952092 0.038788695 
P42765 ACAA2 0.999999771 0.846642464 0.6671988 0.07641258 0.103031084 
Q9H3K2 GHITM 0.999999745 0.968166363 0.9254388 0.013395749 0.029331814 
P36542 ATP5C1 0.999999698 0.85638204 0.48178276 0.1578698 0.21672948 
O95573 ACSL3 0.999999673 0.903963418 0.86692846 0.015700966 0.021333992 
P60174 TPI1 0.999999231 0.992031295 0.95360166 0.007948794 0.030480841 
O95563 MPC2 0.999998709 0.996872045 0.9898324 0.00125087 0.005788775 
O95864 FADS2 0.999998027 0.83357353 0.34142563 0.21895087 0.27319703 
P07602 PSAP 0.999995711 0.999999548 0.96548915 1.01E-05 0.034500297 
P52758 HRSP12 0.99998862 0.702745026 0.64659274 0.030425994 0.025726292 
P51970 NDUFA8 0.999965848 0.986907368 0.9559201 0.007748404 0.023238864 
O43674 NDUFB5 0.99996559 0.974666832 0.8625123 0.030141722 0.08201281 
Q9P015 MRPL15 0.999960817 0.967593416 0.90844643 0.017981716 0.04116527 
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O75390 CS 0.999959115 0.96233335 0.8513451 0.03301527 0.07797298 
P80404 ABAT 0.999904659 0.818368235 0.70205593 0.052943215 0.06336909 
P09669 COX6C 0.999899734 0.995711025 0.9329122 0.010035247 0.052763578 
P07919 UQCRH 0.999868951 0.981966924 0.9230066 0.015123201 0.043837123 
Q9BYD1 MRPL13 0.999867505 0.959208468 0.9108585 0.016014798 0.03233517 
P82933 MRPS9 0.999834966 0.927828898 0.86067957 0.025103291 0.042046037 
Q16775 HAGH 0.999806809 0.983939671 0.9668469 0.004822366 0.012270405 
Q5T653 MRPL2 0.999775432 0.923669619 0.8560511 0.025693253 0.041925266 
O15235 MRPS12 0.999694901 0.858695402 0.7371213 0.051765192 0.06980891 
P14324 FDPS 0.999609711 0.995270333 0.96587366 0.005203997 0.024192676 
P07814 EPRS 0.999600351 0.883251846 0.5792243 0.117965326 0.18606222 
O95168 NDUFB4 0.999593468 0.984854648 0.9063917 0.018709008 0.05975394 
Q9BYD3 MRPL4 0.999582522 0.79711976 0.65005565 0.06798048 0.07908363 
P10606 COX5B 0.99956144 0.932710732 0.8324618 0.035698842 0.06455009 
P56134 ATP5J2 0.999560279 0.996035919 0.9654403 0.005078142 0.025517477 
Q9HAV7 GRPEL1 0.999522541 0.921036153 0.8421767 0.029810553 0.0490489 
P24539 ATP5F1 0.999495428 0.941299891 0.862942 0.027436037 0.050921854 
P00505 GOT2 0.99946463 0.80807475 0.6786997 0.05923132 0.07014373 
Q9NX20 MRPL16 0.999382716 0.952983065 0.9053417 0.016434962 0.031206403 
Q9NRX2 MRPL17 0.999279001 0.910274884 0.8269117 0.03246227 0.050900914 
P62917 RPL8 0.99926424 0.88005756 0.6610446 0.0870298 0.13198316 
Q9BPW8 NIPSNAP1 0.999122184 0.87433542 0.3528 0.21506014 0.30647528 
P82912 MRPS11 0.999086643 0.933971436 0.88202286 0.019474162 0.032474414 
P08708 RPS17 0.99902075 0.95024328 0.4207524 0.16833153 0.36115935 
Q9Y6H1 CHCHD2 0.99899516 0.859900984 0.56307185 0.124488324 0.17234081 
P26640 VARS 0.998779312 0.825309016 0.6901285 0.0595768 0.075603716 
O75964 ATP5L 0.99871666 0.9823885 0.93505913 0.012414165 0.034915205 
Q9Y6C9 MTCH2 0.998700816 0.95755601 0.91616285 0.014102535 0.027290625 
P50213 IDH3A 0.998596657 0.899973977 0.81945014 0.032318797 0.04820504 
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Q9UDW1 UQCR10 0.998571119 0.93399469 0.5453238 0.13386643 0.25480446 
P82675 MRPS5 0.998560777 0.76979549 0.64540416 0.06005313 0.0643382 
O43236 SEPT4 0.99854745 0.7198733 0.41135725 0.15772296 0.15079309 
Q9BUE6 ISCA1 0.998507559 0.962548317 0.92117625 0.013599115 0.027772952 
P21549 AGXT 0.998444299 0.975917892 0.9364598 0.011454645 0.028003447 
O60783 MRPS14 0.998352894 0.929243749 0.85764325 0.026548425 0.045052074 
P56385 ATP5I 0.998343172 0.984722809 0.91975844 0.015751299 0.04921307 
P15954 COX7C 0.998307528 0.993456985 0.9631344 0.006004954 0.024317631 
P30405 PPIF 0.998258416 0.8104547 0.4327974 0.17363392 0.20402338 
Q99832 CCT7 0.998145702 0.8515168 0.4990156 0.15007533 0.20242587 
P09417 QDPR 0.998009528 0.774426472 0.6922043 0.040586688 0.041635484 
P38606 ATP6V1A 0.997452683 0.77667528 0.43734288 0.16184388 0.17748852 
Q5TC12 ATPAF1 0.996798764 0.87689302 0.83500385 0.018780904 0.023108266 
P82664 MRPS10 0.996022378 0.82976844 0.50710803 0.14370336 0.17895705 
Q9P035 HACD3 0.995965535 0.962695977 0.8916399 0.022095652 0.048960425 
P11586 MTHFD1 0.995862881 0.75738943 0.6087643 0.07153441 0.07709072 
Q96EY1 DNAJA3 0.995776821 0.76504846 0.5555413 0.09937516 0.110132 
P46781 RPS9 0.995760936 0.86450712 0.3699404 0.20778747 0.28677925 
P17735 TAT 0.995659512 0.942746657 0.9088279 0.012693172 0.021225585 
P55060 CSE1L 0.995052726 0.81498944 0.41097626 0.1821791 0.22183408 
Q15388 TOMM20 0.993770878 0.938342936 0.8730464 0.023605568 0.041690968 
P22061 PCMT1 0.993657723 0.89045703 0.82204086 0.028551988 0.039864182 
P46199 MTIF2 0.993420773 0.869763907 0.81473553 0.024208331 0.030820046 
P22830 FECH 0.993401795 0.918385133 0.8558514 0.024301708 0.038232025 
Q9H3Z4 DNAJC5 0.993333656 0.88014232 0.7831291 0.040349934 0.056663286 
Q9NYZ2 SLC25A37 0.993049642 0.938110637 0.856382 0.028860917 0.05286772 
Q14318 FKBP8 0.993018472 0.94785632 0.5767666 0.1193501 0.25173962 
Q86SX6 GLRX5 0.992663621 0.79970739 0.4507203 0.16285384 0.18613325 
P62495 ETF1 0.992101274 0.84436428 0.44967067 0.17059991 0.2240937 
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Q9NWU5 MRPL22 0.992064214 0.82307032 0.72731173 0.04402834 0.05173025 
Q16891 IMMT 0.991991148 0.76766029 0.4347314 0.16067722 0.17225167 
Q8NI37 PPTC7 0.991932033 0.923182754 0.83428353 0.03303172 0.055867504 
P13073 COX4I1 0.991908532 0.988485269 0.89813656 0.019388873 0.070959836 
O95139 NDUFB6 0.991646466 0.971645058 0.903631 0.019709634 0.048304424 
Q969G6 RFK 0.991509372 0.984199357 0.9660455 0.005066886 0.013086971 
P17568 NDUFB7 0.990695035 0.934160375 0.8670167 0.024616443 0.042527232 
Q9Y3D5 MRPS18C 0.990413465 0.906525413 0.8485254 0.023581076 0.034418937 
P56378 C14orf2 0.989819475 0.967905521 0.90183496 0.019862851 0.04620771 
P36957 DLST 0.989790029 0.935879489 0.8649041 0.025557581 0.045417808 
O94925 GLS 0.989656023 0.703414204 0.520057 0.09328788 0.090069324 
P80303 NUCB2 0.989422926 0.999652357 0.99866605 7.73E-05 0.000908994 
Q9Y3B7 MRPL11 0.988705415 0.900323527 0.82448465 0.030582732 0.045256145 
Q01433 AMPD2 0.988155483 0.80516585 0.45194465 0.16207395 0.19114725 
O94903 PROSC 0.987922368 0.973557502 0.9425664 0.009496646 0.021494456 
P82914 MRPS15 0.987476972 0.955014271 0.9015805 0.018008264 0.035425507 
Q9Y5L4 TIMM13 0.985842862 0.7635568 0.36487526 0.19566758 0.20301396 
O75947 ATP5H 0.985662228 0.812809875 0.7125632 0.04661164 0.053635035 
P39748 FEN1 0.985518073 0.7845 0.5646535 0.10239811 0.11744839 
P18859 ATP5J 0.985057807 0.936726589 0.88279355 0.019980095 0.033952944 
P00167 CYB5A 0.984428225 0.961573355 0.92502236 0.012217132 0.024333863 
P54136 RARS 0.984069018 0.886944122 0.8115372 0.031244354 0.044162568 
P62269 RPS18 0.983643362 0.727247215 0.49597022 0.11580888 0.115468115 
Q9NZJ6 COQ3 0.983642468 0.992569415 0.9807178 0.002682389 0.009169226 
O14548 COX7A2L 0.983245983 0.968323476 0.9219691 0.014399544 0.031954832 
Q9UBX3 SLC25A10 0.981930237 0.742195495 0.57222307 0.083516695 0.08645573 
Q9Y3D6 FIS1 0.980299712 0.947681133 0.89300835 0.019199455 0.035473328 
O76031 CLPX 0.979929009 0.808380102 0.74335307 0.031143742 0.03388329 
P09543 CNP 0.97593113 0.66570571 0.3867969 0.1495476 0.12936121 
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Q96A35 MRPL24 0.97539132 0.972311727 0.9411239 0.009701977 0.02148585 
Q96E11 MRRF 0.973763687 0.954691408 0.92501974 0.010605049 0.019066619 
Q96B49 TOMM6 0.968544653 0.916165003 0.84520125 0.027580013 0.04338374 
P48047 ATP5O 0.967456736 0.83058316 0.59667826 0.10177458 0.13213032 
O96000 NDUFB10 0.96721466 0.976830463 0.9358703 0.011804013 0.02915615 
Q9Y6N1 COX11 0.961105312 0.817292633 0.7104544 0.049072336 0.057765897 
P00558 PGK1 0.960187728 0.7641828 0.62362146 0.06765278 0.07290856 
Q9Y512 SAMM50 0.960067459 0.838768315 0.7946087 0.020997675 0.02316194 
Q9NX40 OCIAD1 0.959212845 0.916401963 0.8664334 0.020031095 0.029937468 
Q9HD33 MRPL47 0.958944111 0.908648137 0.86249065 0.019041313 0.027116174 
P36969 GPX4 0.958938342 0.99976113 0.9991285 4.02E-05 0.000592398 
Q9Y5P6 GMPPB 0.956877286 0.806883049 0.7065719 0.046884492 0.053426657 
O95182 NDUFA7 0.952662504 0.927328847 0.8496327 0.028920297 0.04877585 
Q9P0U1 TOMM7 0.952376976 0.996876843 0.95633805 0.006025333 0.03451346 
Q96IX5 USMG5 0.949154598 0.860081125 0.8000126 0.02702897 0.033039555 
P54687 BCAT1 0.948124687 0.978533863 0.9573005 0.006395102 0.014838262 
O75608 LYPLA1 0.946975076 0.771693716 0.6136024 0.07542585 0.082665466 
P82673 MRPS35 0.942080958 0.708976343 0.63985676 0.03686995 0.032249633 
Q16774 GUK1 0.939580852 0.921969837 0.86092013 0.02352497 0.037524737 
Q9NWT8 AURKAIP1 0.937337152 0.944021897 0.88739926 0.02017002 0.036452617 
P49406 MRPL19 0.936445338 0.768791716 0.70486456 0.03231939 0.031607766 
Q5HYK3 COQ5 0.935708737 0.981425593 0.96112305 0.005890729 0.014411814 
Q9Y291 MRPS33 0.92634618 0.911569929 0.88233864 0.012488227 0.016743062 
Q14596 NBR1 0.925156663 0.775766578 0.68950796 0.04203652 0.044222098 
O95202 LETM1 0.921411677 0.71059363 0.60236657 0.05566208 0.05256498 
Q9Y320 TMX2 0.920743203 0.854683912 0.8012104 0.024496702 0.02897681 
Q9UJZ1 STOML2 0.915648147 0.874292181 0.77330804 0.042239327 0.058744814 
Q96FC7 PHYHIPL 0.911739706 0.7258185 0.58033913 0.07309326 0.07238611 
Q9HB07 C12orf10 0.906317824 0.980418693 0.96384895 0.004986767 0.011582976 
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P82663 MRPS25 0.906295865 0.777767139 0.7180857 0.03010304 0.029578399 
P09110 ACAA1 0.897477439 0.702555305 0.5420502 0.08213022 0.078374885 
Q9Y3D9 MRPS23 0.89551333 0.835546004 0.7769891 0.027500274 0.03105663 
P0C7P0 CISD3 0.894011326 0.880085488 0.7867447 0.038905684 0.054435104 
Q14197 ICT1 0.892908863 0.645576434 0.45904768 0.09997071 0.086558044 
Q9NTX5 ECHDC1 0.892366386 0.96318731 0.9083242 0.01744389 0.03741922 
O43677 NDUFC1 0.891106557 0.935199 0.8235425 0.03900591 0.07265059 
Q8WVC6 DCAKD 0.890800888 0.930028214 0.89696395 0.013109689 0.019954575 
Q9H2W6 MRPL46 0.890552064 0.921824172 0.8871525 0.014109984 0.020561688 
Q9Y4U1 MMACHC 0.887494748 0.973019859 0.9531256 0.006449508 0.013444751 
P30041 PRDX6 0.881335543 0.939182111 0.89736813 0.015677566 0.026136415 
Q9NWU1 OXSM 0.866230492 0.904589089 0.88403964 0.009175346 0.011374103 
P56181 NDUFV3 0.855572576 0.924639874 0.8385541 0.031971317 0.054114457 
P49901 SMCP 0.853794429 0.852027298 0.8362065 0.008006006 0.007814792 
Q15005 SPCS2 0.849865176 0.901360019 0.82635635 0.030277431 0.044726238 
O00411 POLRMT 0.849211067 0.700765137 0.61670005 0.04405421 0.040010877 
P22234 PAICS 0.844293164 0.717275604 0.62144244 0.049489677 0.046343487 
O43920 NDUFS5 0.84223548 0.718862777 0.66980314 0.026596863 0.022462774 
P36551 CPOX 0.839316435 0.699601429 0.5926145 0.055763405 0.051223524 
O75414 NME6 0.837644036 0.74021342 0.61349046 0.06324178 0.06348118 
P23919 DTYMK 0.836283774 0.760272076 0.67516315 0.04249355 0.042615376 
Q9P0M9 MRPL27 0.832595376 0.884776108 0.8192811 0.027794456 0.037700552 
O95900 TRUB2 0.829801767 0.547594812 0.47464713 0.043028574 0.029919108 
O95258 SLC25A14 0.82366455 0.78210471 0.3653433 0.19942978 0.21733163 
Q13405 MRPL49 0.816120205 0.637316244 0.42264682 0.11655322 0.098116204 
Q9GZT3 SLIRP 0.815323301 0.922936451 0.8729574 0.019617373 0.030361678 
Q7Z7F7 MRPL55 0.814006527 0.752728653 0.6765044 0.038853247 0.037371006 
O14957 UQCR11 0.811862697 0.84967788 0.577967 0.11622169 0.15548919 
Q8IYB8 SUPV3L1 0.80547563 0.761885599 0.6673476 0.046563562 0.047974437 
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P62072 TIMM10 0.804332366 0.766549775 0.61861014 0.07138363 0.076556005 
Q9UL15 BAG5 0.802877423 0.73450506 0.5897278 0.07200756 0.0727697 
Q9Y2S7 POLDIP2 0.798356137 0.822921587 0.7657796 0.027255112 0.029886875 
P35270 SPR 0.794333684 0.661695826 0.43487206 0.120775506 0.10604826 
Q99766 ATP5S 0.792894344 0.843395552 0.7987084 0.021168942 0.02351821 
Q9NW81 ATP5SL 0.791169581 0.735451911 0.6730162 0.03277297 0.029662741 
Q8NFF5 FLAD1 0.788951952 0.943214579 0.9040373 0.014398047 0.024779232 
Q9H6R3 ACSS3 0.779506068 0.873342138 0.81051046 0.027262898 0.03556878 
Q8IWL3 HSCB 0.774124299 0.928007563 0.88498 0.016780153 0.02624741 
P14406 COX7A2 0.770559034 0.947933359 0.93226117 0.006218928 0.009453261 
Q9NQ50 MRPL40 0.752255527 0.716518898 0.66446537 0.028133448 0.02392008 
O14735 CDIPT 0.751504078 0.898553168 0.81300896 0.034312 0.051232208 
Q9NX00 TMEM160 0.750906422 0.76432836 0.3508839 0.20253602 0.21090844 
Q9BW91 NUDT9 0.740541518 0.745344225 0.709495 0.019329878 0.016519347 
Q9NPL8 TIMMDC1 0.730023459 0.767077704 0.69608176 0.035760604 0.03523534 
O00408 PDE2A 0.706240744 0.60035161 0.41142341 0.10451077 0.08441743 
Q92934 BAD 0.702448465 0.74354683 0.2693425 0.24129803 0.2329063 
Q9NQR4 NIT2 0.698045523 0.904232002 0.8610993 0.018081037 0.025051665 
P39656 DDOST 0.694534586 0.72359277 0.42194134 0.15307432 0.14857711 
Q96AG4 LRRC59 0.692619523 0.75330493 0.5749117 0.086674616 0.091718614 
Q96EL2 MRPS24 0.68984259 0.791297245 0.7408782 0.025417935 0.02500111 
Q9GZY4 COA1 0.682649195 0.73913152 0.6516452 0.04468327 0.04280305 
O95167 NDUFA3 0.67950088 0.804961981 0.69285977 0.052279823 0.059822388 
Q9Y5J6 TIMM10B 0.670093512 0.716732913 0.66417277 0.028384028 0.024176115 
Q6IPR1 LYRM5 0.662561542 0.94137401 0.9087096 0.01242048 0.02024393 
Q9NRP4 SDHAF3 0.654017316 0.844110753 0.77318877 0.03232197 0.038600013 
P31939 ATIC 0.648697411 0.569111463 0.48343268 0.049275953 0.03640283 
Q9Y5J7 TIMM9 0.620269469 0.683070792 0.5703568 0.059629142 0.05308485 
A1L0T0 ILVBL 0.590399161 0.6175807 0.5396109 0.04377454 0.03419526 
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O95749 GGPS1 0.589032414 0.767482137 0.67438024 0.04589662 0.047205277 
Q96ND0 FAM210A 0.588803701 0.723036599 0.6875015 0.019522138 0.016012961 
P49448 GLUD2 0.584449152 0.72225469 0.60040563 0.06161824 0.06023082 
Q9Y5J9 TIMM8B 0.584215203 0.726049013 0.6324649 0.048198953 0.04538516 
O14874 BCKDK 0.583864984 0.72053466 0.39059737 0.1689627 0.16097459 
Q13268 DHRS2 0.581219703 0.859773491 0.7958174 0.028562086 0.035394005 
Q8WV93 LACE1 0.563172624 0.831644476 0.79162526 0.01936703 0.020652186 
Q7KZF4 SND1 0.558688631 0.759443834 0.5490256 0.100469984 0.10994825 
Q9H0R6 QRSL1 0.555869486 0.548132892 0.49644646 0.030898862 0.02078757 
Q9P0K7 RAI14 0.529432414 0.70516797 0.40773857 0.15349455 0.14393485 
O60238 BNIP3L 0.520541841 0.713961984 0.5350126 0.09056191 0.088387474 
Q7Z7K0 CMC1 0.51909254 0.772054375 0.73560554 0.019181686 0.017267149 
Q8TEL6 TRPC4AP 0.516953404 0.71021734 0.41088727 0.15381874 0.14551133 
Q15119 PDK2 0.514144133 0.742510788 0.668313 0.03807633 0.036121458 
O00198 HRK 0.500041187 0.680429584 0.52135944 0.08326562 0.075804524 
P31930 UQCRC1 0.456511955 0.663313235 0.46684277 0.103812255 0.09265821 
Q8WWR8 NEU4 0.435576091 0.587391673 0.49588835 0.05201459 0.039488733 
 
